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General introduction
The kidneys are paired organs and the renal parenchyma comprises a cortex and an 
outer and inner medulla (1, 2). Each kidney contains approximately one million 
nephrons, which are the functional unit of the kidney. Each nephron is made up of a
glomerulus, proximal tubule, loop of Henle, distal tubule and collecting duct. The renal
tubules are lined by epithelial cells, which are cuboidal except in the thin limb of the 
loop of Henle where they are flat. Proximal tubular cells differ from other cells of the 
system as they have a luminal brush border. The collecting ducts contain two cell 
types with different functions, namely principal cells and intercalated cells. An 
essential feature of renal function is that a large volume of blood passes through the
two million glomeruli. A hydrostatic pressure provides the driving force for ultrafiltra-
tion of virtually protein-free and fat-free fluid across the glomerular capillary wall into
Bowman’s space and so into the renal tubule.
Each day, ultra-filtration of 170–180 L of water and unbound small- molecu-
lar-weight constituents of blood occurs. If these large volumes of ultra-filtrate were 
excreted unchanged as urine, it would be necessary to ingest huge amounts of water 
and electrolytes to stay in balance. This is avoided by the selective reabsorption of 
water, essential electrolytes and other blood constituents, such as glucose and amino 
acids, from the filtrate in transit along the nephron. Accordingly, 60–80% of filtered 
water, sodium and potassium is reabsorbed in the proximal tubule along with almost
all the bicarbonate, glucose and amino acids. Additional water and sodium chloride is 
reabsorbed more distally, and fine-tuning of salt and water balance is achieved in the 
distal tubules and collecting ducts resulting in final urine volume of 1–2 L per day.
Water is the main component of the human body and is essential to facilitate many 
enzymatic processes, but also to maintain blood volume and osmolality homeostasis. 
The regulation of volume homeostasis is important for proper control of blood 
pressure, which is essential for providing tissues a proper supply of energy and oxygen 
via perfusion. Volume balance is mainly regulated by the modulation of urinary
reabsorption of sodium as sodium is the major determinant of plasma osmolality and
water crosses cell membranes freely from areas of low solute concentration to areas of 
high solute concentration. Thus, with increased sodium reabsorption and water that 
follows the generated osmotic gradient, our blood volume is increased. Besides 
volume balance, our body uses water to regulate the osmobalance. Osmobalance
disturbances, named hypo- and hypertonicity or hypo- and hypernatremia, 
respectively, need to be corrected to prevent changes in cell volume, which would 
compromise cell function. This is mainly regulated by the modulation of drinking and
steering the reabsorption of water from pro-urine through renal action of vasopressin.
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Blood volume is sensed by low- and high-pressure baroreceptors that trigger increased
action potential generation rates when blood vessel pressure is increased and provide
this information to the central nervous system. The brain translates this signal into
several responses that can affect blood volume over either the short or the long term.
The short-term effects occur as the autonomic nervous system and humoral
mechanisms modulate the heart and blood vessels to control blood pressure while
long-term effects occur as nervous, humoral, and hemodynamic mechanisms
modulate the kidney to control sodium excretion by using four parallel effector 
pathways. The first effector pathway is the renin-angiotensin-aldosterone system
(RAAS) that promotes sodium retention in the kidney via the actions of both angiotensin
II (ANG II) and aldosterone. A reduced blood volume is sensed by the juxtaglomerular 
cells in the kidneys that convert intracellular prorenin into renin and then secrete this 
directly into the circulation. Plasma renin then converts angiotensinogen into
angiotensin I that is subsequently converted into angiotensin II by the enzyme angio-
tensin-converting enzyme (ACE) found in the endothelial cells of the capillaries 
throughout the body, within the lungs and the epithelial cells of the kidneys.
Angiotensin II causes blood vessels to constrict, resulting in increased blood pressure,
and stimulates the secretion of aldosterone from the adrenal cortex. Both stimulate
the renal reabsorption of sodium. The second and third effector pathways are neural.
Baroreceptors detect decreases in blood volume and communicate this via afferent
neurons to the medulla of the brain stem. From the medulla, two types of efferent
signals emerge that ultimately act on the kidney. In one, increased activity of the 
sympathetic division of the autonomic nervous system reduces renal blood flow, and
thus reduces sodium excretion. In the other effector pathway, the posterior pituitary 
increases its secretion of arginine vasopressin (AVP; also known as antidiuretic
hormone; ADH). The latter mechanism becomes active only after large declines in
effective circulating volume. The final pathway is also hormonal. Reduced blood
volume decreases the release of atrial natriuretic peptide (ANP), therewith reducing 
sodium excretion. All four parallel effector pathways modulate renal sodium excretion,
correcting the primary change in blood volume. These pathways are also interlinked.
For example, by binding their receptors in AVP-producing supraoptic nucleus (SON), 
Angiotensin II also stimulates AVP secretion, while ANP inhibits AVP secretion (3).
Blood osmolality is tightly regulated to maintain a blood osmolality around 290 
mOsm/kg (4). Extracellular osmolality is sensed by osmoreceptors that are located in
the vascular organ of lamina terminalis (OVLT) and subfornical organ (SFO) (5). When
blood osmolality is elevated by only 2%-3%, the osmoreceptors induce a thirst
sensation to increase water intake, but this signaling also results in the release of AVP 
from the posterior pituitary to increase renal water reabsorption and increase in urine 
osmolality (6). After secretion into the circulation from the posterior pituitary gland, 
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AVP is delivered to the kidney, where it binds the V2 receptor (V2R) (Figure 1). The V2R 
is a G protein-coupled receptor that is expressed in the basolateral membrane of the
renal connecting tubuli and collecting ducts (7). The binding of AVP to the V2R 
increases intracellular level of cyclic AMP (cAMP) (8). This rise in intracellular cAMP 
increases aquaporin-2 water channel (AQP2) transcription through phosphorylated
activation of the cAMP response element-binding protein (CREB) transcription factor 
and induces translocation of AQP2 from intracellular vesicles to the apical membrane 
by dephosphorylating AQP2 at Ser261 and by phosphorylating AQP2 at Ser256, Ser264 
and Thr269 thereby increasing water permeability and allowing urine concentration 
(Figure 1) (8).
Disorders of excessive water reabsorption 
As may become apparent from its function above, inappropriate secretion of ADH
leads to increased retention of water and thus hyponatremia. The presentation is
usually vague, with confusion, nausea, irritability and, later, fits or in acute cases even
coma (1). There is no oedema nor hypervolemia/hypertension. Mild symptoms usually
occur with plasma sodium levels below 125 mmol/L and serious manifestations are
likely below 115 mmol/L. The elderly may show symptoms with milder abnormalities. In 
individuals with the syndrome of inappropriate antidiuretic hormone secretion 
(SIADH), high levels of circulating vasopressin persist even when serum osmolality 
falls to levels that totally suppress neurohypophyseal vasopressin secretion (9). 
Consequently, the kidney continues to reabsorb free water, leading to a progressive
fall in serum sodium concentration, and thus osmolality (Figure 2). SIADH is the most 
common cause of hyponatremia in hospitalized patients with causes ranging from 
neurological diseases, small-cell carcinoma of the lung, pulmonary lesions, congestive
heart failure, hepatic cirrhosis or through the use of a wide variety of medications such 
as chlorpropamide and carbamazepine (10). There are four distinct categories of 
SIADH, which can be classified according to the pattern of AVP secretion (11). Type A is 
the most common pattern of abnormal AVP secretion (40%). This type has been 
reported particularly with small cell lung tumors, which can synthesize and secrete 
bioactive AVP. Plasma AVP secretion is completely unregulated in Type A SIADH and 
plasma AVP secretion is not suppressed as plasma osmolality falls and significant 
hyponatremia may occur, if drinking continues (12). In type B SIADH, the pattern of AVP 
secretion is characterized by a lower osmotic threshold for AVP secretion. The threshold 
is reset to a lower level than would be physiologically normal. Type C and D SIADH 
forms are rare where type C is characterized by plasma osmolalities above the usual 
osmotic threshold of 284 mOsm/kg but the linear relationship between plasma AVP
and plasma osmolality is preserved. However, lowered plasma osmolalities do not 
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suppress AVP secretion, probably due to dysfunction of inhibitory neurons in the
hypothalamus, so that low plasma concentrations of AVP are always detectable in the
plasma (12). In type D SIADH, also called nephrogenic syndrome of inappropriate 
antidiuresis (NSIAD), the clinical presentation consist of hyponatremia and the lack of 
Figure 1. The regulation of AQP2-mediated water reabsorption. With water loss or increase in
plasma osmolality, osmoreceptors in the brain sense this and trigger a thirst response and
stimulate the release of vasopressin (AVP) form the pituitary. Upon binding of AVP to its V2R in
the principal cell of the collecting duct in the kidney, it initiates a cAMP signaling cascade
resulting in increased AQP2 gene and protein expression, de-phosphorylation of AQP2 at 
Ser261, and phosphorylation of AQP2 at Ser256, Ser264, and Thr269. This leads to the 
redistribution of AQP2 from intracellular vesicles into the apical membrane thereby increasing 
water permeability. Water enters the principal cell through AQP2 and subsequently exit the cells 
through AQP3 and AQP4 thereby allowing urine concentration.
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urinary dilution with very low or undetectable plasma AVP levels (13). NSIAD is rare and 
caused by an activating mutation in the V2R, resulting in constitutive AVP-indepen-
dent renal reabsorption of water (13).
Inappropriately increased plasma AVP levels in SIADH increase the expression of 
AQP2 in the renal tubule and water retention causing hyponatremia. Fortunately, the 
degree of the hyponatremia is limited by a process that is called ‘vasopressin escape’
that counters the water-retaining action of vasopressin and allows the kidneys to 
excrete more free water despite sustained high levels of circulating vasopressin (14).
There is still little known about the molecular mechanisms underlying this escape. 
However, Ecelbarger et al. developed an animal model for vasopressin escape in which
rats were infused with dDAVP, a V2R-selective agonist of vasopressin, while being fed
a liquid diet (15). In this study, they demonstrated that the onset of vasopressin escape 
coincided temporally with a marked decrease in renal AQP2 protein and mRNA 
expression in renal collecting ducts. It is worth to mention that the phenomenon of 
vasopressin escape has never been shown in humans.
Disorders of excessive aquaresis
Disorders of excessive aquaresis, named diabetes insipidus (DI), are characterized by
impaired renal water reabsorption caused by the downregulation of AQP2, resulting in 
polyuria and polydipsia. DI patients can present with hypernatremia, but this is often
corrected by an adapted extent of drinking induced by the thirst mechanism. There are 
four forms of DI (central, gestational, dispogenic and nephrogenic), each with a 
different set of causes. In central DI, normal AVP production is impaired and this can 
be caused by mutations in the AVP gene, but might also occur due to head trauma or 
diseases in the hypothalamus or pituitary gland (16). Gestational DI might occur during
pregnancy, due to an unusual increase in AVP-degrading enzyme, vasopressinase, 
that is produced by the placenta (17). Dipsogenic DI is rare and is due to abnormal
thirst stimulation in the hypothalamus. The fourth form of DI is nephrogenic DI (NDI)
that is caused by the failure of the kidney to respond to AVP stimulation. 
There are two forms of NDI, congenital or acquired. The congenital form can be 
further divided into X-linked, autosomal recessive and autosomal dominant NDI. More 
than 90% of all congenital NDI patients suffer from X- linked NDI that is caused by loss-
of-function mutations in the V2R gene (18). This results in principal cells that are
insensitive to AVP and a severe urine concentration defect. About 10% of the patients
diagnosed with NDI have mutations in the AQP2 gene of which 90% is of autosomal
recessive inheritance. Nearly all mutations in autosomal recessive NDI cause misfolding 
of the protein that is subsequently trapped in the ER and further degraded by the
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proteasomes (19). Autosomal dominant NDI is caused by mutations in the C-terminal
tail of AQP2. In this form, AQP2 mutants form heterotetramers with wild-type AQP2 
and are missorted to other subcellular destinations (19). This leads to severely decreased 
amounts of AQP2 in the apical membrane of principal cells. This explains the dominant 
mode of inheritance of NDI in these patients. The acquired form of NDI is caused by
drug therapy (e.g. lithium), hypokalemia, hypercalcemia, malnutrition of protein, and
recovery from ureteral obstruction (20, 21). Lithium-induced nephrogenic diabetes 
insipidus (Li-NDI) is the most common form of NDI and will be further discussed below.
Lithium-induced nephrogenic diabetes insipidus (Li-NDI)
Lithium is the main treatment of bipolar disorder that is a severe mental illness that
affects about 2% of the world’s population (22, 23). Patients suffer from a disturbance 
of mood with periods of depression or elation. This has a severe impact on the lives of 
most patients, demonstrated by the fact that more than 30% of bipolar patients
attempt suicide during their lifetime (24, 25). Moreover, the annual direct and indirect
economic burden of bipolar disorder was estimated to be 151 billion American dollars 
in the USA only (26). Lithium is the best-established long-term treatment for bipolar 
disorder and it has been shown to reduce the risk of manic relapses by 38%, depressive 
relapse by 28% and the risk of suicide by more than 50% (27, 28). Prior to the introduction
of lithium, individuals with manic-depressive illness often required months or years of 
hospitalization, experienced both a severe disruption in their social lives and a loss of 
productivity, and frequently committed suicide (29, 30). Those who are treated with
lithium often respond well and live a remarkably improved life. At least 1 per 1000 
people in western countries uses lithium and, as such, lithium usage saves our society 
huge amounts of health costs. An important drawback of lithium medication is the 
development of severe renal side effects (21). On the short term (months-years),
lithium causes NDI in ~20% of patients. This inability to concentrate urine causes 
polyuria, dehydration, thirst, and compensatory polydipsia. Furthermore, dependent
on dose and duration of treatment, long term (decades) lithium therapy causes a 
6-8-fold increase in the chance to develop chronic kidney disease (CKD) (31-33). Li-NDI
and Li-CKD are explained in more detail below.
As explained earlier, urine concentration is mediated by the principal cells of the 
collecting duct that express AQP2 in their apical membrane and thereby allow 
transcellular water reabsorption. Lithium treatment causes down regulation of AQP2 on
the short-term and loss of principal cells on the long-term (Figure 2) (34, 35). Lithium-
induced AQP2 downregulation is a consequence of ENaC-mediated influx of lithium 
into principal cells, as shown by studies on cultured mpkCCD cells (36). In agreement, 
ENaC inhibition or ablation prevented the development of lithium-induced NDI (37-39).
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Lithium inhibits glycogen synthase kinase type 3 (GSK3), a serine/threonine protein 
kinase regulating many signaling pathways including cell cycle progression, cell differ-
entiation and normal epithelial function and survival (40-44). GSK3 consists of two 
isoforms (т and у), which are directly inhibited by lithium, but also indirectly, via the
increased phosphorylation of serine 9 and 21 on GSK3у and –т, respectively (45). 
Different studies demonstrated that GSK3 plays an important role in urine concentration 
and lithium-induced NDI, as the use of other GSK3 inhibitors, structurally different from 
lithium, also reduced AQP2 abundance in collecting duct cell cultures (36). Furthermore,
ablation of GSK3т or -у in mice caused polyuria and a reduced AQP2 abundance, while
subsequent lithium treatment in the GSK3т knockout mice only slightly reduced their 
urine concentrating ability (46, 47). How inhibition of GSK3 by lithium ultimately leads 
to NDI has not been identified.
Li-induced chronic kidney disease
The most relevant clinical side effect of lithium is the development of CKD, which is 
marked by development of renal interstitial fibrosis. CKD implies long-standing, and 
usually progressive, impairment in renal function that is characterized by decrease in 
glomerular filtration rate. The prevalence of CKD in lithium-using patients is ~1.5%, 
which is 6-8 times higher than in the general population (33, 48). The duration of 
lithium treatment is an important factor as the vast majority of CKD patients was 
Figure 2. The pathophysiology of AQP2 in SAIDH and Li-NDI. Under physiological conditions, 
binding of AVP to its V2R results in expression and translocation of AQP2 to the apical membrane
thereby allowing water reabsorption from pro-urine (middle). However, in SIADH (left), plasma 
AVP levels are high resulting in increased apical abundance of AQP2 and subsequent increased 
water reabsorption. With Li-NDI, however, lithium enters the principal cells through ENaC and 
downregulates AQP2 by a mechanism that is most likely GSK3 related (right). Due to the decrease 
in the abundance of AQP2 in the apical membrane, water reabsorption in the principal cells is 
reduced.
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treated for more than 15 years with lithium. Although a report in 2014 suggested that
the less-controlled treatment regime for lithium in the 1960s and 1970s likely contributed 
to the development of CKD, a later report demonstrated that 5% of patients who 
started lithium treatment after 1980 and continued for 10-29 years also displayed
evidence of CKD (32, 49). Whether the current treatment regime reduces the occurrence 
of lithium-induced CKD as compared to the practices in the 1960s and 1970s remains 
to be addressed.
Kidney damage in humans and rodents chronically treated with lithium is virtually 
always characterized by proximal tubular atrophy and chronic interstitial fibrosis 
(50-53). Some lithium-treated patients also display glomerulosclerosis, but animal
studies revealed that this pathology only occurs long after the onset of interstitial 
fibrosis and tubular atrophy (33, 50, 53-56). Besides these pathological features, a
number of lithium treated patients display renal microcysts as shown by histology on 
biopsies or MRI scans (56, 57). The development of these cysts is likely a direct 
consequence of lithium uptake by principal cells, as these cysts mainly originate from 
the distal tubule and collecting duct (56). Renal cyst formation often results from 
disturbances in the function of the primary cilium (58). As cilium function is dependent
on GSK3 activity (58), the high levels of inactive GSK3, as observed in renal tubules
and cysts from lithium-treated animals (59), might be the primary cause for renal cyst
formation.
Aim of the thesis
The maintenance of water homeostasis is critical for body and cell function. However, 
this tightly-regulated mechanism is disturbed in diseases such as Li-NDI and SIADH.
Therefore, the aim of this thesis was to gain insight into the pathophysiology of water 
balance disturbances with the focus on renal side effects of lithium and SIADH.
Chapters 2-7 focus on the renal effects of lithium, whereas chapters 8 and 9 focus on 
the role of AQP2 in other renal pathologies
The first chapters focus on the renal side effects of lithium. Beside the downregulation
of AQP2 water channel in the collecting duct, lithium treatment decreases the
percentage of these cells in the long-term resulting in a phenomenon called collecting 
duct remodeling, which is paradoxical as lithium induces proliferation in these cells
specifically. In chapter 2, we investigate the cause of lithium-induced collecting duct
remodeling. Moreover, Li-NDI patients are currently treated with amiloride and hydro-
chlorothiazide. Amiloride blocks the entrance of lithium into the principal cells through 
ENaC, but hydrochlorothiazide was shown to have anti carbonic anhydrase activity 
beside the inhibition of the sodium chloride cotransporter (NCC) (60, 61). Accordingly, 
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in Chapter 3 we explored whether acetazolamide, that is specific carbonic anhydrase
inhibitor, is a better treatment for Li-NDI than co-treatment of amiloride and hydrochlo-
rothiazide. Furthermore, proliferating cells often generate their energy by a process 
called “aerobic glycolysis”, which takes place regardless of tissue oxygen levels.
In Chapter 4, we investigated whether lithium induces aerobic glycolysis in principal 
cells of the collecting duct and if the inhibition of glycolysis could serve as an alternative
treatment for Li-NDI in mpkCCD cells and mice. One of the metabolites that is extensively
produced during aerobic glycolysis and glutaminolysis is succinate. Secreted succinate 
binds to the succinate receptor 1 (SUCNR1), which is also expressed at the plasma 
membrane of tubular cells. In chapter 5, therefore, we studied the role of SUCNR1 in 
the development of Li-NDI. Additionally, as mentioned earlier, amiloride blocks the 
entrance of lithium into the principal cells and prevents Li-NDI. However, it still not
known whether amiloride attenuates proliferation and collecting duct remodeling that
are induced by lithium. Therefore, in chapter 6, we explored the other renal ameliorating
effects of amiloride. Furthermore, as long-term lithium treatment is associated with
development of renal interstitial fibrosis, in Chapter 7 we present mice as a model to 
investigate lithium induced interstitial fibrosis. 
In the remaining chapters, we focused on the role of AQP2 water channel in
other renal pathologies. In Chapter 8, we employed RNA-seq technique to determine 
pathways involved in the development of syndrome of inappropriate antidiuretic 
hormone secretion (SAIDH). In chapter 9, we employed mpkCCD cells and with the 
help of an NDI patient lacking AQP2, we tested the potential role of AQP2 in cell 
migration, proliferation and microcyst formation. Finally, the thesis concludes with a 
summary and general discussion presented in chapter 10.
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Abstract
Vasopressin-regulated expression and insertion of Aquaporin-2 (AQP2) water channels
in the luminal membrane of renal principal cells is essential for urine concentration.
Lithium, the mainstay treatment of bipolar disorder, affects urine concentrating ability, 
resulting in ~20% of patients with nephrogenic diabetes insipidus (NDI), a disorder 
characterized by polyuria and polydipsia. Lithium-induced NDI is caused by AQP2
downregulation and a reduced ratio of principal/intercalated cells. Surprisingly, 
lithium induces principal cell proliferation, as shown by increased principal cell 
staining for the proliferation marker PCNA. Here, we studied how lithium-induced
principal cell proliferation can lead to a reduced ratio of principal/intercalated cells. 2D
and 3D polarized cultures of mouse renal collecting duct (mpkCCD) cells and mice 
were treated with clinically-relevant lithium concentrations. DNA image cytometry and 
immunoblotting for proteins of different cell cycle stages revealed that lithium initiated
proliferation of mpkCCD cells, but also increased the G2/S ratio, indicating a G2/M
phase arrest. Mice treated with lithium for 4, 7, 10 or 13 days developed NDI (polyuria,
reduced urine osmolality/AQP2) and demonstrated many PCNA-positive principal
cells in the papilla. Remarkably, 30-40% of the PCNA-positive principal cells also 
stained for pHistone-H3, a late G2/M phase marker, which is around 20% in undisturbed
cell proliferation. Our data thus reveal that lithium treatment initiates proliferation of 
renal principal cells, but that a significant percentage is arrested in the late G2 cycle
phase, providing an explanation for the reduced principal/intercalated cell ratio and 
possibly the molecular pathway for long-term development of lithium-induced renal
fibrosis.
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Introduction
Lithium is widely used as treatment for bipolar disorders, a common chronic psychiatric 
illness typically requiring treatment for the rest of the patient’s life. An important side
effect of lithium treatment, however, is Nephrogenic Diabetes Insipidus (NDI), a disorder 
in which urine concentration is impaired, resulting in polyuria and polydipsia (1). While 
lithium treatment for a period of weeks already reduces urine concentrating ability in
humans (2), approximately 20% of patients receiving long-term lithium therapy will 
develop clinically extreme concentration defects resulting in NDI (3). Nevertheless, 
cessation of lithium therapy is usually not an option because bipolar disorder has a larger 
impact on the patient’s quality of life than NDI. Moreover, due to its efficacy, toxicity 
profile, and low cost, lithium remains the preferred therapy for bipolar disorders (4).
Urine concentration is regulated by arginine vasopressin (AVP), which is released from 
the pituitary in response to hypovolemia or hypernatremia. In the kidney, AVP binds its 
type-2 receptor at the basolateral membrane of principal cells of the collecting duct,
leading to the redistribution of aquaporin-2 (AQP2) water channels from intracellular 
vesicles to the apical membrane. Driven by the transcellular osmotic gradient, water then 
enters the cell via AQP2 and exits through aquaporin-3 (AQP3) and -4 (AQP4) in the 
basolateral membrane, resulting in correction of the water deficit and in concentrated 
urine (5).
Based on studies in rodents, the development of lithium-induced NDI is thought to 
occur in two phases. In the first short-term phase, lithium causes a decrease in AQP2 
expression (6). Lithium mainly enters principal cells through the epithelial sodium
channel (ENaC) at the apical surface (6, 7) and consequently accumulates in principal
cells due to the low affinity of the basolateral Na+ efflux pump Na+/K+-ATPase for 
lithium (6, 8). How lithium downregulates AQP2 remains unclear, but likely involves 
glycogen synthase kinase type 3у (GSK-3у) which is of importance in AVP-regulated 
antidiuresis and which is inhibited by lithium (9-11). Lithium also affects AQP2-mediated 
water reabsorption by the elevated tubular release of prostaglandin E2 (PGE2) (11-13).
In a second phase, lithium reduces the percentage of principal cells in the collecting
duct, which are “exchanged” for intercalated cells, involved in acid-base homeostasis.
(14) Paradoxically, but in line with increased WNT/уcatenin induced activity,(15, 16) 
lithium is known to induce proliferation of principal cells (17, 18). Apoptosis or principal-to-
intercalated cell conversion could be explanations, but Christensen et al. concluded
that the number of detected apoptotic events or cells co-staining for principal and 
intercalating cell marker proteins in lithium-NDI rats was too low to support these 
explanations (17). In this study, we provide an explanation for this paradox.
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Materials and Methods
Animal experiments
Mice (C57bl6/j), 15-20 g, were obtained from Harlan Laboratories and maintained at 
the animal facility of the Radboud UMC. Mice were divided in 5 groups of 3 male and 3
female mice. Group 1 (control): mice received normal rodent diet (ssniff® R/M-H V1534,
ssniff Spezialdiaten GmbH, Germany) for 7 days. Groups 2-5; mice received lithium 
chloride in a concentration of 40 mmol/kg of chow and were sacrificed after 4 (group
2), 7 (group 3), 10 (group 4) or 13 (group 5) days of lithium exposure. All mice had free
access to water, food, and a sodium chloride block. For the last 48 hours of the 
experiment, mice were housed in metabolic cages in order to measure water intake 
and urine output during the last 24 hours. Mice were anaesthetized with isofluorothane
and, after removal of blood by eye extraction, killed by cervical dislocation, after which 
the kidneys were removed.
One kidney was fixed for immunohistochemistry by overnight immersion in 4%
(wt/vol) paraformaldehyde in PBS, while the other kidney was stored at -20°C for 
immunoblotting. These experiments were approved by the Animal Experiments
Committee of the Radboud University Nijmegen Medical Centre.
Urine was centrifuged at 4000g for 5 min to remove sediment. Urine samples were
then analysed for osmolality with use of Micro-Osmometer Model 3320 (Advanced® 
instruments Inc., Massachusetts, USA).
Cell culture and lithium treatment assay
2D filter model: Murine principal collecting duct (mpkCCD) cells were cultured as
described (19). In short, the cells were cultured in a modified defined medium 
containing DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate, 5 μg/ml transferrin, 2
mM glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 10 ng/ml epidermal 
growth factor, 5 μg/ml insulin, 20 mM D-glucose, 2% fetal calf serum, and 20 mM 
HEPES (pH 7.4). Cells were seeded at a density of 1.5x105 cells/cm2 on semi-permeable
filters (Transwell, 0.4 μm pore size, Corning Costar, Cambridge, MA). After 72 hours, the
cells were treated with 1 nM 1-deamino-8-Darginine vasopressin (dDAVP) at the 
basolateral side to induce AQP2 expression. Simultaneously, cells were incubated with 
1 mM lithium chloride at the basolateral side and 10 mM lithium chloride at the apical 
side. After 4, 7 or 11 days of lithium exposure, the cells were either trypsinized, collected
in medium and then used for the DNA image cytometry or peletted and prepared for 
immunoblotting.
3D spheroid model: MpkCCD cells were prepared at a concentration of 12x105
cells/ml in medium containing 2 nM dDAVP with or without 20 mM lithium chloride, 
and mixed 1:1 (vol/vol) with Matrigel (Becton Dickinson, Bedford, United Kingdom).
Then, 0.36 ml aliquots were plated into 48 well plates (Corning Costar, New York, USA). 
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 29
Lithium causes G2 arrest of renal principal cells | 29
The cell/Matrigel mix was incubated at 37°C for 2 hours to allow gelling. Afterwards, 
the wells were filled with dDAVP-containing medium with/without lithium. After three
days, the cells were collected in Recovery medium (Becton Dickinson, Bedford, United 
Kingdom) and used for DNA Image cytometry or peletted and prepared for 
immunoblotting.
DNA image cytometry
DNA image cytometry was performed as described (20). In short, the cells were
collected in medium and centrifuged at 150g for 10 minutes, after which the pelleted 
cells were fixed in 4% formalin for 30 minutes. After centrifugation at 150g for 10 
minutes, the pellets were collected in PBS. Samples from the spheroid 3D model were
then treated with 5 mg/mL pepsin (Sigma Aldrich, Zwijndrecht, The Netherlands) in 
PBS (pH 1.5 with HCl) for 10 minutes at 37°C. Next, the pellets of nuclei were collected 
by centrifugation (150g) and counted using a Coulter counter (Beckman Coulter, 
Woerden, The Netherlands). Subsequently, the suspensions were centrifuged (150g) 
and the pellets were re-suspended in PBS to a dilution of 4x105 nuclei per ml. A 
cytospin of 4x104 nuclei /100 μL was prepared (100 μL, 10 min, 100g), followed by
fixation in Böhm fixative at room temperature for 60 minutes. Next, the slides were
rinsed with methanol, dried to air, incubated in 1 M HCl solution for 60 min at 25°C, 
washed in distilled water and stained for 60 min in Schiff’s reagent. After incubation, 
the slides were washed for 20 min in running tap water followed by increasing 
concentrations of alcohol and after washing in xylol mounted with permount (Fisher 
Scientific, Fair Lawn, USA).
Thereafter, DNA Image cytometry was performed with Q-path DNA software to
determine DNA ploidy of the nuclei (Leica Imaging Systems Ltd, Cambridge, UK). The
analysis was performed as described (20). Briefly, DNA content of 5000 nuclei was 
calculated automatically for each sample. Images of overlapping nuclei were manually 
excluded from the analysis. The data were then further analyzed using the MultCycle™
AV software (Phoenix Flow Systems, Washington, USA). Cell cycle phase was
determined according to the consensus criteria of the European Society for Analytical 
Cellular Pathology (21). In short, the measured Internal Optical density (IOD) of each 
segmented nucleus is plotted in a histogram and the G1 phase is recognized by a 
Gaussian peak. G2 and mitotic cells, having twice the normal G1 DNA content produce 
a Gaussian peak with a mean position of approximately twice of that of the G1 peak. S 
phase cells are observed just above the position occupied by all the G1 cells and 
extends to just below the position of the G2 cells. MultiCycle AV (Phoenix flow systems, 
San Diego, CA, USA) was used to determine the amount of cells in each phase via a 
deconvolution method and curve fitting.
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Immunoblotting 
Cells were lysed in Laemmli buffer, incubated at 37°C for 30 minutes, sonicated with a 
Branson Sonifier (Branson Ultrasonics Corporation, Danbury, USA) and analyzed by
SDS-PAGE and immunoblotting as described.(22) As primary antibodies, affinity-
purified rabbit R7 AQP2 (1:1500) (23), mouse cyclin B1 (1:1000, Abcam, Cambridge, UK),
rabbit Histone-H3 (1:5000, Abcam, Cambridge, UK), rabbit phosphoSer10-Histone-H3
(pHistone-H3; 1:4000, Cell Signaling, Massachusetts, USA), mouse PCNA (1:1000,
Abcam, Cambridge, UK), mouse Cdc2 (CDK1; 1:1000, Santa Cruz Biotechnology, Santa
Cruz, USA), rabbit phosphoTyr15-cdc2 (p-CDK1; 1:1000, Cell Signaling, Massachusetts, 
USA), mouse у-actin (1:10000, Sigma, St. Louis, USA), and rabbit cyclin D1 Sp4 (1:800,
ImmunoLogic, Duiven, Netherlands) were used. As secondary antibodies 1:10000-
diluted goat anti-rabbit or sheep anti-mouse peroxidase-conjugated antibodies were 
used. Proteins were visualized using enhanced chemiluminescence (ECL; Thermo
scientific, Rockford, USA). Pictures of the blots were taken using BioRad Universal 
Hood II and Quantity I software package (Bio-rad Laboratories Inc., Hercules, USA).
Later, blots were stained with coomassie blue G250 (Serva, Heidelberg, Germany) to
confirm loading of protein equivalents.
Immunocytochemistry
Culture medium was removed from matrigel-cultured mpkCCD cells and cells were 
subsequently washed 3 times with ice-cold PBS/0.5 mM CaCl2/1.0 mM MgCl2 and fixed 
for 30 min at room temperature with 4% w/v paraformaldehyde in PBS. After washing 
twice with PBS, cells were treated with permeabilization buffer (0.5% v/v Triton X-100 
and in PBS with 0.7% w/v gelatin) for 30 min. Then, cells were incubated at 4°C
overnight with primary antibodies (1:50 Rb5 AQP2 and 1:500 т-tubulin (Invitrogen,
Camarillo, USA) in permeabilization buffer and after washing for 3 times with secondary 
antibodies conjugated to Alexa dyes (Invitrogen, Paisly, UK) (1:500) for 2-3 hours at 
37°C. Finally, cells were mounted in Vectashield containing DAPI (Vector Laboratories, 
Burlingame, USA) and imaged by confocal microscopy (Olympus FV1000, Center 
Valley, PA, USA).
Immunohistochemistry
Immunohistochemistry was performed as described (24). In short, the kidneys were
removed and incubated O/N in paraformaldehyde (4%) in PBS at 4°C. After fixation,
kidneys were dehydrated and embedded in paraffin. Five-micrometer sections were
cut, stretched in 37°C water, and dried on gelatin-coated object glass (Menzel Gläser, 
Braunschweig, Germany) for at least 1 hour at 37°C. After the sections were
deparaffinized with xylol and rehydrated with ethanol and water, sections were boiled
in 10 mM sodium citrate (pH 6.0) for 30 min. After cooling down in TN buffer (0.15 M 
NaCl, 0.1 M Tris/HCl, pH 7.5) for 3 hours, sections were incubated for 30 min in 20mM
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Glycine in TN buffer and subsequently, after washing, incubated for 30 min with 0.3% 
H2O2 in TN buffer. Next, sections were incubated for 30 min in TNB buffer (TN buffer 
containing 0.5% (w/v) blocking reagent from NEN Life Science Products, Zaventem,
Belgium) and incubated O/N at 4°C with 1:1000 rabbit anti-pHistone-H3 in TNB buffer. 
Sections were then washed three times with TNT buffer (TN buffer containing 0.05% 
(v/v) Tween 20) and incubated for 60 min at room temperature with biotin-labeled 
secondary anti-rabbit antibody (1:1000). After washing with TNT, sections were 
incubated for 30 min with 1:100 Streptavidin-HRP (TSA Fluorescein System, PerkinElmer,
Waltham, USA) in TNB, washed again and incubated O/N at 4°C with 1:100 mouse 
PCNA and 1:400 rabbit H+-ATPase (gift from Dr. S. Nielsen, Denmark) in TNB. After 
washing, sections were incubated with secondary antibodies conjugated to Alexa 
dyes (1:1000) for 1 hour at 37 °C, washed again and incubated O/N at 4°C with 1:100 
guinea pig AQP4. Next day, sections were washed, incubated with an Alexa-conjugat-
ed secondary antibody against guinea pig for 1 hour at 37°C, washed again, and
incubated for 7 min with 1:50 Fluorescein Tyramide in Amplification Diluent (TSA 
Fluorescein System, PerkinElmer, Waltham, USA). After washing and incubation with 
DAPI (1:10.000 in TN) for 30 min, sections were embedded in Fluoromount G (Southern 
Biotech, Birmingham, USA).
Statistical analysis
The difference between groups was tested by student t-test and one-way ANOVA 
corrected by the Newmans-Keuls multiple-comparisons procedure. A p-value < 0.05
was considered statistically significant.
Results
Lithium initiates proliferation of mpkCCD cells
To study lithium-induced NDI in vitro, mpkCCD cells were cultured on 2D Transwell 
filters as described (6, 12) and treated with 1 and 10 mM lithium at the basolateral and 
apical side, respectively, for 4, 7 and 11 days. Immunoblotting showed significant 
downregulation of the dDAVP-induced expression of endogenous AQP2 at all 
time-points (Figure 1A). The effect of lithium on mpkCCD cells was also studied when
grown as spheroids, as this condition mimics the physiological 3D structure of the 
collecting duct (25). Immunoblotting and immunocytochemistry revealed that 
treatment of spheroid-grown mpkCCD cells with 10 mM lithium for 3 days significantly 
reduced endogenous AQP2 abundance (Figure 1B and C).
To assess the effect of lithium on proliferation, mpkCCD cell cycle profiles were 
obtained using DNA image cytometry (Figure 2A) and immunoblotting. In line with 
lithium-induced proliferation, the 2D model demonstrated a significant decrease in 
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cells in the G0/1 phase, which was accompanied by a significant increase of cells in the 
S and G2 phase at all days tested (Figure 2B). With 3D grown cells, similar data were
obtained (Figure 2C). Immunoblotting revealed that in our transwell model lithium
significantly increased the abundance of the S/G2 and G2/M phase marker proteins
PCNA and phospho-Histone-H3 (pHistone-H3), respectively, but the effect gradually
decreased in time (Figure 3A,B). The abundance of cyclin-D1, a protein essential for the
transition from the G0/1- to the S-phase and whose proteolysis is mediated by GSK3у
activity (26), was strongly elevated upon lithium treatment, while у-actin levels 
remained constant. With 3D spheroids, the effects of lithium on PCNA, pHistone-H3 
and cyclin-D1 levels was similar as in 2D-grown mpkCCD cells, but у-actin abundance
was significantly reduced (Figure 3C,D). The reduction in у-actin levels in lithium-treat-
ed spheroids is due to a reduced cell number as the total Histone-H3 abundance and
area-equivalents of proteins (not shown) were also reduced.
Figure 1. Lithium-induced AQP2 downregulation in two mpkCCD cell models. (A) MpkCCD
cells were cultured on Transwell filters to study the long-term effect of lithium (Li) treatment.
Following growth to confluency for 96 hours, cells were treated at the basolateral side with 1 
mM lithium chloride and at the apical side with 10 mM lithium chloride. After 4, 7 and 11 days of 
lithium exposure, cells were collected, lysed and immunoblotted for AQP2 (upper panel). 
Quantification is depicted in the lower panel (n=4 for each condition and time point). (B, C) 
MpkCCD cells were cultured in Matrigel and treated with (Li) or without (CTR) 10 mM lithium 
chloride. After three days, cells were lysed and immunoblotted for AQP2 and signals quantified,
corrected for у-actin (n=4 for each condition). Figure C demonstrates immunocytochemistry of 
3D-grown mpkCCD cells. AQP2 expression is visualized in green, while т-tubulin and the nuclear 
DAPI-staining are depicted in red and blue, respectively. The asterisk denotes a significant 
difference (P<0.05) from CTR.
A B C
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Figure 2. Lithium treatment induces proliferation. (A) Representative cell cycle profiles of 
Matrigel-cultured mpkCCD cells treated with 10 mM lithium chloride for three days (right panel)
or without lithium (control; left panel). The x-axis represents the DNA content of the nuclei
population, whereas the y-axis identifies the number of nuclei. The DNA content per cell cycle 
phase is indicated. (B) Distribution of the cell cycle phases of mpkCCD cells cultured on
Transwell filters for 4, 7 or 11 days treated with (Li) or without (CTR) lithium chloride (n=6 for 
each conditions and time point). (C) Averaged data of the distribution of the cell cycle phases of 
Matrigel-cultured mpkCCD cells treated without (CTR) or with (Li) lithium chloride (n=4 for each
condition). Asterisks indicate to a significant difference (P<0.05) as compared to CTR.
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Lithium induces a Chk1-dependent accumulation in the G2 phase
To ensure that cell division occurs flawlessly, the transition from one phase to the next 
phase of the cell cycle is controlled at the G1/S and G2/M checkpoints.(27) As lithium 
increased the number of cells present in S and G2 phase, we investigated whether 
lithium affects the G2/M transition step; we therefore assessed the percentage of cells
in the G2 phase relative to all cells in the S and G2 phase. Interestingly, in both cell 
models, we observed a significant accumulation of cells in the G2 phase after lithium
treatment as compared to the control situation (Figures 4A, D). Importantly, this 
percentage remained significantly elevated at all time-points tested (Figure 4A),
demonstrating that the G2 cell cycle arrest was sustained for these cells. Subsequent
Figure 3. The effect of lithium on different cell cycle markers. MpkCCD cells were cultured 
and treated with lithium on Transwell filters (A) or in matrigel (C) as described in the legend of 
Figure 1. lysed and immunoblotted for PCNA, cyclin D1, Histone H3, phospho-Histone H3
(pHistone-H3) and у-actin  (B, D) Quantification of protein abundances of filter (B) or matrigel 
(C) grown cells, corrected for у-actin and related to the abundances of control cells of day 4 (n=4 
for each conditions and time point). Asterisks indicate to a significant difference (P<0.05) as
compared to CTR.
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assessment of several proteins essential for G2/M transition revealed that in both
models cyclin-B1 and phospho-CDK1 protein levels were significantly increased 
(Figures 4B, C, E, F). Comparison between the two model systems demonstrated that 
the abundance of cyclin-B1 and phospho-CDK1 gradually declined over time in the 2D 
model and that the abundance of CDK1 was only elevated in the spheroid culture
system.
Figure 4. Lithium treatment of mpkCCD cells causes accumulation in G2 phase. MpkCCD
cells were cultured and treated with lithium on Transwell filters (A-C) or in matrigel (D-F) as 
described in the legend of Figure 1 and the percentage of cells in the G2 phase was determined 
(A,D; transwell: n=6 for each conditions and time point; matrigel: n=4 for each condition).  Cell
lysates of Transwell filter-cultured (B) or matrigel-cultured (D) cells were lysed and immunoblotted
for cyclin B1, CDK1, pCDK1 and у-actin. (C,F) Quantification of protein abundances of filter (B) or 
matrigel (E) grown cells, corrected for у-actin and related to the abundances of control cells of 
day 4 (n=4 for each conditions and time point). Asterisks indicate to a significant difference 
(P<0.05) as compared to CTR.
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Because a G2 cell cycle arrest is often coupled with activation of checkpoint kinase 1
(Chk1) (28), the involvement of Chk1 was studied by use of the selective Chk1 inhibitor 
CHIR-124. Treatment of mpkCCD cells with 500nM CHIR-124 for the last 4 days did not
affect the lithium-induced reduction of cells in the G0/G1 phase or increase of cells 
present in S-phase. However, the lithium-induced increase in cells present in the G2 
was abolished in cells treated with CHIR-124, demonstrating an essential role for Chk1
in lithium-induced G2 accumulation (Figure 5).
In vivo lithium treatment induces a G2 cell cycle arrest of principal cells
Our in vitro data revealed that, besides proliferation, lithium induced a G2/M phase 
cell cycle arrest. To investigate whether lithium also caused a G2 cell cycle arrest in 
vivo, mice were treated with or without 40 mmol lithium/kg food for 4-13 days. As 
anticipated, lithium treatment caused a time-dependent increase in urine volume 
(Figure 6A) and decrease in urine osmolality (Figure 6B). Of note and for unexplained 
reasons, at 13 days of lithium treatment, the urine volume decreased as compared to 
10 days, but was still significantly increased as compared to controls. Immunoblotting
confirmed a parallel reduction in AQP2 abundance (Figure 6C). Subsequently, kidney 
sections were co-stained with antibodies against AQP4, H+-ATPase, PCNA and 
pHistone-H3 to mark principal cells, intercalated cells, proliferation, and the late G2
phase of the cell cycle, respectively. As reported earlier (17), lithium strongly increased
the number of cells positive for PCNA, being most pronounced at the inner stripe of the 
outer medulla (ISOM). A representative staining of the ISOM of mice treated for 7 days
with lithium is given in Figure 7A. Counting collecting duct cells (~500 cells/mouse) in 
the ISOM demonstrated that the principal/intercalated cell ratio had the tendency to
decrease with longer lithium exposure (3.1 (± 0.1) at day 0 to 2.6 (± 0.5) at day 13), but 
Figure 5. Chk1 kinase blockage prevents lithium-induced cell cycle arrest. MpkCCD cells 
were grown and treated with or without lithium (Li) on transwells for 4 days as described in the
legend of Figure 1 Cells treated with lithium were cultured in the presence or absence of 500 nM 
of the Chk blocker CHIR-124. Then, cells were trypsinized, stained and analyzed by DNA image
cytometry (n=5). The asterisk denotes a significant difference (P<0.05) from CTR.
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did not reach significance (Figure 7B). The percentage of PCNA-positive principal cells 
changed from 0% at day 0 to 25%, 58%, 26% and 27% at days 4, 7, 10 and 13,
respectively (Figure 7B). This was higher than of intercalated cells, as the percentage 
of PCNA-positive intercalated cells changed from 0 at day 0 to 4%, 12%, 23% and 20% 
on days 4-13. 
To assess whether the PCNA-positive principal and/or intercalated cells were 
accumulating in the late G2 phase, cells with pHistone-H3-positive nuclear foci (Figure 
7A) were counted. The percentage of PCNA-positive principal cells in the late G2 phase
changed from 17% at day 4 to 36%, 27% and 38% at days 7, 10 and 13, respectively
(Figure 7C). For the intercalated cells, these numbers ranged from 51% to 34% and 
30% at days 7, 10 and 13 (Figure 7C). The percentages for PCs and ICs at day 7 and for 
PCs at day 13 were significantly elevated compared to the percentage of pHis-
tone-H3-positive PCNA-positive cells found in a renal cell population of non-treated
mice (22%; reference value obtained from Yang et al(29)). Note that percentages for 
pHiston-H3-PCNA-positive PC and IC cells for t=0 and for t=4 days for IC cells could not 
be given, because of the too low number of PCNA-positive cells. Of note, at 10 days a
small subset of cells (2.5%) expressed marker proteins of intercalated and principal 
cells (Figure 7D).
Figure 6. Lithium-treated mice develop nephrogenic diabetes insipidus. Mice were exposed 
to food without (CTR) or with 40 mM lithium chloride/kg food for 4, 7, 10 and 13 days. Mice were 
placed in metabolic cages for 48 hours and urine output (A) and urine osmolality (B) was 
determined during the last 24 hours (n=6 per time points for CTR and Li 4-10 days, n=5 for Li 13
days). (C) AQP2 immunoblotting data of whole kidneys of (CTR) and lithium chloride treated (Li) 
mice. The asterisk denotes a significant difference (P<0.05) from CTR.
A B C
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 38
38 | Chapter 2
Discussion 
Lithium enhances G1/S cell cycle progression
In this study the 3D spheroid cell model was used for the first time to study the effect
of lithium on AQP2 regulation. It is stated that cells grown in 3-dimensions (i.e. 
spheroids) are more like renal tubules and can thereby reach a higher level of epithelial
Figure 7. Lithium causes a G2 cell cycle arrest of principal cells in vivo. Kidneys of mice 
treated or not with lithium chloride as described in the legend of Figure 6 were isolated, fixed, 
paraffin-embedded, sectioned, and subjected to immunohistochemistry. Simultaneous staining
was done for AQP4 (principal cell [PC]; red), H+-ATPase (intercalated cell [IC]; green), PCNA 
(nucleus; purple), and pHistone-H3 (G2 cell cycle phase; green). (A) representative immunohis-
tochemical staining of ISOM area of a mouse treated for 7 days with lithium. (B) The principal-in-
tercalated cell composition (in % of the total number of cells) of the collecting duct of the inner 
stripe of the outer medulla (ISOM) of mice treated for 0-13 days (indicated) with lithium and the
% of PCNA-positive cells in PC and IC cells. For each time point ~500 collecting duct cells per 
mouse for in total 3 mice were counted. (C) Percentage of positive pHistone-H3 cells from the 
PCNA positive population at day 4-13. The asterisk denotes a significant difference (P<0.05) from
the reference value, obtained from a renal cell population of non-treated mice. (D) Immunohis-
tochemical staining of a kidney after 10 days of lithium treatment. The arrow indicates cells that
stain for markers of both intercalated and principal cells.
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polarity compared to 2D cell culture (30). However, in our study the percentage of 2D
cells in the S-G2 phase (2%) was more similar to in vivo as compared to spheroids 
(~12%). Therefore, we rather see the spheroid-grown cells as an alternative model for 
2D-grown cells instead of a better model. Lithium treatment of mpkCCD cells grown as 
polarized monolayer or as spheroids increased the number of cells in S and G2 phase.
This was accompanied by an enhanced expression of the proliferation markers PCNA
and cyclin D1, which was also found at the later time points of 7 or 11 days. The
sustained effect of lithium on cell cycle progression is in line with the progressive 
decline of collecting duct function and morphology in rodents treated with lithium 
(31). In addition to our mpkCCD model, we observed a stimulatory effect of lithium on 
the initiation of cell division in mice, as demonstrated by the high number of cells
positive for PCNA. At day 4 and day 7 of lithium treatment a large number of principal 
cells was positive for PCNA (25% and 58% respectively), while these percentages were 
much smaller for intercalated cells (4% and 12%) or for both cell types in control mice,
in which a negligible number of PCNA positive cell was found. This is in agreement with 
earlier findings (9, 17). The percentages of PCNA positive cells are similar between 
both cell types at 10 and 13 days. The observation that lithium first initiates proliferation 
of principal cells and only later of intercalated cells indicates that there might be two 
different mechanisms by how lithium induces proliferation of both cell types. 
Lithium induces a Chk1-dependent G2 cell cycle arrest
At clinically relevant concentrations (1 mM basolateral and 10 mM apical) we show 
here for the first time that lithium causes a G2 phase arrest of polarized collecting duct 
cells. This cell cycle arrest is likely the cause of the reduced у-actin abundance in the 
lithium-treated spheroids, as it prevents the continuation of cell division, leading to a 
reduced number of cells. Protein levels of cyclin B1 and CDK1 in the lithium-treated
mpkCCD cells were elevated, suggesting that CDK1-cyclin complex formation, essential 
for cell cycle progression through the G2 phase, was not affected by lithium. Next, we
observed that lithium caused an accumulation of the Tyr15-phosphorylated form of 
CDK1. CDK1 phosphorylation should indeed take place after complex formation,
however this complex will remain inactive until the phosphate is removed. This final
and essential step of the removal of the inhibitory phosphate is performed by cdc25 
phosphatase, which in turn is negatively regulated by Chk1 (32). The accumulation of 
pCDK1 upon lithium treatment suggests that removal of the phosphate did not take 
place, supporting a role for the cdc25-Chk1 signaling pathway in lithium-induced G2
phase arrest. Indeed, treatment with 500 nM CHIR-124, a selective Chk1 inhibitor (33), 
prevented the G2 phase arrest induced by lithium, indicating to the involvement of 
Chk1 kinase in the lithium-induced G2 phase arrest. These findings are in line with data 
of Wang et al. (2008), who showed that lithium enhanced the activity of Chk1 kinase in 
7721 cells (34). How lithium increases Chk1 activity is unknown.
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Besides mpkCCD cells, our data indicate that lithium also induced a G2 cell cycle arrest
in vivo. Using the pHistone-H3 positive foci as a marker for late G2 phase, we found
that 30-40% of principal cells were in the late G2 phase during the 7-13 days of lithium 
treatment, which is markedly higher than found in renal tubular cells (~20%) in
non-treated 8-10 weeks old male BALB/c mice (29). Thus, lithium also induced a G2
phase arrest in vivo. The question whether chronic lithium treatment for months or 
years would lead to a sustained cell cycle arrest was not answered by our study, as the 
mice received lithium for a maximum of 13 days. However, we did not see any decrease 
in the percentage of arrested principal cells during the time course 7-13 days in mice or 
in cells treated for 4-11 days with lithium. Interesting in this aspect are the findings of 
Kling et al. who demonstrated an increased presence of nuclear variation (irregular 
size and shape) of collecting duct cells in rats treated with lithium for 3, 9 and 18 weeks 
(31). These data are consistent with cells arrested in the G2 phase because an altered 
nuclear morphology in G2-arrested cells has been previously documented (35-37). The 
consequences of such a prolonged G2 cell cycle arrest are not fully understood,
although recent investigations of different acute kidney injury models indicate that 
activation of c-jun NH2-terminal (JNK) signaling in G2-arrested cells can lead to renal
fibrosis due to the upregulation of profibrotic cytokines, including transforming growth
factor-у1 (TGF-у1) (29). As fibrosis and chronic kidney disease are also observed after 
long-term lithium treatment (38), and lithium has been shown to activate JNK signaling
(16) and stimulate TGF-у1 production in the collecting duct (38), the role of G2-arrested 
cells in lithium-induced fibrosis should be further investigated.
Various studies demonstrated that lithium increased the number of principal cells 
incorporated with 3H-thymidine or positive for PCNA and concluded that lithium 
enhances proliferation of principal cells (17, 31, 39). Our study reveals that PCNA 
positive cells are not necessarily proliferating and that additional proof is required to 
assess whether cells are actually dividing or whether their cell cycle is arrested. We 
also noted that the small number of PCNA positive intercalated cells also exhibited a 
higher percentage of pHistone-H3 positivity than cells with unaffected cell division.
Considering the generally-accepted view that lithium cannot enter intercalated cells, 
we do not have an explanation for cell cycle arrest of the intercalated cells. Possibly,
the altered cell polarization/proliferation status of its neighboring principal cells might
also affect the intercalated cells. Another explanation may be that these intercalated 
cells are derived from principal cells, as principal cells can transit to intercalated cells 
(40). Perhaps the pHistone-H3 positive intercalated cells were originally principal
cells, but transformed into intercalated cells upon lithium entry. In line with this 
hypothesis, a small subset of ISOM CD cells (2.5%) at day 10 of lithium treatment
expressed marker proteins of intercalated and principal cells.
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The G2 arrest of principal cells may contribute to collecting duct 
remodeling in lithium-induced NDI
Besides the loss of AQP2 expression, lithium treatment induces collecting duct 
remodeling, in which the ratio of principal-to-intercalated cells decreases (14, 41). We 
found a tendency of collecting duct remodeling after 13 days of lithium treatment. The
paradoxical finding that lithium induces cell proliferation of principal cells, but
nevertheless ends up in a reduced principal/intercalated cell ratio is not understood.
Christensen et al., being aware of this paradox, checked different options, but only 
sparsely observed apoptosis of principal cells or conversion into intercalated cells 
during lithium treatment and therefore excluded these as potential causes for the 
reduced percentage of principal cells (17). Our study provides an explanation for this 
paradox as a large proportion of PCNA-positive principal cells is arrested in the late G2 
phase, indicating that they do not divide further. 
We, however, believe that the G2-phase arrest of principal cells is not the sole 
factor leading to collecting duct cell remodeling. Different earlier studies demonstrated 
that lithium treatment of rats induced an increased number of cells in the collecting 
duct (31, 39, 42). The increased number of cells likely constitutes mostly intercalated 
cells. The question remains why intercalated cells proliferate. Interestingly, as lithium
treatment is known to cause a metabolic acidosis (43-45), this might be the trigger for 
intercalated cells to divide to get rid of the excess of acid. Accordingly, an acetazol-
amide-induced metabolic acidosis did indeed stimulate the proliferation of intercalated
cells, resulting in a similar collecting duct remodeling as observed during lithium-NDI
(46). Thus, the lithium-induced collecting duct remodeling could be explained by a
rather stable population of principal cells, which are partly in a cell cycle arrest, and a 
proliferating population of intercalated cells.
In conclusion, in the present study we demonstrated that lithium not only induces 
principal cell division in vitro and in vivo, but also and for the first time, that lithium
induces an cell cycle arrest in the late G2 phase, likely involving inhibited Chk1 activity.
The lithium-induced cell cycle arrest is likely to contribute to the reduced percentage 
of principal cells and collecting duct remodeling in developed lithium-induced NDI. 
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Abstract
To reduce lithium-induced nephrogenic diabetes insipidus (lithium-NDI), bipolar 
patients are treated with thiazide/amiloride, which are thought to induce antidiuresis
by a compensatory increased pro-urine uptake in proximal tubules. However, as
thiazides induced an antidiuresis in lithium-NDI mice lacking the sodium-chloride 
co-transporter and alkalinized their urine, this concept was challenged and suggested 
that inhibition of carbonic anhydrases (CA) conferred the beneficial thiazide effect. 
Therefore, we here tested the effect of the CA-specific blocker acetazolamide in
lithium-NDI.
In collecting duct (mpkCCD) cells, acetazolamide reduced the cellular lithium
content and attenuated lithium-induced downregulation of AQP2 through a mechanism
different from amiloride. Treatment of lithium-NDI mice with acetazolamide or thiazide/
amiloride revealed a similar antidiuresis, increased urine osmolality and AQP2 
abundance. The reduced inulin clearance and cortical NHE3 expression demonstrated 
that the antidiuresis with acetazolamide was partially due to a tubular-glomerular 
feedback (TGF) response and reduced GFR. The TGF response and/or direct effect on 
collecting duct principal or intercalated cells may underlie the reduced urinary PGE2 
levels with acetazolamide, thereby contributing to the attenuated lithium-NDI.
Thiazide/amiloride-treated mice showed hyponatremia, hyperkalemia, hypercalcaemia,
metabolic acidosis and increased serum lithium concentrations; side effects also 
observed in patients, but not seen in acetazolamide-treated mice. 
In conclusion, we have shown that CAs activity contributes to lithium-NDI 
development, that acetazolamide attenuates lithium-induced NDI by inducing a TGF 
response and through a direct action on collecting duct cells, and that acetazolamide
attenuates lithium-NDI development similar to thiazide/amiloride but with less side
effects.
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Introduction 
Lithium is the drug of choice for the treatment of bipolar disorders and is also regularly
used to treat schizoaffective disorders and depression. Lithium is a frequently 
prescribed drug as it is provided to 0.1% of the western population. Unfortunately, in
2-85% of patients, and depending on age, lithium usage leads to nephrogenic diabetes
insipidus (Li-NDI), a disorder characterized by an impaired response of the kidney to 
vasopressin (AVP) leading to polyuria and polydipsia (1-3). Patients with Li-NDI are at 
risk for dehydration-induced lithium toxicity, and prolonged lithium treatment might 
lead to cyst formation and end stage renal disease (4). However, cessation of lithium 
therapy is not an option for most patients with NDI, because bipolar disorder symptoms 
have a larger impact on the patient’s quality of life.
From studies in rats, it became clear that Li-NDI develops in two stages. At short 
term (10 days), Li-NDI coincides with downregulation of aquaporin-2 (AQP2) water 
channels, which is due to a reduced AQP2 transcription (5-7). Despite an increased
proliferation of the AQP2-expressing principal cells of the collecting duct, long-term 
lithium treatment (4 weeks) also results in a severe loss of AQP2-expressing principal 
cells, which might be attributed to a lithium-induced G2/M phase cell cycle arrest (8, 9).
This principal cell loss is ‘compensated’ by an increased number of т-intercalated 
cells, which are involved in acid secretion (8).
To reduce polyuria in patients receiving lithium, a low-sodium diet together with 
thiazide and amiloride diuretics is prescribed (10). Amiloride acts on the principal cell 
epithelial sodium channel (ENaC) and we and others found that amiloride blocks
principal cell lithium entry through ENaC, thereby attenuating polyuria in rodents and 
humans (11-13). Thiazides are known to block sodium and chloride reabsorption via 
the NaCl co-transporter (NCC) in the renal distal convoluted tubule and the antidiuretic
effect has been ascribed to a hypovolemia-induced activation of the renin-angioten-
sin-aldosterone system (RAAS) and a compensatory increased uptake of sodium and 
water in proximal tubules. Recently, however, we discovered that thiazide also has an 
NCC-independent effect, as NCC knockout mice with Li-NDI showed a clear antidiuretic
response upon treatment with thiazide (14). 
As urine of our thiazide-treated mice was alkalinized and thiazides are derived 
from carbonic anhydrase (CA) inhibitors (15), our data indicated that the antidiuretic 
effect of thiazide in Li-NDI may involve CA inhibition. CAs catalyse the hydration of 
carbon dioxide to form carbonic acid, which then rapidly dissociates to form protons 
and bicarbonate, and play major roles in pH balance regulation. Here, we show that 
CAs are indeed involved in lithium-induced AQP2 downregulation and that, by inducing
a tubular glomerular feedback response and through direct action on collecting duct
cells, the CA-selective drug acetazolamide not only attenuates Li-NDI, but yields
superior in vivo effects as compared to the presently-used treatment for Li-NDI.
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Materials and Methods
Cell culture
MpkCCD cells were cultured as described (16). Cells were seeded at a density of 1.5x105
cells/cm2 on semi-permeable filters (Transwell, 0.4 μm pore size, Corning Costar,
Cambridge, MA) and cultured for 8 days. Unless stated otherwise, the cells were 
exposed to 1 nM of dDAVP at the basolateral side for the last 96 hr, to induce AQP2 
expression. Lithium and compounds were administered as indicated. At the end of the 
experiment, transcellular electrical resistance and voltage were measured using a 
Millicell-ERS meter (Millipore corp., Bedford, MA, USA). On day 8, cells were harvested 
and lysed in Laemmli buffer for western blotting or stored in Trizol reagent (Invitrogen,
Carlsbad, CA) at -80°C for RNA-isolation. 
Lithium assays
Determination of intracellular lithium concentrations was done as described (11). 
Shortly, mpkCCDcl4 cells were grown on 4.7 cm2 filters. To determine the extent of 
lithium contamination from the extracellular side, fluorescein isothiocyanate (FITC)
dextran was added to the lithium-containing medium to a final concentration of 10 μM
just before harvesting, after which the medium was mixed. Then, the filters were
washed three times with iso-osmotic sucrose (pH 7.3) at 4°C and cells were lysed by 
sonication in 1 ml milli-Q water. Of 800 μl sample, the amount of lithium was determined
by flame photometry, from which the total amount of lithium in the sample was
calculated.
Of 100 μl sample, the amount of FITC-dextran was measured using spectrofluoro-
photometry (Shimadzu RF-5301, Japan) at 492 nM (excitation) and 518 nm (emission) 
wavelengths. By comparing the obtained values with a two-fold FITC-dextran dilution 
series, the FITC-dextran concentration in each sample was determined, from which the 
extent of extracellular lithium contamination was calculated. This was subtracted from 
the total amount to obtain the intracellular lithium amount. With the used FITC-dextran 
concentration, a contamination above 1:5000 would be detected. To correct for 
differences in cellular yield, the intracellular lithium amounts were normalized for the
protein amount in each sample, which was determined using the Biorad Protein Assay 
(München, Germany). 
Experimental animals
8-10 weeks old female C57Bl6/JOlaHsd mice (Harlan Laboratories, The Netherlands)
were maintained in a temperature-controlled room with lights on 8.00 AM and PM. 
They received normal diet (ssniff R/M-H V1534, ssniff Spezialdiaten GmbH, Soest,
Germany) with additions (see below) and water ad libitum for 10 days. For the 
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experiments, mice were divided into four groups (n = 8), which were treated as follows:
Group 1: Control mice given a normal diet; Group 2: Normal diet with 40 mmol LiCl /kg
of dry food (17). Group 3: diet of group 2 with 200 mg amiloride (11) and 350 mg hydro-
chlorothiazide per kg dry food(18). Group 4: diet of group 2 with 180 mg acetazolamide 
/kg dry food.(19) LiCl, amiloride, hydrochlorothiazide and acetazolamide were 
solubilized in water and mixed with the chow after which it was dried. All mice had free 
access to water, food, and a sodium-chloride block.
For the last 48 hr of the experiment, mice were housed in metabolic cages to
measure water intake and urine output during the last 24 hr. Mice were anesthetized 
with isofluorothane after which their blood was removed by orbita extraction. Then, 
mice were killed by cervical dislocation and the kidneys rapidly removed. One kidney 
was processed for immunohistochemistry, whereas the other kidney was used for 
immunoblotting, both as described below. For immunoblotting, the tissue was
homogenized using a Polytron homogenizer (VWR international, Amsterdam, The 
Netherlands) in 1 ml of ice-cold homogenization buffer A (20 mM Tris, 5 mM MgCl2, 5 
mM Na2HPO4, 1 mM EDTA, 80 mM sucrose and protease inhibitors (1 mM PMSF, 5 μg/
ml pepstatin A, 5 μg/ml leupeptin, and 5 μg/ml a-protinin) and cleared from nuclei and 
unbroken cells by centrifugation at 4000 x g for 15 min and diluted in Laemmli buffer 
to a final protein concentration of 1 μg/μl.
Determination of glomerular filtration rate using FITC-inulin.
To determine the glomerular filtration rate via the FITC-inulin clearance method (20, 21) 
we used mice as described above and these mice were also treated as before (n=8/
group). Four days after the start of the diet, minipumps (Model 2001, Alzet) containing
3% FITC inulin were subcutaneously implanted in the isofluorane-anesthetized mice.
At treatment days 9 and 10, mice were housed in metabolic cages and 24 hr urine was
collected in amber tubes at day 10. During this 24 hr, metabolic cages and urine
collection tubes were covered with aluminium foil to prevent exposure to light. Traces
of left FITC-inulin urine in metabolic cages were added to the collected urine by washing 
the cage with 5 mL of 500 mmol HEPES buffer. On day 10, mice were anesthetized with 
isofluorane, blood was collected by retro-orbital bleeding and mice were killed by 
cervical dislocation. Urine fluorescence was determined using a Cytofluor II 
fluorescence multi-well plate reader (PerSeptive Biosystems, Framingham, MA, USA)
with 485 nm excitation and 538 nm emission. The excretion rate of inulin (24 hr urinary 
fluorescence counts/plasma fluorescence counts per ml) was taken as the GFR.
Blood and urine analysis
Whole blood was analyzed immediately for sodium, potassium, hematocrit, and pH
using the EG7+ cartridge and the I-Stat Clinical Analyzer (Abbott BV, Hoofddorp, The 
Netherlands). The remaining blood was collected in a BD microtainer SST tube (REF 
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#365968, Becton Dickinson BV, Breda, The Netherlands) for serum and centrifuged at 
10.000 x g for 3 min to sediment the red blood cells. Serum and urine samples were 
analyzed for osmolality using an osmometer (Fiske, Needham Heights, MA), and
electrolyte concentrations were measured on a Synchron CX5 analyzer (Beckman 
Coulter, Brea, CA), following the manufacturer’s protocols. Urine PGE2 levels were
determined by measuring stable PGE2 metabolite (PGEM) after chemical derivation of 
PGE2 and its primary metabolites, 13,14-dihydro-15-keto PGE2 and 13,14-dihydro-15-
keto PGA2, to the single PGEM compound. PGEM concentrations were determined
with the prostaglandin E metabolite EIA kit (Cayman Chemical Company, Ann Arbor, 
MI, USA) according to the manufacturer’s instructions.
Immunoblotting
MpkCCD cells from 1.13 cm2 filters were lysed in 200 μl Laemmli buffer and sonicated.
MpkCCD lysate and 5-10 μg kidney material in Laemmli were denatured for 30 min at 
37°C. Protein concentration was determined using the BioRad protein assay (Bio-Rad
Laboratories GmbH, München, Germany), according to manufacturer’s instructions.
SDS-PAGE, blotting and blocking of the PVDF membranes were done as described
(22). Membranes were incubated for 16 hr at 4°C with 1:2000 affinity-purified rabbit 
pre-c-tail AQP2 antibody recognizing aa 236-255,(23) in Tris-Buffered Saline Tween-20
(TBS-T) supplemented with 1% non-fat dried milk. In an identical way, other blots were 
incubated with a rabbit CA12 antibody (kind gift from Prof. William S. Sly, Saint Louis
University School of Medicine, St. Louis, MO, USA) and a rabbit CA2 antibody (Abcam,
Cambridge, UK). After washing in TBS-T, all blots were incubated for 1 hr with
1:5000-diluted goat anti-rabbit IgG’s (Sigma, St. Louis, MO) as secondary antibody 
coupled to horseradish peroxidase. Proteins were visualized using enhanced chemilu-
minescence (ECL, Pierce, Rockford, IL). Densitrometric analyses were performed using 
Biorad quantification equipment (Bio-Rad 690c densitometer, Chemidoc XRS) and 
software (QuantityOne, Bio-Rad Laboratories GmbH, München, Germany). Equal 
loading of the samples was confirmed by staining of the blots with Coomassie blue.
Immunohistochemistry
Kidneys were fixed by immersion for 24h in 4% paraformaldehyde in 0.1M phosphate 
buffer at 4°C, embedded in paraffin and cut into 3-4 μm-thick sections. After de-paraf-
finization, sections were placed into a microwave oven and heated for 10 minutes at
98°C in 0.01 M sodium-citrate buffer (pH 6.0) for antigen retrieval. Subsequently,
sections were incubated overnight at 4°C with 1:80000-diluted rabbit polyclonal AQP2 
antibodies or 1:2000-diluted rabbit polyclonal H+-ATPase antibodies as described
(24, 25). The bound primary antibodies were revealed with Cy3-coupled goat-anti 
rabbit IgG (Jackson ImmunoResearch Laboratories, PA, USA). To check for unspecific 
binding of primary or secondary antibodies, incubations with non immune sera or 
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 53
Acetazolamide attenuates Lithium-Induced Nephrogenic Diabetes Insipidus | 53
without any primary antibodies were performed. All control experiments were 
negative. Cryosections were studied by epifluorescence using a Leica microscope 
(Wetzlar, Germany). Connecting tubules and cortical collecting ducts were 
distinguished based on their specific localization in the cortical labyrinth and the 
medullary rays, respectively. Images were acquired with a charge-coupled device 
camera. For overviews, single images were taken with the automated scanning mode 
of the microscope and afterwards stitched using the Leica Application Suite. Digital 
images were processed electronically with Adobe Photoshop and Microsoft Powerpoint 
software. Adjustments for brightness and contrast were kept constant for each kidney 
section.
Statistics 
One-way ANOVA with Bonferroni correction was applied. A p value of less than 0.05
was considered significant. Data are presented as mean and standard error of the 
mean (SEM).
Study approval
All animal studies (DEC nr 2011-010) were approved by the Animal Ethical Committee 
of the Radboud University Medical Center.
Results 
The clinically used drug acetazolamide attenuates lithium-induced 
downregulation of AQP2 in mpkCCD cells
MpkCCD cells are mouse collecting duct cells showing dDAVP-dependent expression 
of endogenous AQP2 and we have shown that thiazide reduces lithium-induced 
downregulation of AQP2 in these cells, while they lack NCC expression (7, 11, 14). As 
our previous animal studies suggested that thiazides reduced polyuria in our NCC
knockout mice by inhibiting CAs, we wanted to test whether acetazolamide, a stable 
CA inhibitor and commonly used in patients, could also rescue lithium-induced AQP2 
downregulation in mpkCCD cells. Indeed, whereas lithium again reduced the AQP2 
abundance in mpkCCD cells, acetazolamide significantly attenuated this down-
regulation (Fig. 1A, B). As our data suggest that both thiazide and acetazolamide 
influence lithium-reduced AQP2 abundances through CAs, we assessed whether the 
action mechanism of acetazolamide differs from that of amiloride. If so, we anticipated
that acetazolamide and amiloride together should attenuate the lithium-induced AQP2 
downregulation better than cells treated with amiloride only. Indeed, immunoblotting 
revealed a significantly higher AQP2 abundance in cells treated with amiloride and
acetazolamide as compared to amiloride only (Fig. 1C, D). Others and we discovered 
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that ENaC is the main cellular entry site for lithium and that amiloride strongly reduced
the intracellular lithium levels in mpkCCD cells (11, 14). Determination of the intracellular 
lithium concentrations revealed that amiloride indeed reduced the intracellular lithium 
concentration with 87%, while this was only 30% with acetazolamide (Fig. 1E). 
The mean intracellular lithium concentration was nominally lower with amiloride/
acetazolamide; however, there was no significant difference (p=0.23). Transcellular 
transport of sodium and potassium via ENaC, ROMK and the Na/K-ATPase is 
electrogenic and therefore generates a transcellular voltage (Tv) over mpkCCD cell
monolayers. Lithium slightly reduced the Tv, which was not further decreased with 
acetazolamide (Fig. 1F). In contrast, amiloride completely blocked the Tv in lithium-
treated mpkCCD cells. Together, these data reveal that the CA-specific inhibitor 
acetazolamide attenuates lithium-induced downregulation of AQP2 in vitro and that
its mechanism of action is different from that of amiloride.
Acetazolamide attenuates development of lithium-induced NDI in mice
To investigate whether acetazolamide attenuates development of Li-NDI, mice were
maintained on lithium chow only or on lithium combined with acetazolamide or 
thiazide/amiloride for 10 days. As reported (11, 26), mice treated with lithium developed
severe polyuria and polydipsia, combined with a significantly-reduced urine osmolality 
(Fig. 2A-C). Interestingly, acetazolamide treatment induced a significant antidiuresis
and increase in urine osmolality, which was slightly, but not significantly, better than
in mice treated with thiazide/amiloride. Consistent with the induced antidiuresis, water 
intake was significantly reduced with the acetazolamide treatment as compared to 
lithium only.
As long-term lithium treatment coincides with reduced AQP2 and increased H+-ATPase 
abundance in the kidney (6), we also analyzed their abundances. Immunoblot analysis 
revealed that lithium reduced AQP2 abundance (Fig. 3A, B), which was significantly 
attenuated by both acetazolamide and thiazide/amiloride (Figs. 3A-D). With 
acetazolamide or thiazide/amiloride, however, AQP2 levels did not return to control 
levels. H+-ATPase levels were similar for all groups (Supplementary Figs. 1A-D), which 
is in line with the notion that lithium-induced collecting duct remodeling is not present 
after 10 days of lithium treatment in rodents (9, 26).
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Figure 1. Acetazolamide reduces lithium-induced downregulation of AQP2 abundance in
mpkCCD cells. Native mpkCCD cells were grown to confluence for 4 days and subsequently 
exposed to 1 nM dDAVP for another 4 days. During the last 2 days, cells were incubated in the 
absence (Ctr) or presence of lithium only (Li+) or with lithium and 100 μM acetazolamide (Acz),
10 μM amiloride (Am), 100 μM hydrochlorothiazide and amiloride (T+Am) or amiloride and 
acetazolamide (Am+Acz). At the basolateral and apical side, final concentrations of 1 and 10 mM 
lithium were used, respectively. Following measurements of transcellular voltage (F), cells were
lysed and subjected to AQP2 immunoblotting (A, C). Molecular masses (in kDa) are indicated. 
The signals for non-glycosylated (29 kDa) and complex-glycosylated (40-45 kDa) AQP2 were 
densitometrically quantified (B, D). Mean values +/- SEM of normalized AQP2 abundance are
given relative to control. (E) Intracellular lithium concentrations were determined, which were
corrected for contamination with extracellular lithium and normalized for the amount of protein 
([Li+] +/- SEM in pmol/μg protein). Data from 3 independent experiments, one way ANOVA,
Bonferroni’s Multiple Comparison Test, *p<0.05.
A
B
E
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To examine segment-specific effects of the different therapies on AQP2 abundance, 
immunohistochemistry was performed. Consistent with our immunoblot data, lithium
treatment strongly reduced AQP2 staining, which was clearly attenuated in kidneys
of mice treated with lithium and acetazolamide or thiazide/amiloride (Fig. 3E). 
Interestingly, while lithium abolished AQP2 expression in the entire kidney, the 
increased AQP2 abundance in the thiazide/amiloride treated group mainly localized
to the inner medulla of the kidney, whereas in the acetazolamide treated mice, 
AQP2 abundance was increased along the connecting tubule and entire collecting 
duct. Consistent with our immunoblot data, immunohistochemistry revealed no clear 
changes in H+-ATPase labeling between the different groups (Supplementary Fig. 2). 
Acetazolamide shows an improved overall electrolyte balance over 
thiazide/amiloride. 
Some patients on thiazide/amiloride therapy have been reported to develop hypo- 
natremia, hyperkalemia, metabolic acidosis and/or hypercalcemia (27-30). Moreover,
initiating thiazide/amiloride treatment in Li-NDI patients often leads to elevated blood
lithium levels, necessitating adjustment of the lithium dose (31). Therefore, to assess
and compare the effect of acetazolamide and thiazide/amiloride on these parameters,
we analyzed blood and urine for lithium and electrolyte levels (Table 1). Indeed,
while mice treated with thiazide/amiloride had a reduced bodyweight and developed
hyponatremia, hyperkalemia, and a metabolic acidosis, these parameters were not
affected in acetazolamide-treated mice. Also, thiazide/amiloride treatment induced
Figure 2. The antidiuretic effect of thiazide/amiloride and acetazolamide treatment on 
lithium-treated mice. Urine volume (A), water intake (B) and urine osmolality (C) of untreated
mice (CTR) or of mice treated for 10 days with lithium (Li+) or in combination with thiazide/
amiloride (T+Am) or acetazolamide (Acz). During the last 48 hr mice were housed in metabolic
cages and during the last 24 hr water intake was measured and urine was collected to determine 
urine volume and osmolality. n=8 mice/group, one way ANOVA, Bonferroni’s Multiple
Comparison Test, *p<0.05.
A B C
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Figure 3. Thiazide/amiloride and acetazolamide reduce lithium-induced downregulation of 
AQP2 in lithium-NDI mice. (A-D) Immunoblot and corresponding densitometric analysis of 
AQP2 of mouse kidneys that are untreated (Ctr), treated with lithium only (Li+) or with lithium 
together with acetazolamide (Acz) or thiazide/amiloride (T+Am). The signals for AQP2 densito-
metrically quantified (B and D). Mean values +/- SEM of normalized AQP2 abundance is given 
relative to control. Asterisks indicate significant differences (p<0.05) from controls. Equal 
loading of the samples was confirmed by staining of the blots with coomassie blue (Cm). One 
way ANOVA, Bonferroni’s Multiple Comparison Test, *p<0.05. (E) Paraffin sections of immer-
sion-fixed kidneys from control (Ctr; A, E, I), lithium-treated (Li+; B, F, J), lithium/amiloride/thia-
zide-treated (Li+ + T + Am; C, G, K), and lithium/acetazolamide-treated mice (Li+ + Acz; D, H, L) 
were incubated with a rabbit polyclonal AQP2 antibody followed by a Cy3-coupled goat-anti 
rabbit IgG. Overviews (A-D) and high magnifications of representative connecting tubules (CNT; 
E-H), and cortical collecting ducts (CCD; I-L).
A
C
E
B
D
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hypercalcemia, which was significantly reduced with acetazolamide, although not to
control levels. Moreover, and consistent with patients, serum lithium concentrations were 
significantly increased in our thiazide/amiloride mice, but were unchanged in our 
acetazolamide mice as compared to lithium controls. 
The antidiuretic effect of acetazolamide coincides with a lowered GFR and 
a reduced prostaglandin E2 release
Paradoxically, the clear antidiuresis found in our acetazolamide group (Figs. 2A-C)
coincided with a significantly-increased creatinine clearance (Fig. 4A). However, as the 
creatinine clearance in especially mice highly depends on both creatinine secretion
and reabsorption in the proximal tubule, the segment mainly influenced by 
acetazolamide (32, 33), we hypothesized that acetazolamide may affect proximal
tubular creatinine reabsorption/secretion in our mice and thus that the creatinine 
Supplementary ﬁgure 1. Effect thiazide/amiloride and H+-ATPase abundance in lithium-NDI
mice. (A-D) Immunoblot and corresponding densitometric analysis of H+-ATPase abundance of 
mice that are untreated (Ctr), treated with lithium only (Li+) or with lithium together with 
acetazolamide (Acz) or thiazide/amiloride (T+Am). The signals for H+-ATPase were densitomet-
rically quantified (B and D). Mean values +/- SEM of normalized H+-ATPase abundance is given
relative to control. Asterisks indicate significant differences (p<0.05) from controls. Equal 
loading of the samples was confirmed by staining of the blots with coomassie blue (Cm).
A
C
B
D
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clearance did not properly reflect the GFR. Therefore we used FITC-inulin to determine 
the GFR in an identically-performed animal experiment. While acetazolamide again
significantly attenuated Li-NDI (not shown), the clearance of FITC-inulin was significantly 
reduced with acetazolamide (Fig. 4B), indicating that acetazolamide reduced the GFR. 
Urinary prostaglandin E2 (PGE2), which extensively contributes to AQP2 downregulation 
in Li-NDI(34), was significantly increased in our Li-NDI mice, but was fully attenuated 
in our mice treated with lithium/acetazolamide (Fig. 4C). Moreover and consistent with
its CA inhibitory action in proximal tubules, acetazolamide further increased urinary
pH (Fig. 4D) and strongly reduced the abundance of NHE3 in the renal cortex as 
compared the cortex of mice treated with lithium only (Fig. 4E, F).
Supplementary ﬁgure 2. Expression and distribution of H+-ATPase in kidneys of lithium-NDI 
mice treated with thiazide/amiloride or ACZ. Paraffin sections of immersion-fixed kidneys 
from control (Ctr; A, E, I), lithium-treated (Li+; B, F, J), lithium/amiloride/thiazide-treated (Li+ + T 
+ Am; C, G, K), and lithium/ACZ-treated mice (Li+ + Acz; D, H, L) were incubated with a rabbit 
polyclonal H+-ATPase antibody followed by a Cy3-coupled goat-anti rabbit IgG. Overviews (A-D)
and high magnifications of representative connecting tubules (CNT; E-H), and cortical collecting 
ducts (CCD; I-L).
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Table 1. Metabolic parameters of mice treated for 10 days with standard chow 
only (Ctr) or together with lithium (Li+), lithium + thiazide + amiloride
(Li+ + T + Am), or lithium + acetazolamide (Li+ + Acz).
Ctr Li+ Li+ + Am + T Li+ + Acz
Serum Osmolality (mOsm/kg) 320 ± 1 319 ± 1 311 ± 0.5** 321 ± 3 †
Serum Sodium (mmol/l) 150 ± 0.3 149 ± 0.4 139 ± 0.8** 150 ± 0.5†
Serum Potassium (mmol/l) 5.3 ± 0.1 5.6 ± 0.2 7.6 ± 0.5** 5.4 ± 0.2†
Serum Lithium (mmol/l) / 0.63 ± 0.04* 2.11 ± 0.12** 0.69 ± 0.04†
Serum Creatinine (mg/dl) 0.08 ± 0.01 0.09 ± 0.00 0.06 ± 0.01** 0.04 ± 0.01**/†
Blood Ionized Calcium (mmol/l) 1.24 ± 0.00 1.32 ± 0.01* 1.34 ± 0.01 1.27 ± 0.01**/†
Blood pH 7.34 ± 0.01 7.32 ± 0.01 7.24 ± 0.02** 7.35 ± 0.02†
Urine sodium (mmol/l) 352 ± 40 46 ± 6* 484 ± 68 ** 112 ± 12†
Urine potassium (mmol/l) 870 ± 83 131 ± 15* 154 ± 19 271 ± 31**/†
Urine lithium (mmol/l) / 20 ± 3* 24 ± 3 38 ± 8
Urine Creatinine (mg/dl) 70 ± 7 10 ± 1* 14 ± 2 18 ± 2**
Total sodium excretion
(mmol/24 hr)
0.17 ± 0.02 0.16 ± 0.01 1.26 ± 0.12** 0.22 ± 0.02†
Total potassium excretion
(mmol/24 hr)
0.42 ± 0.05 0.55 ± 0.02* 0.40 ± 0.03** 0.54 ± 0.05
Total lithium excretion (mmol/24
hr)
/ 84 ± 3* 64 ± 6 72 ± 11
Bodyweight (g) 18.9 ± 0.4 18.0 ± 0.2* 16.0 ± 0.5** 17.4 ± 0.4†
Food Intake (mg/g/24 hr) 214 ± 8 198 ± 10 188 ± 5 228 ± 5**/†
Feces Production (mg/g/24 hr) 111 ± 7 98 ± 8 82 ± 2 123 ± 9†
Li+, lithium; T, thiazide; Am, amiloride; Acz, acetazolamide.
Values are means ± s.e.m.
* P<0.05 compared to control treatment
** P<0.05 compared to lithium treatment
† P<0.05 compared to lithium/thiazide/amiloride treatment
/ Below detection limit
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 61
Acetazolamide attenuates Lithium-Induced Nephrogenic Diabetes Insipidus | 61
Discussion
Acetazolamide is superior to thiazide/amiloride to attenuate lithium-NDI
Our mouse studies revealed that acetazolamide attenuates development of Li-NDI to 
the same extent as thiazide/amiloride, but, in contrast to acetazolamide, our thiazide/
amiloride treated mice developed hyponatremia, hyperkalemia, and metabolic 
acidosis. In humans, hyponatremia is mostly a consequence of upregulated AQP2 
expression by high circulating AVP levels. Although AVP levels are elevated in Li-NDI,
this cannot explain hyponatremia in our thiazide/amiloride treated mice, because 
AQP2 is downregulated here. Instead, our data indicate that the hyponatremia is due
to the induced natriuresis caused by thiazide and amiloride in a status of polyuria and 
Figure 4. The effect of acetazolamide on urinary pH, NHE3 abundance, glomerular ﬁltration
rate and prostaglandin-E2 release. Mice were treated for 10 days with control diet (Ctr) or diet 
containing lithium (Li+) only or lithium in combination with acetazolamide (Acz). During the last
48 hr, mice were housed in metabolic cages and during the last 24 hr urine was collected to
determine creatinine clearance (A), PGE2 levels (C) and urinary pH (D). At day 10, mice were
sacrificed and blood and kidneys were isolated, enabling the analysis of renal NHE3 abundance
(E, F). In (E) the arrow indicates the ~85kDa band of NHE3. To measure GFR, using FITC-inulin,
the above-mentioned experiment was repeated, however at day 4 osmotic minipumps
containing FITC-inulin, were implanted and at day 10 FITC-inulin levels were measured in 24 hr 
urine and serum (B). n=8 mice/group, one way ANOVA, Bonferroni’s Multiple Comparison Test, 
*p<0.05.
A
D
B
E
C
F
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polydipsia, because our Li-NDI mice were normonatremic and our thiazide/amiloride
mice were highly natriuretic as compared to the other groups. Note, however, that part 
of the increased natriuresis must be due to an increased consumption of salt from the 
provided salt block, because food intake was not increased. The mice apparently
drank water to satiety, because the hematocrit was not different between the groups 
(not shown). Similarly, congenital NDI patients also sometimes develop hyponatremia 
when treated with thiazide combinations (35, 36).
The observed hyperkalemia is likely due to inhibition of ENaC by amiloride, as
renal secretion of potassium occurs only in exchange of ENaC-mediated sodium
reabsorption (37). Lithium itself can lead to metabolic acidosis (38), which would even
be increased with inhibition of bicarbonate uptake by acetazolamide, but we only 
found metabolic acidosis in our thiazide/amiloride treated mice. Whereas metabolic
acidosis in our acetazolamide group may have been compensated by increased 
ventilation, metabolic acidosis in the thiazide/amiloride group may be secondary to
the observed hyperkalemia, as mammals attenuate hyperkalemia at the expense of 
development of metabolic acidosis (39).
Our Li-NDI mice developed hypercalcemia, which was sustained in our thiazide/
amiloride treated mice, but not in our acetazolamide mice. Hyperparathyroidism is 
common with lithium-using patients and the occurrence of hypercalcemia in Li-NDI
has been ascribed to inhibition of calcium-sensing receptor signaling by lithium in the 
parathyroid (40-42). The corrected blood calcium levels with acetazolamide, however,
may be unrelated to the parathyroid effect of lithium, because plasma calcium is 
increased by bone resorption, a process that involves CA2 activity in osteoclast and
that is strongly inhibited by acetazolamide (43, 44).
Another important advantage of the use of acetazolamide over thiazide/amiloride is 
that plasma lithium concentrations remained unchanged with acetazolamide. Blood 
lithium is mainly set by the amount reabsorbed in proximal tubules, a process in which 
the apical NHE3 is highly involved and which is stimulated by thiazide (18, 45). 
Considering this, the unaltered blood lithium levels with acetazolamide is best
explained by combinatory effects of the reduced NHE3 abundance in proximal tubules 
and the reduced GFR. 
Acetazolamide attenuates Li-NDI by a dual mode of action
Our data indicate that the observed antidiuresis and reduced GFR with acetazolamide
is due to a tubular glomerular feedback (TGF) response caused by inhibition of CAs in
the proximal tubule (46, 47). Ninety percent of renal HCO3- is reabsorbed in proximal
tubules, which is strongly facilitated by CA4/14 (luminal/apical), CA2 (intracellular)
and CA4/12 (basolateral) hydrating CO2 and dehydrating H2CO3 (48). In this process, 
secretion of protons by NHE3 is important. By blocking these CA, acetazolamide
prevents the intracellular generation of H+, which is needed for NHE3 to reabsorb 
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filtered Na+ (49-52). The consequently increased tubular salt and water load in the
proximal tubule leads to an increased fluid delivery and tubular [Cl-] at the macula 
densa, which induces a TGF response (i.e. a reduced GFR) (47). Indeed, acetazolamide in our 
Li-NDI mice led to an increased urinary pH, reduced NHE3 abundance and reduced
GFR and are in agreement with reported data on NHE3 knockout mice (47, 50, 53).  
Besides intercalated cells (see below), the increased fluid delivery to the macula 
densa with acetazolamide may also partially explain the observed lower urinary levels 
of PGE2, thereby attenuating Li-NDI. By acting on EP1/3 receptors, increased urinary 
PGE2 levels in Li-NDI reduce principal cell AQP2 expression and thus water reabsorption 
(54). In Li-NDI, a fraction of the elevated urinary PGE2 levels is thought to be derived
from macula densa and surrounding cTAL cells, which produce PGE2 to increase renin
synthesis and release in response to a reduced fluid delivery to the TAL/hypovolemia. 
As such, the increased fluid delivery to the TAL with acetazolamide will reduce the 
cortical release of PGE2 and therewith Li-NDI.
However, our in vitro data indicate that acetazolamide also directly protects collecting
duct cells from lithium, but it is at present unclear whether in vivo acetazolamide acts 
directly on principal cells or indirectly via intercalated cells. Support for the first is that
mpkCCD cells endogenously express and show proper regulation of the typical 
principal cell proteins, AQP2 and ENaC. Moreover, mpkCCD cells express high CA2
mRNA levels (http://esbl.nhlbi.nih.gov/mpkCCD-transcriptome/), which is also 
expressed in principal cells in vivo (48, 55-57). Also, the in vivo activity of ENaC, the 
lithium entry site of principal cells, has been reported to be functionally paired with CA 
activity, as, CA inhibition by acetazolamide reduced the intracellular pH and reduced 
ENaC activity in sweat duct cells and colon (58, 59).
However, mpkCCD cells may not fully represent principal cells and, as intercalated 
cells express abundant levels of CAs 2, 4, 12, and 15 (48), acetazolamide may increase
principal cell AQP2 expression and water uptake indirectly by inhibiting ACs in 
intercalated cells. Indeed, long-term lithium treatment leads to metabolic acidosis,
which underlies the increased number of т-intercalated cells (11, 60) and, as lithium
inhibits intercalated cell H+-ATPase and H+/K+-ATPase activity (61, 62), it has been 
suggested that acidosis-induced proliferation of т-intercalated cells may contribute to 
Li-NDI (26). It is unlikely, however, that attenuation of Li-NDI in our mice is due to direct 
action of acetazolamide on т-intercalated cells or collecting duct remodeling for 
several reasons: At first, acetazolamide increases the number of т-intercalated cells in
rodents, as it causes acidosis itself (63, 64). Secondly and consistent with the
unchanged H+-ATPase expression in our mice, collecting duct remodeling is not
observed with 10 days of lithium treatment, but only starts at about 4 weeks of 
treatment (9, 65).
An effect of acetazolamide on у-intercalated cells, however, may be more likely. While
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lithium treatment did not reduce the number of these cells (66), exciting recent studies 
revealed the existence of extensive cross-talk between ʹ-intercalated and principal 
cells in the regulating collecting duct function (67-70). While Eladari et al elegantly 
showed that in rodents, the sodium-dependent chloride bicarbonate exchanger 
(NDCBE/SLC4a8) and chloride bicarbonate exchanger protein pendrin allow for NaCl 
reabsorption through у-intercalated cells, chloride permeation through pendrin also 
appeared necessary for ENaC mediated sodium reabsorption and expression (71).
Also, in mice lacking functional intercalated cell-specific H+-ATPase, the observed 
natriuresis and aquaresis was due to dysfunctional and lower abundances of ENaC 
and pendrin/NDCBE, and reduced AQP2 levels, respectively (69). The authors further 
showed that the lack/inhibition of ʹ-intercalated cells H+-ATPase led, via flow-
stimulated luminal ATP release, to autocrine and paracrine release of PGE2, which 
reduced the cortical and medullary ENaC activity and AQP2 abundance. Importantly, 
thiazides inhibited NCC-independent NaCl reabsorption through NDCBE/pendrin (68)
and acetazolamide reduced pendrin abundance(72), drugs we showed to attenuate 
Li-induced downregulation of AQP2 and Li-NDI through a similar mechanism. As such,
the attenuated Li-NDI with acetazolamide, which was given during the entire lithium 
treatment, may be due to an impaired functioning of pendrin, resulting in increased
ATP/PGE2 release, reduced ENaC activity in principal cells, and thus reduced influx of 
lithium from pro-urine. The finding that acetazolamide is beneficial chiefly in the 
cortical segments that contain intercalated cells is consistent with the possibility that 
intercalated cell CAs could be involved. A prime candidate here is CA12, as it is highly
sensitive to acetazolamide and patients with reduced CA12 activity have a 
preponderance to hyponatremic dehydration (73). Whether one of these mechanisms
underlies the beneficial effect of acetazolamide in Li-NDI remains to be studied.
Taken together, we have shown that CAs activity contributes to Li-NDI development,
that acetazolamide attenuates lithium-induced NDI by inducing a TGF response and
through a direct action on the collecting duct, and that acetazolamide attenuates
Li-NDI development similar to thiazide/amiloride but with less side effects.
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Abstract
Lithium, given to bipolar disorder patients, causes nephrogenic diabetes insipidus 
(Li-NDI), a urinary concentrating defect. Li-NDI is due to downregulation of principal
cell AQP2 expression, which coincides with principal cell proliferation. The metabolic 
effect of lithium on principal cells, however, is unknown and investigated here.  Earlier, 
we have shown that the carbonic anhydrase (CA) inhibitor acetazolamide attenuated 
Li-induced downregulation in mouse collecting duct (mpkCCD) cells. Of the eight CAs
present in mpkCCD cells, siRNA and drug treatments showed that downregulation of 
CA9 and to some extent CA12 attenuated Li-induced AQP2 downregulation. Moreover, 
lithium induced cell proliferation and increased the secretion of lactate. Lithium also 
increased urinary lactate levels in wildtype mice that developed Li-NDI, but not in 
lithium-treated mice lacking ENaC, the principal cell entry site for lithium. Inhibition 
of aerobic glycolysis with 2-deoxyglucose (2DG) attenuated lithium-induced AQP2 
downregulation in mpkCCD cells, but did not attenuate Li-NDI in mice. Interestingly, 
NMR analysis demonstrated that lithium also increased the urinary succinate, 
fumarate, citrate, and NH4+ levels, which were, in contrast to lactate, not decreased by 
2DG. Together, our data reveal that lithium induces aerobic glycolysis and glutaminolysis 
in principal cells and that inhibition of aerobic glycolysis, but not the glutaminolysis, 
does not attenuate Li-NDI.
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Introduction 
Lithium is the first-choice medication for treatment of bipolar disorder and is frequently 
given to patients with depression (1). This drug is taken by 0.1% of the western 
population and its use is expected to increase as it is also tested as a treatment for 
other neurological disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s (2). In
approximately 50% of treated patients, however, lithium causes a urine concentrating
defect, which develops in 20% of patients into symptomatic Nephrogenic Diabetes 
Insipidus (NDI), a disorder characterized by polyuria and polydipsia due to the 
downregulation of aquaporin-2 (AQP2) water channels in the principal cells of the 
collecting duct (3-5). Lithium also alters the cellular composition of the collecting duct,
as it increases the fraction of type-A intercalated cells and lowers the fraction of 
principal cells (4, 6). Despite the fact that the fraction of principal cells in the collecting
duct decreases compared to the fraction of intercalated cells, lithium treatment results
in principal cells that are in the proliferative state, as they were positive for proliferating 
cell nuclear antigen (PCNA), a marker for cell proliferation (7). It is however questionable
whether these PCNA-positive cells are actually dividing, as we found that lithium 
induces a G2/M cell cycle arrest, which partly explains the discrepancy between the
reduced percentage of principal cells while being positive for PCNA (8).
Recently, we found that the carbonic anhydrase (CA) inhibitor acetazolamide attenuated 
AQP2 downregulation in mouse collecting duct (mpkCCD) cells and in mice treated 
with lithium, which coincided with a reduced Li-NDI (9). To understand its mechanism, 
we here analyzed the CA involved, which indicated that lithium induces aerobic 
glycolysis in principal cells. Differentiated cells, such as principal cells, generate their 
energy primarily via mitochondrial oxidative phosphorylation in which biomolecules 
and ATP are produced from glucose and in which oxygen is required (10)’. However, 
proliferating cells, including tumors, often generate their energy by a process called 
“aerobic glycolysis”, also known as the Warburg effect, which takes place regardless 
of tissue oxygen levels. Although this process is an inefficient way to generate ATP, 
it allows the synthesis of biomolecules such as nucleotides, amino acids, and lipids
that are required to build the new cells (10). Aerobic glycolysis is characterized by an 
increase in lactate production (10). As principal cells are in a proliferative state when 
treated with lithium, we here subsequently investigated whether lithium induces 
aerobic glycolysis in collecting duct principal cells and, if so, whether inhibition of 
aerobic glycolysis attenuates Li-NDI.
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Materials and methods
Animal experiments
Animal experiments were performed as described (8). Female C57BL/6 mice were
obtained from The Jackson Laboratory (Bar Harbor, USA). Collecting duct-specific 
epithelial sodium channel knockout (NMR16J ENaC-KO) mice (11) were kindly provided 
by Edith Hummler, Lausanne, Switzerland and crossed with C57BL/6 mice, obtained 
from Harlan Laboratories (Horst, the Netherlands). Male ENaC-KO mice and their 
wild-type (WT) littermates were used for the experiments. Mice were housed in a cli-
mate-controlled facility with a 12-hour:12-hour light-dark cycle. All mice had free
access to rodent diet (7013, NIH-31 Modified, Harlan Laboratories, Inc., Madison, WI,
USA), acidified water and a sodium chloride block throughout the experiment. At 10
weeks of age, one group of mice received normal rodent diet, while the other mice 
received the same diet supplemented with 40 mmol lithium chloride (LiCl)/kg food or 
LiCl diet with twice daily IP injection with 250 mg/kg BW 2-Deoxy-D-glucose in saline
for 10 days (8). During the last 48 hours of an experiment, mice were housed in 
metabolic cages in order to measure water intake and urine output during the last 24 
hours. Next, mice were anesthetized with isoflurane and euthanized by cervical 
dislocation, after which the kidneys were removed. All animal studies were approved
by the Animal Ethical Committee of the Radboud University Medical Center and by The 
Jackson Laboratory’s Animal Care and Use Committee.
1H NMR Spectroscopy 
One-dimensional 1H NMR spectroscopy was performed as described (12). 24h Urine 
was centrifuged 10 minutes at 3000xg before analysis. A small volume of 20 μL of 20.2
mM trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP, sodium salt; Aldrich) in D2O 
was added to 700 μL of the urine to serve as an internal quantity reference for 
subsequent handlings. The pH of each sample was adjusted to 2.50 ± 0.05 with 
concentrated HCl. Finally, 650 μL of the sample was placed in a 5 mm NMR tube 
(Wilmad Royal Imperial; Wilmad LabGlass, USA). 1H NMR spectra were obtained using
a Bruker 500 MHz spectrometer (pulse angle, 90°; delay time, 4 s; number of scans, 
256). Water resonance was suppressed by gated irradiation centered on the water 
frequency. The spectral width in the F1 and F2 domains was 5500 Hz. A total of 2K data
points were collected in t2, 256 t1 increments with 32 transients per increment were
used. The relaxation delay was set to 2 seconds. Before the Fourier transformation, a
sine-bell function was applied in both time domains. During the relaxation delay, the
water resonance was pre-saturated.
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The free-induction decays measured for these samples were processed using Topspin
software (Bruker BioSpin, Rheinstetten, Germany). Fourier transformation was applied
on the free-induction decay of the samples and the resulting spectra were phase and 
baseline corrected. The chemical shifts in the spectra were referenced to the internal
standard, TSP. Assignment of peak positions for compound identification was 
performed by comparing the peak positions in the spectra of the metabolites with the 
reference spectral database of model compounds at pH 2.5 using Amix version 3.9.14 
(Bruker BioSpin, Rheinstetten, Germany). Quantification of identified compounds was 
performed by manual integration of chosen peak(s) for a specific metabolite. 
Cell culture assays
MpkCCD cells were cultured as described (4). In short, cells were cultured in a modified 
defined medium containing DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate,
5 μg/ml transferrin, 2 mM glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 
10 ng/ml epidermal growth factor (EGF), 5 μg/ml insulin, 28 mM D-glucose, 2% fetal 
calf serum (FCS), and 20 mM HEPES (pH 7.4). Cells were seeded at a density of 1.5x105
cells/cm2 on semi permeable filters (Transwell, 0.4 μm pore size, Corning Costar, 
Cambridge, MA). After 96 hours, cells were treated with 1 nM 1-deamino-8-D-arginine 
vasopressin (dDAVP) at the basolateral side to induce AQP2 expression. For the last 
48 hours, cells were cultured in a FCS/EGF-free medium and treated with or without 
1 mM LiCl at the basolateral side and 10 mM LiCl at the apical side in the presence or 
absence of 10 μM 6- and 7-hydroxycoumarin (6HC and 7HC) , 10 μM amiloride or 1 mM 
2-deoxy-d-glucose (2DG). To determine the cell viability and extent of transcellular 
sodium transport, Trans Epithelial Electrical Resistance (TEER) and transcellular 
voltage (Tv) were measured on day 8. Next, cells were harvested and prepared for 
immunoblotting as described (4). The concentrations of 2DG, 6HC and 7HC were
determined experimentally by testing concentrating series on mpkCCD cells that were 
cultured as described above. For siRNA knockdown in mpkCCD cells, siGENOME 
SMARTpool (Thermo Fisher Scientific, Lafayette, CO, USA) siRNAs were obtained 
against the indicated mouse carbonic anhydrases (CAs) and a scrambled non-targeting 
siRNA as a control. The SMARTpool siRNA consists of a mixture of 4 siRNA provided as 
a single reagent and have been shown in large scale siRNA screens to have high 
potency and specificity to silence the target gene (13, 14). The cells were seeded at 
1.5*105 cells/cm2 on 24-well (0.33 cm²) semi-permeable filters (Costar Corning
Transwell®, 0.4 μm pore size) and transfected with 20 pmol siRNA, combined with 1 μl 
Metafectene Pro (Biontex, Martinsried, Germany) at day 1. For the last 72 hours, 1 nM
dDAVP was added to the medium at the basolateral side, while cells were treated with 
lithium for the last 48 hours as describe above. After 4 days, cells were harvested and 
prepared for immunoblotting. Of note: we found that mpkCCD cells are best transfected 
before seeding and that the ability of siRNAs to knockdown mRNAs in mpkCCD cells 
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 76
76 | Chapter 4
only last about 4 days. Therefore, to allow determination of the effect of siRNAs,
mpkCCD cells had to be analysed for AQP2 at 4 days following seeding/transfection, at
which they are less polarized and thus express less AQP2.  Consequently, lithium
induced downregulation of AQP2 is less prominent in siRNA experiments compared to
our standard protocol in which we culture these cells for 8 days.
RT-PCR.
MpkCCD cells were grown as described (15). Total RNA was isolated using TriZol 
extraction reagent (Gibco BRL, Life Technologies, Rockville, USA), according to the
manufacturer’s instructions. To remove potentially contaminating DNA, total RNA was 
treated with DNase (Promega, Madison, USA) in DNase buffer, incubated for 1 hr. at 37
°C, extracted with phenol/chloroform and precipitated using sodium acetate (3M, pH
5.2) and100% ethanol. 1.5 μg RNA was reverse-transcribed into cDNA using MMLV
Reverse Transcriptase (RT, Invitrogen, Carlsbad, USA) and random primers. A control
reaction using H2O instead of MMLV RT was conducted to exclude amplification of 
genomic DNA.
Intron-spanning primers were designed using primer3 primer design software on 
mouse cDNA sequences (table 1), see http://frodo.wi.mit.edu/primer3/ (16). Amplification
of the proper fragments with the designed primers was verified by amplification of 
mouse cDNA from brain tissue (as indicated in table 1) as a positive control.
Amplification was performed using the cDNA equivalent of 5 ng of RNA in a total 
volume of 50 μL for 40 cycles (95°C 45 sec, 50°C 1 min, 72°C 1.30 min). DNA was 
separated through agarose gel electrophoresis and visualized using ethidium bromide.
Biochemical analyses
To determine the lactate concentration of apical cell culture medium and urine 
samples, the Amplex® Red Glucose/Oxidase Assay Kit (Thermo Fisher scientific,
Massachusetts, USA) was used according to the manufacturer’s instructions, but 
adapted to measure lactate concentrations as described (17). Cell culture medium was
refreshed an hour prior to the collection of the media. Urinary ammonium was
determined using a Pointe Scientific kit (A7553; Canton, USA) modified for small
volumes as described (18).
Cell surface biotinylation
Cell surface biotinylation was done as described (19). In short, mpkCCD cells were
cultured in Transwells and treated with drugs as described above, incubated for 30 
minutes at 4°C with 0.5 mg/ml sulfo-NHS-LC-LC-biotin (Pierce, Rockford, USA) diluted
in PBS-CM (Phosphate buffered saline with 1 mM MgCl2 and 0,5 mM CaCl2) at the 
apical side of the cells, lysed (lysis buffer: 150 mM NaCl, 5 mM EDTA, 50 mM Tris (pH
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7.5), 1% triton X-100), and incubated overnight with neutravidin-agarose beads (Pierce,
Rockford, USA) to isolate cell surface biotinylated proteins. After washing of the beads 
with lysis buffer, proteins were eluted and denatured in Laemmli buffer, and 
immunoblotted.
Immunoblotting 
Laemmli samples were denatured for 30 minutes at 37°C. SDS-PAGE, blotting, and 
blocking of the PVDF membranes was done as described (20). Membranes were 
incubated for 16 hours at 4°C with 1:1000 affinity–purified rabbit (Rb2) C tail AQP2 
antibody in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% nonfat dried
milk (21). In an identical way, other blots were incubated with 1:1000 rabbit CA12 
antibody (kind gift from Prof. William S. Sly, Saint Louis University School of Medicine, 
St. Louis, MO, USA) and a rabbit CA2 antibody (Abcam, Cambridge, UK) and Cyclin D1
(Rabbit; cell signaling, Massachusetts, USA). After washing in TBS-T, all blots were 
incubated for 1 hour in TBS-T containing 1:10000-diluted goat anti–rabbit IgGs (Sigma-
Aldrich, St. Louis, USA) coupled to horseradish peroxidase. Proteins were visualized 
using enhanced chemiluminescence (ECL; Pierce, Rockford, USA). Densitrometric 
analyses were performed using Bio-Rad quantification equipment (Bio-Rad 690c 
Densitometer; Chemidoc XRS) and Image studio software (LI-COR, Nebraska, USA). 
Equal loading of the samples was confirmed by staining of the blots with coomassie 
brilliant blue R-250 (BioRad, Hercules, USA).
Immunocytochemistry
Immunocytochemistry was done as described (22). In short, after removal of culture 
medium, mpkCCD cells were washed 3 times with ice-cold PBS-CM and fixed for 30 
min at room temperature with 4% w/v paraformaldehyde in PBS. After washing twice
with PBS, cells were treated with a permeabilization buffer (0.5% v/v Triton X-100 and 
in PBS with 0.7% w/v gelatin) for 30 min. Then, cells were incubated at 4°C overnight
with AQP2 (Rb2 1:50; (21)) primary antibody in permeabilization buffer. After 3 washing 
steps, cells were incubated with anti-rabbit secondary antibody conjugated to an
Alexa dye (Invitrogen, 1:500) for 2-3 hours at 37°C. Finally, cells were mounted in 
Vectashield containing DAPI (Vector Laboratories, Burlingame, USA) and imaged by 
confocal microscopy (Olympus FV1000, Center Valley, PA, USA).
Statistical analysis
Analysis of the difference between groups was performed with student t-test or 
one-way ANOVA corrected by the Bonferroni multiple-comparisons procedure. A 
p-value <0.05 was considered statistically significant.
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Results
Inhibition of CA 9/12 attenuates lithium-induced AQP2 downregulation
in mpkCCD cells
Recently, we have shown that acetazolamide, a specific carbonic anhydrase (CA)
inhibitor, attenuated lithium-induced AQP2 downregulation in mpkCCD cells and mice 
(9). Next, we set out to identify, which CA was involved in the attenuation of lithium-
induced downregulation of AQP2. Sixteen CA isoforms are known and most of them
are expressed in the kidney (23). To examine which CAs are expressed in lithium-treated 
mpkCCD cells, we grew mpkCCD cells to polarization, induced AQP2 expression with 
dDAVP for 4 days and treated them with lithium for the last 2 days. Subsequent RNA
isolation and RT-PCR analysis revealed DNA bands of the expected mass for CAs 1, 2,
5B, 6, 7, 9 and 11 to 15, which were absent in the RT- lanes (Fig.1A). The appearance of 
anticipated DNA fragments upon restriction enzyme digestion confirmed that the 
specific CA were amplified (Fig. 1B and Table 1).
If acetazolamide would act on one of these CAs, it was to be expected that down-
regulation of the particular CA would attenuate lithium-induced downregulation of 
AQP2. Therefore, following transfection with CA-specific siRNAs against all CA-isoforms 
detected in this cell line, mpkCCD cells were grown to polarization and treated with
dDAVP. Subsequent AQP2 immunoblotting revealed that only siRNAs silencing CA9
led to a significant increase in AQP2 abundance above the basal levels (Fig. 1C, D).
Treatment with siRNAs downregulating CA12 showed a tendency to increase AQP2 
abundance, but this effect was not significant. To validate the relevance of CA9/12
inhibition in this process differently, we employed 6- and 7- hydroxycoumarin (6HC and 
7HC), which are drugs that inhibit CA9 and 12 far more efficient than other CA isoforms 
(24). Following treatment of mpkCCD cells with lithium as above and with or without 
6HC or 7HC addition, subsequent immunoblotting for AQP2 revealed that both drugs 
indeed fully rescued the lithium-induced AQP2 downregulation (Fig. 1E, F).
Lithium increases lactate production in mpkCCD cells and mice through 
ENaC-mediated entry in the collecting duct
As an increased expression of especially CA9 and CA12 is observed in tumor cells (25,
26) and entry of lithium in principal cells leads to cell proliferation, which, in cancer 
cells often coincides with aerobic glycolysis, a metabolic state characterized by
glycolysis and lactate production at physiological oxygen levels, we wanted to test
whether lithium induces aerobic glycolysis in renal principal cells. For this, we grew
mpkCCD cells, which are mouse collecting duct cells that endogenously express AQP2 
in response to vasopressin (15), to confluence, stimulated them with dDAVP, and 
treated them for 2 days with lithium. To determine the cell viability and extent of 
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Figure 1. CA9 downregulation rescues lithium-induced AQP2 downregulation. Native mpkCCD
were grown to confluence for 4 days and exposed to 1 nM dDAVP for another 4 days. During the
last 24 hrs., the cells were incubated with lithium. On day 8, cells were harvested and RNA was 
isolated. After reverse transcriptase treatment and PCR amplification, the PCR products were 
visualized with ethidium bromide staining of agarose electrophoresis gels (A). Restriction 
enzyme digestion confirmed the specificity of the observed bands (B). For the siRNA experiment, 
mpkCCD cells were transfected with siRNAs targeting different CAs, seeded on Transwell filters 
and treated for the last 2 days without (CTR) or with lithium (Li+). AQP2 abundance as assessed 
by immunoblotting (C) and quantification of 4 independent experiments (D). Confluent mpkCCD
cells were incubated during the last 2 days in the absence (CTR) or presence of lithium only (Li+) 
or lithium with 6-hydroxycoumarin (6HC) or 7-hydroxycoumarin (7HC). Unglycosylated AQP2
abundance as detected by immunoblotting (E) and quantification of 3 independent experiments
(F). Equal loading of the samples was confirmed by staining of the blots with у-actin or 
Coomassie blue (Cm). Data presented are mean ± SEM. One way ANOVA, Bonferroni’s Multiple 
Comparison Test, * p<0.05. NT. Abbreviations: NT, non-targeting; CA, carbonic anhydrase; RT, 
reverse transcriptase; M, marker; RE, restriction enzyme; WK, whole kidney.
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transcellular sodium transport, the Trans Epithelial Electrical Resistance (TEER) and 
transcellular voltage (Tv) were measured. Lithium caused a slight reduction in TEER 
and Tv (Fig. 2), indicative of a reduced extent of cell polarization. Indeed, and as
observed in vivo (8), lithium increased the cyclin D1 abundance, besides decreased
AQP2 levels (Fig. 2C). Analysis for lactate in medium indeed revealed that lithium
treatment increased its release in mpkCCD cells (Fig. 2D). Earlier, we have shown that 
lithium enters principal cells via ENaC and that rodents lacking ENaC or in which ENaC 
was blocked with amiloride showed an absent/attenuated development of Li-NDI (4, 
27). Interestingly, co-treatment of lithium with amiloride attenuated the reduction in
TEER caused by lithium but further reduced the Tv. More importantly, amiloride 
attenuated lithium induced AQP2 downregulation and lithium induced increase in
cyclin D1 abundance and lactate release (Figs 2A-D). Furthermore, we also analyzed
lactate release after cotreatment with lithium and 6HC and 7HC. Consistent with their 
effect on lithium-induced downregulation of AQP2, we found that both inhibitors also 
attenuated the lithium-induced increase in lactate release (Fig 2E).
To test whether lithium also induces aerobic glycolysis in vivo, we treated normal and
CD ENaC-KO mice with lithium and tested the urinary content for lactate. As shown
before (27), lithium increased urine volume and decreased urine osmolality in WT 
mice, but not in ENaC-KO mice (Fig. 2F, G). Importantly and in line with the data above, 
the 24-hrs urinary lactate levels were strongly elevated in lithium treated WT mice, but
not in lithium treated ENaC-KO mice (Fig. 2H). Together, these data indicated that 
ENaC-mediated entry of lithium causes principal cell aerobic glycolysis in vitro and in 
vivo.
2DG partly attenuates lithium-induced AQP2 downregulation in 
mpkCCD cells.
Recently, a switch to aerobic glycolysis has also been found to underlie autosomal 
dominant polycystic kidney disease (ADPKD) and treatment with 2DG, which reduces 
cellular glucose entry and usage in aerobic glycolysis, attenuated further ADPKD
development (28). We therefore tested whether 2DG would also attenuate the in vitro
effects of lithium.  For this lithium and 2DG were added simultaneously to the apical 
and basolateral medium of mpkCCD cells during the last 2 days, always in the presence
of dDAVP. Interestingly, 2DG treatment increased the TEER (Fig. 3A) and significantly 
reduced the lactate production (Fig. 3B). Moreover, 2DG treatment fully recovered the 
lithium-induced downregulation of unglycosylated AQP2, but the abundance of 
complex-glycosylated AQP2 remained low after co-treatment with lithium and 2DG
(Figs. 3C-E). Earlier, the Golgi complex retention of AQP2-N123Q, which cannot be
glycosylated anymore, in polarized cells indicated that glycosylation is important for 
cell surface expression of AQP2 (29) and, as such, the reduced abundance of complex-
glycosylated AQP2 could indicate that AQP2 was impaired in its trafficking to the
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plasma membrane. To test whether 2DG impaired proper trafficking of AQP2 to the plasma 
membrane, a cell surface biotinylation assay and immunocytochemistry was performed. 
Immunoblotting of biotinylated cell surface proteins, however, revealed that the
abundance of unglycosylated AQP2 in the plasma membrane of lithium-2DG co-treated
cells was indifferent from control cells, but significantly higher than of lithium-treated 
cells (Figs. 3F-H). These data were supported by our Immunocytochemistry, as a clear 
apical membrane expression of AQP2 was observed in cells treated with Li and 2DG, 
which was similar to dDAVP-control cells, but not observed in Li-treated cells (Fig. 3I).
Figure 2. Lithium increases lactate production in mpkCCD cells and wildtype mice but not in 
ENaC KO mice. MpkCCD cells were cultured on Transwell filters for 8 days with or without lithium
or lithium and amiloride in the last 2 days. Then resistance (A) and transcellular voltage (B) were
determined prior to the collection of cells and apical medium, which were used to perform AQP2 
and cyclin D1 immunoblot analyses (C) and measure lactate (D), respectively. Lactate release
was also measured in apical medium of cells treated with 6HC and 7HC (E) The data presented 
is the mean of three independent experiments. In the animal experiment, mice received normal
rodent diet (CTR), while the other mice received the same diet supplemented with 40 mmol LiCl/
kg food for 10 days. They were individually housed in metabolic cages for the last 48 hours.
Urine production (F), osmolality (G) and lactate (H) were determined for the last 24h. An asterisk
denotes a significant difference (P<0.05) from CTR. Abbreviations: CTR, control; Li+, lithium; AM,
amiloride; 6HC and 7HC, 6- and 7-hydroxycoumarin; WT, wildtype, ENaC KO, Epithelial sodium 
channel knockout mice; AQP2, aquaporin-2, cg; complex glycosylated, hm; high mannose
glycosylated, un; unglycosylated and Cm, coomassie blue staining.
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2DG does not attenuate lithium-NDI in mice
Considering the positive in vitro effects, we subsequently investigated the effect of 
2DG on Li-NDI in vivo. For this, mice were exposed to food without or with lithium or 
lithium with 2DG for 10 days. However, the lithium-induced increase in urine volume
and decrease in urine osmolality were not attenuated by 2DG (Fig. 4A, B).  The urinary
lithium concentrations were similar in both lithium treated groups (Fig. 4C). To measure 
lactate and other metabolites in urine, NMR was employed (Figs. 4D-I). Importantly,
the 2DG treatment reduced the lithium-induced increase in lactate production,
indicating that the 2DG treatment on blocking aerobic glycolysis was effective (Fig. 4D).
Figure 3. 2DG partly rescues lithium-induced AQP2 downregulation in mpkCCD cells MpkCCD 
cells were cultured on Transwell filters for 8 days with or without lithium or lithium and 2DG in
the last 2 days. The resistance (A) was measured prior to the collection of apical medium, which 
was used for lactate measurements (B). Then, cells were either collected for immunoblot 
analysis to determine total AQP2 (C-E) and cell surface AQP2 protein abundance (F-H) or stained
using immunocytochemical analysis for AQP2 (I; AQP2 green; DAPI blue). The data presented is
the mean of at least three independent experiments performed in triplicate. A significant 
difference (P<0.05) from CTR is denoted by an asterisk. Abbreviation: CTR, control; Li+, lithium;
2DG, 2-deoxyglucose; AQP2, aquaporin-2, cg; complex glycosylated, hm; high mannose
glycosylated, un; unglycosylated and Cm, coomassie blue staining.
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Figure 4. 2DG does not attenuate lithium-induced NDI in mice  One group of the mice received
normal rodent diet while the other mice received the same diet supplemented with 40 mmol 
LiCl/kg food or LiCl with 2-deoxyglucose (2DG; 250 mg/kg food) for 10 days and individually 
housed in metabolic cages for the last 48 hours. Urine production (A), urine osmolality (B) were
determined for the last 24h and blood was collected to measure plasma lithium levels (C).
1H-NMR analysis was performed to determine urinary lactate (D), succinate (E), fumarate (F),
citrate (G) and cis-aconitate (H) levels while urinary ammonium (I) was measured using
ammonium assay. A significant difference (P<0.05) from CTR is denoted by an asterisk. 
Abbreviation: CTR, control; Li+, lithium and 2DG, 2-deoxyglucose.
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Interestingly, however, NMR analysis revealed that the creatinine-normalized levels of 
metabolites such as succinate, fumarate and citrate were increased with lithium, but
not attenuated by 2DG (Figs. 4E-G). The cis-aconitate levels were similar in all groups 
(Fig. 4H) and biochemical analysis further revealed that the increased excretion of 
ammonium with lithium treatment was not decreased by 2DG (Fig. 4I).
Discussion
ENaC mediated lithium influx into principal cells causes aerobic glycolysis
Earlier, we and others have shown that, by entering via ENaC, lithium initiates
proliferation of principal cells in vitro and in vivo (7, 8). Moreover, we have shown that 
lithium influx in principal cells also induces a G2/M cell cycle phase block in vitro and 
in vivo, which may at least partially explain the overall loss of principal cells observed
in Li-NDI (8).  Here, we provide in vitro and in vivo data which show that the lithium-
induced principal cell proliferation coincides with metabolic changes, characteristic 
for aerobic glycolysis. In the continuous presence of oxygen, lithium treatment induced 
an increased (in vitro) release and (in vivo) urinary excretion of lactate, which was
absent in mice lacking ENaC in collecting ducts. The observed slight increase in urine 
volume and decrease in urine osmolality with lithium in ENaC-KO mice may be due to 
remaining ENaC-mediated influx of lithium in connecting tubules, as these cells 
contribute weakly to urine concentration and AQP2 and ENaC are still expressed in 
these cells of these mice (27). Blocking lithium entry into mpkCCD cells with amiloride
did not only attenuate lithium-induced AQP2 downregulation but also prevented cell
proliferation and aerobic glycolysis. Our NMR analysis furthermore revealed that 
lithium treatment strongly increased urinary levels of succinate, fumarate and citrate,
metabolites which are known to increase during glutaminolysis (30). With aerobic 
glycolysis, glutaminolysis is typically upregulated as well, because glutamine provides 
the cell of nitrogen and citrate, needed for amino acid and lipid synthesis, respectively 
(31). Moreover, during aerobic glycolysis, the increased intracellular acid production, 
such as lactate, necessitates the cell to ignite pathways to buffer acid excess, besides 
secretion of lactate through MCT proteins. Cellular glutamine influx and glutaminolysis 
serve this buffering function, as the two molecules of NH3 released from glutamine 
and glutamate during glutaminolysis are effective H+ buffers (32). In line with this, 
urinary ammonium (NH4+) was strongly increased with lithium.
Our in vitro data on the CAs involved in the ACZ-induced suppression of lithium-
induced downregulation of AQP2 are in line with the above. Although we have not 
solidly proven that the mix of four siRNAs against the different CAs indeed 
downregulated the expression of each CA, a dogma concluded from an extensive 
study in which thousands of siRNAs were tested to block cancer cell growth (13, 14), 
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our siRNA (Fig. 1 C, D) and CA-specific drug treatments clearly revealed that inhibition 
of CA9, and possibly CA12, attenuated the lithium-induced AQP2 downregulation in 
mpkCCD cells. The increase in CA9 abundance was higher in the siRNA experiment 
compared to the experiment with CA-specific drugs. This is possibly due to the longer 
culturing time in drug treatment assay that allowed the polarization of the cells that
will express more AQP2 even in the control condition. CA9 and -12 are normally located
to the basolateral membrane of epithelial cells, but appear in both plasma membranes 
in proliferative cells (33-35). CA12 is abundantly expressed in the collecting duct of 
healthy kidneys, however the cell specificity seems to depend on the species tested: 
while in humans and rabbits CA12 is mainly found in principal cells, its expression 
seems restricted to type-A intercalated cells in rodents (33, 36, 37). CA9 is hardly
expressed in healthy kidneys, but CA9 and CA12 expression is markedly increased in 
renal carcinomas, where they facilitate proliferation of these tumor cells by facilitating 
the cellular removal of acids (25, 26). CA9/12 generate HCO3-, which is taken up by
tumor cells to neutralize their excessive production of acids, such as lactate, produced
during aerobic glycolysis (10). The action of CA9/12 allows tumor cells to continue their 
Warburg-like proliferation and acid secretion, of which the latter helps cell proliferation 
by disassembling junctional proteins (38-40). Unfortunately, the CA9 antibodies used
in clinics to reduce tumor growth (41) did not reveal any signal with our kidney samples,
which has been attributed to human CA9 specificity (42).
Unfortunately, and in contrast to mice suffering from ADPKD (28), inhibition of 
aerobic glycolysis with 2DG did not attenuate Li-NDI. In vitro, 2DG attenuated the
Li-induced downregulation of total and apical membrane abundance of AQP2. AQP2 
with 2DG was mainly of the unglycosylated form, which is in line with the fact that
glucose uptake is necessary for Asn-glycosylation of proteins through its utilization 
in the hexosamine biosynthetic pathway. The hexosamine pathway branches off 
from glycolysis at fructose-6-phosphate and produces UDP-N-acetylglucosamine 
(UDP-GlcNAc), the substrate for N-glycosylation (43). 2DG enters the cells via glucose
transporters (GLUTs) (44). In mpkCCD cells, GLUT1 and GLUT8 are likely present, as 
their mRNAs were detected by RNAseq analysis, whereas GLUT1, GLUT4, GLU6 and 
GLUT8 mRNA expression was detected in rat collecting ducts (45) (46). This difference 
is, however, not likely to explain the difference in response of AQP2 rescue with
between mpkCCD cells and the kidney, because the normalization of urinary lactate 
excretion with 2DG illustrated the blocking effect of aerobic glycolysis of 2DG in our 
mice. However, 2DG did not attenuate the lithium-induced increases in urinary 
succinate, fumarate, citrate and ammonium excretion, indicating that 2DG did not 
affect the effect of lithium on glutaminolysis. Our data indicate lithium, which can still 
enter principal cells through ENaC in our 2DG experiment, induces aerobic glycolysis 
and glutaminolysis through different pathways, and may suggest that the increased 
glutaminolysis is of more relevance to Li-NDI, as Li-NDI was not improved with 2DG. As 
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such, future studies should focus on the potential role of glutaminolysis in the
pathogenesis of Li-NDI.
Principal cell aerobic glycolysis may underlie collecting duct remodeling 
in Li-NDI.
It is well-known that Li-NDI coincides with collecting duct cell remodeling in which the 
number of principal cells decrease and the number of acid-secreting (alpha) 
intercalated cells increase (6), but how lithium causes this remodeling is unclear.
An important stimulus could be the development of metabolic acidosis, which is often, 
but not always, observed with lithium treatment in rodents and man (9, 47), because 
a state of metabolic acidosis increases the numbers of alpha-intercalated cells as an
adaptive response (48, 49). How lithium causes metabolic acidosis, however, is
unclear. As lithium attenuated the activity of H+-ATPase and H+/K+-ATPase, earlier 
studies suggested lithium-induced that metabolic acidosis and collecting duct 
remodeling could be due to a direct inhibition of these transporters of intercalating 
cells (50, 51). However, if true, the effect of lithium on collecting duct remodeling
should be independent from its influx in the principal cells, which does not seem to
be the case:  First, Kortenoeven et al. showed that amiloride, which inhibits lithium entry
in principal cells only, attenuated collecting duct remodeling (4). Moreover, the 
abundance of H+ATPase, a marker protein for alpha-intercalated cells, was not
increased lithium-treated ENaC-KO (27). These studies thus indicate that lithium-
induced remodeling is a direct effect of principal cell lithium entry. Our present data
now reveal that lithium induces aerobic glycolysis in principal cells, a condition
coinciding with increased lactic acid production and principal cell acid secretion. 
As such, the increased number of alpha-intercalated cells in Li-NDI may be induced 
by the increased local acidification due to principal cell acid secretion. Future studies 
are required to test this hypothesis.
Lithium and renal cancer
The lithium-induced increase in proliferation rate and the metabolic switches towards
aerobic glycolysis and glutaminolysis as found here are hallmarks of cancer cells (30)
Moreover, we also found that, at least in vitro, the lithium-induced downregulation of 
AQP2 is inhibited by CA9/12 siRNAs or blockers, which are also often upregulated in
diverse cancers to counteract intracellular acidification due to extensive lactate 
production (1, 25). Although these data could be interpreted to fuel the thought that
lithium may increase renal cancer development in bipolar patients, as has recently 
been suggested in a small epidemiological study (52), this hypothesis has later been
convincingly refuted in several larger and more robust epidemiological studies (53-55). 
Moreover, several other arguments can be brought about against a connection
between lithium and renal cancer. At first, one should realize that glutaminolysis 
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fueling cell proliferation is also a feature of a normal cell-physiological responses of 
cells to increased metabolic demands, which occurs daily in many tissues (56). In this 
respect, one should also realize that, in contrast to an oncogenic mutation, activation 
of these pathways by lithium is only temporarily and not complete, as drugs never 
block proteins fully. Secondly, we did not observe any tumor in the kidneys of 40 weeks 
old mice that were treated from birth onwards with a clinical dose of lithium (not 
shown).
In conclusion, this study demonstrates that lithium induces aerobic glycolysis and 
glutaminolysis in renal principal cells. While aerobic glycolysis does not seem to play
a role in the development of Li-NDI, future research will have to elucidate whether 
blocking glutaminolysis by e.g. CA9 inhibitors may attenuate Li-NDI development.
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Abstract
Lithium remains the drug of choice in the treatment of bipolar disorder. However, the 
drug treatment causes lithium-induced nephrogenic diabetes insipidus (Li-NDI) that is
marked by the downregulation of aquaporin-2 (AQP2) water channel. Recently, we
have shown that lithium treatment was associated with a metabolic switch towards 
aerobic glycolysis that goes with elevated succinate release. SUCNR1 in principal cells 
has been coupled to calcium pathway, which normally reduces AQP2. Therefore, in this 
study we investigated the involvement of the SUCNR1 receptor in Li-NDI development. 
Succinate was elevated in the urine of lithium treated humans and mice compared to
controls. No increase in succinate level was observed in lithium treated ENaC KO mice, 
indicating that succinate was derived from principal cells. Finally, to determine whether 
the SUCNR1 had a role in the development of Li-NDI, wildtype and SUCNR1 knockout
mice received either control or lithium containing diet. Based on the indifferent urine
output and urine osmolality we can conclude that SUCNR1 has no role in Li-NDI 
development. 
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Introduction
Lithium is the drug of choice for the treatment of bipolar disorder and is also regularly 
used to treat schizoaffective disorders and depression. Lithium is a frequently 
prescribed drug as it is provided to 0.1% of the western population (1, 2). Unfortunately, 
in 20% of the patients, lithium usage leads to nephrogenic diabetes insipidus (NDI), a
disorder characterized by an impaired response of the kidney to vasopressin (AVP) 
leading to polyuria and polydipsia (3-5). Therewith, lithium-induced NDI is the most 
common form of NDI. Patients with lithium-NDI are at risk for dehydration and 
hypernatremia. Moreover, prolonged lithium treatment might lead to cyst formation 
and end stage renal disease (6). However, cessation of lithium therapy is not an option 
for most patients with NDI, because bipolar disorder symptoms have a larger impact 
on the patient’s quality of life.
From studies in rats, it became clear that lithium-NDI develops in two stages. At short 
term, lithium-NDI coincides with downregulation of aquaporin-2 (AQP2) water 
channels, which is due to a reduced AQP2 transcription (7-9). Despite an increased 
proliferation of the AQP2-expressing principal cells of the collecting duct, long-term 
lithium treatment also results in a severe loss of AQP2-expressing principal cells, 
which might be attributed to a lithium-induced G2/M phase cell cycle arrest (10, 11).
This principal cell loss is ‘compensated’ by an increased number of intercalated cells, 
which are involved in acid/base homeostasis (10).
Interestingly, purinergic signaling mediated by extracellular nucleotides opposes the 
action of AVP on renal collecting duct by decreasing the cellular cAMP and thus AQP2
protein levels (12). Kishore et al., showed that rat inner medullary collecting ducts that
were perfused with ATP reduced the AVP-induced intracellular cAMP levels and 
transcellular water permeability (13). The same group also showed that mice lacking 
the purinergic P2Y2 receptor were significantly more resistant to develop Li-NDI than 
healthy littermates and that pharmaceutical blockage of the ADP-activated 
P2Y12 receptor in the kidney ameliorated their Li-induced NDI (12).  These findings 
indicate that activation of purinergic receptors aggravate the development of Li-NDI 
and that targeting the purinergic signalling pathway may attenuate Li-NDI development.
Recently, we have shown that, besides cell proliferation, lithium also induces aerobic 
glycolysis, which coincides with the cellular release of lactate and succinate (14).
Succinate is a metabolite released from mitochondria and cells under conditions of 
stress (15). Succinate is specifically bound by the succinate receptor type 1 (SUCNR1), 
also known as GPR91, which is a plasma membrane G-protein coupled receptor. The
SUCNR1 is a member of the P2Y purinergic receptor family and reported to be expressed 
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in different segments of the kidney, including the collecting duct (15). As Li-NDI can be
considered a consequence of a toxic cell stress event of lithium on collecting duct 
principal cells and lithium treatment led to elevated urinary levels of succinate, we 
here tested whether the SUCNR1 has a role in Li-NDI development using SUCNR1 
knockout (SUCNR1 KO) mice.
Material and Methods
Human urine samples
Human urine samples were from an earlier clinical study and were collected and stored 
as described (16). In short, urines were collecting in the morning after an overnight
fluid deprivation, centrifuged at 2000xg for 5 min to remove sediment and stored at
-80°C until succinate was measured. The samples were derived from bipolar patients
(seven females, three males), who were on chronic lithium therapy for the management 
of their mood disorder. These patients were matched with six healthy volunteers (three 
females, three males). Participants were recruited from a cohort of individuals on
long-term lithium therapy who have previously participated in our clinical studies (17). 
Inclusion criteria included individuals with bipolar disorder treated with lithium
carbonate, who were clinically stable, with no change in their medications over the 
preceding 3 months, and who had no known history of renal disease. Exclusion criteria 
included the inability to give informed consent, a history of known renal disease, the 
continued use of a diuretic or angiotensin-converting enzyme inhibitor, unstable
psychiatric condition, or recent changes in psychotropic medications. All participants 
gave written informed consent to take part in the study, which was approved by the
New Zealand (Lower South Regional) Ethics Committee.
Animal experiments
Animal experiments were performed as described (11). Heterozygous SUCNR1 mice on 
a C57BL/6 background were a kind gift from Amgen (Thousand Oaks, CA, USA) and
were generated as described (18, 19). The animals were intercrossed with wildtype 
(WT) C57BL/6 littermates to yield homozygous SUCNR1 KO offsprings as described
(19). Collecting duct-specific epithelial sodium channel knockout (NMR16J ENaC KO)
mice (20) were kindly provided by Edith Hummler, Lausanne, Switzerland and crossed
with C57BL/6 mice, obtained from Harlan Laboratories (Horst, the Netherlands). 8-12
weeks old male SUCNR1 KO, ENaC KO mice and their WT littermates were used in the
experiments. The mice were housed in a climate-controlled facility with a 12-hour:12-
hour light-dark cycle. All mice had free access to rodent diet (7013, NIH-31 Modified,
Harlan Laboratories, Inc., Madison, WI, USA), acidified water and a sodium chloride 
block throughout the experiment. During the experiment, one group (n=6) of mice 
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received normal rodent diet, while the other mice received the same diet supplemented 
with 40 mmol lithium chloride (LiCl)/kg food. During the last 48 hours of an experiment, 
mice were housed in metabolic cages in order to measure water intake and urine 
output of the last 24 hours. Next, mice were anesthetized with isoflurane and
euthanized by cervical dislocation, after which the kidneys were removed. All animal 
studies were approved by the Animal Ethical Committee of the Radboud University 
Medical Center.
Urine analysis
Urine samples from the mice experiment were centrifuged at 2000xg for 5 minutes to 
remove any sediment precipitated. Subsequently, the supernatant was transferred to 
a new tube and urine osmolality was measured using a Micro-Osmometer Model 3320 
(Advanced Instruments, Inc., Norwood, MA). After that, urine was stored in eppendorf 
tubes at -80°C until NMR analysis was performed.
1H NMR Spectroscopy
One-dimensional 1H NMR spectroscopy was performed as described (21). 24h Urine 
was centrifuged for 10 minutes at 3000xg before analysis. 20 μL of 20.2 mM trimethyl-
silyl-2,2,3,3-tetradeuteropropionic acid (TSP, sodium salt; Aldrich) in D2O was added 
to 700 μL of the urine to serve as an internal quantity reference for subsequent 
handlings. The pH of each sample was adjusted to 2.50 ± 0.05 with concentrated HCl. 
Finally, 650 μL of the sample was placed in a 5 mm NMR tube (Wilmad Royal Imperial; 
Wilmad LabGlass, USA). 1H NMR spectra were obtained using a Bruker 500 MHz 
spectrometer (pulse angle, 90°; delay time, 4 s; number of scans, 256). Water resonance
was suppressed by gated irradiation centered on the water frequency. The spectral 
width in the F1 and F2 domains was 5500 Hz. A total of 2K data points were collected 
in t2, 256 t1 increments with 32 transients per increment were used. The relaxation 
delay was set to 2 seconds. Before the Fourier transformation, a sine-bell function was 
applied in both time domains. During the relaxation delay, the water resonance was
pre-saturated. The free-induction decays measured for these samples were processed 
using Topspin software (Bruker BioSpin, Rheinstetten, Germany). Fourier transformation
was applied on the free-induction decay of the samples and the resulting spectra were
phase and baseline corrected. The chemical shifts in the spectra were referenced to 
the internal standard, TSP. Assignment of peak positions for compound identification
was performed by comparing the peak positions in the spectra of the metabolites with 
the reference spectral database of model compounds at pH 2.5 using Amix version 
3.9.14 (Bruker BioSpin, Rheinstetten, Germany). Quantification of identified compounds 
was performed by manual integration of chosen peak(s) for a specific metabolite.
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Statistics
One-way ANOVA with Bonferroni correction was applied. A p value of less than 0.05 
was considered significant. Data are presented as mean and standard error of the 
mean (SEM).
Results 
Lithium increases urinary succinate in mice and humans
Recently, we have shown that lithium treatment increased urinary succinate in mice 
(14). To investigate whether the released succinate was coming from collecting duct
principal cells, we determined whether the urinary content of succinate with lithium
differed between WT and ENaC KO mice. In the kidney, ENaC is specifically expressed
in the apical membrane of the principal cells of the collecting duct. It is the entry site
for lithium into the principal cells, as NDI development was prevented in ENaC KO mice 
treated with lithium (14). NMR analysis revealed that lithium treatment increased the
urinary succinate content in WT mice, but not in ENaC KO mice (Fig. 1A).To determine
whether lithium also increases succinate excretion in urine of humans, urine was 
collected from participants that were chronically treated with lithium and healthy
volunteers who have previously participated in our clinical studies (17). Subsequent 
NMR analysis revealed that urinary succinate levels were indeed also elevated in lithi-
um-treated patients (Fig. 1B). These data revealed that lithium increases urinary 
succinate release in mice and man.
Lithium induces NDI in wildtype and SUCNR1 KO mice
To subsequently determine whether the presence of the SUCNR1 may affect Li-NDI 
development, WT and SUCNR1 KO mice received a normal rodent diet with or without 
40 mmol lithium chloride/kg food for 10 days after which their 24-hr urine was 
collected. Lithium treatment led to a somewhat reduced urine output in SUCNR1 KO 
mice as compared to WT littermates, but the difference was not significant (Fig. 2A).
Lithium also reduced the urine osmolality, which was indifferent between SUCNR1 KO
and WT mice (Fig. 2B). These results reveal that the presence of the SUCNR1 does not
influence Li-NDI development in mice.
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Figure 1. Lithium increases urinary succinate in mice and humans. (A) Mice received normal
rodent diet (CTR) or the same diet supplemented with 40 mmol lithium chloride/kg food for 10
days (Li+). They were individually housed in metabolic cages for the last 48 hours. Of the urine 
collected during the last 24h, succinate concentration was determined using NMR. (B) To 
determine urinary succinate in humans, NMR analysis was performed on urines derived from 
participants, who were on chronic lithium therapy for the management of their mood disorder 
(Li+) and healthy volunteers (CTR). An asterisk denotes a significant difference (P<0.05) from 
CTR. Abbreviations: CTR, control; Li+, lithium; WT, wildtype, ENaC KO, Epithelial sodium channel 
knockout mice.
Figure 2. Lithium induces NDI in wildtype and SUCNR1 KO mice. WT and SUCNR1 KO mice
received normal rodent diet (CTR), or the same diet supplemented with 40 mmol lithium
chloride/kg food for 10 days. Mice were individually housed in metabolic cages for the last 48 
hours, urine collected during the last 24 hrs and analysed for volume (A) and osmolality (B). An
asterisk denotes a significant difference (P<0.05) from CTR. Abbreviations: CTR, control; Li+, 
lithium; WT, wildtype, SUCNR1 KO, Succinate receptor 1 knockout mice.
A
A B
B
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Discussion
The origin of succinate
Previously, we and others have shown that, by entering via ENaC, lithium initiates 
proliferation of principal cells in vitro and in vivo (11, 22). Furthermore, we have shown
that lithium influx in principal cells also induces a G2/M cell cycle phase block in vitro
and in vivo, which may at least partially explain the overall loss of principal cells 
observed in Li-NDI (11). We also provided in vitro and in vivo data which show that the 
lithium-induced principal cell proliferation coincides with metabolic changes,
characteristic for aerobic glycolysis and glutaminolysis (14). Succinate was one of the
metabolites that was increased. Although we cannot exclude the possibility that ENaC 
KO mice do not release succinate, because they have an NMR16J instead of a C57BL6 
background, it is most likely that the lack of lithium entry in principal cells in these
mice prevented the observed absence of succinate excretion. Lithium induces principal 
cell glycolysis and glutaminolysis. With glycolysis, pyruvate is mainly converted into
lactate, whereas the TCA cycle is mainly fueled by glutaminolysis with the use of 
glutamine, the most abundant circulating amino acid in blood, as an energy source. 
Moreover, when urinary succinate was measured in humans, the concentration of 
succinate in lithium-treated patients was significantly higher than in healthy volunteers.
This suggests that the metabolic switch towards glycolysis and glutaminolysis also 
takes place in humans. Future studies might compare amiloride treated and non-treated 
lithium receiving patients to determine whether succinate is also coming from principal 
cells in humans. 
The role of the succinate receptor in the development of Li-NDI
The SUCNR1, located in the luminal membrane of macula densa cells, or in the plasma 
membrane of afferent arteriole cells, induces the release of PGE2 and nitric oxide (23). 
This mediates the release of renin from the juxtaglomerular apparatus (JGA) in the
kidney and subsequently the activation of the renal RAAS (23). With Li-NDI, RAAS is
continuously activated due to the hypovolemia that is caused by the downregulation 
of AQP2 in the collecting duct. Therefore, the absence of SUCNR1 was expected to
result in the loss of this compensatory mechanism and worsening of Li-NDI. However,
in our study, the absence of SUCNR1 did not reduce nor aggravate Li-NDI development.
As explained, SUCNR1 is a local sensor of stress and has been shown to expressed in
collecting duct principal cells (15). Robben et al. showed that the activation of the 
MDCK cells by succinate caused Gq and Gi-mediated intracellular calcium mobilization,
transient phosphorylation of extracellular regulated kinase (ERK)1/2 and the release 
of arachidonic acid along with PGE2 (24). In lithium-induced NDI, urinary PGE2 levels 
are increased and contribute significantly to the development of Li-NDI (25-27). PGE2 
activates the EP3 receptor in principal cells, leading to a reduced cAMP signaling, 
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AQP2 expression, and plasma membrane targeting (28, 29).  Our study reveals that 
development of Li-NDI is not influenced by the SUCNR1, as both WT and SUCNR1 KO 
mice developed LI-NDI to a similar extent. At present, it is unclear whether the SUCNR1 
does not play a role at all in LI-NDI development or whether compensatory mechanisms 
play a role here: Missing SUCNR1, as in SUCNR1 KO mice, might be disadvantageous on
the systemic level where the renin-angiotensin system (RAAS) cannot be activated 
properly to compensate for Li-induced hypovolemia, but advantageous for principal 
cells where less AQP2 is downregulated by prostaglandin E2 (PGE2).
Taken together, we have shown that lithium treatment increases urinary succinate in 
mice and humans, supporting our hypothesis that Li-NDI is a stress condition, and that 
urinary succinate is specifically coming from principal cells. Our mouse study, however, 
reveals that the SUCNR1 does not influence Li-NDI development.
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Abstract
Lithium is the drug of choice in the treatment of bipolar disorder. However, this drug is
associated with devastating side effects including lithium-induced nephrogenic 
diabetes insipidus (Li-NDI). The mechanism how lithium causes NDI is not clearly
understood, but it is known that lithium downregulates aquaporin-2 (AQP2) water 
channel. Moreover, lithium also induces cell proliferation, collecting duct remodeling,
and metabolic acidosis. Amiloride blocks the entry of lithium into the principal cells of 
the collecting duct. Previous studies demonstrated that amiloride attenuates lithi-
um-induced AQP2 downregulation and collecting duct remodeling, but the effects of 
amiloride on metabolic acidosis and proliferation of collecting duct cells is not
determined. Here, we treated rats with standard chow or supplemented with lithium or 
lithium and amiloride to investigate the development of these side effects. First, we 
found that amiloride attenuated Li-NDI, which coincided with the rescue of AQP2 in the 
inner and outer medulla but not in the cortex. Moreover, amiloride also prevented
lithium-induced collecting duct remodeling and cell proliferation. Lithium did not 
induce hypercalcemia nor did it affect blood pH. However, analysis of urinary
ammonium revealed that amiloride attenuated lithium-induced increase in urinary
ammonium. Taken together, our data reveal that amiloride does not only rescue AQP2 
downregulation but also prevents the development of metabolic acidosis and 
proliferation of collecting duct cells.
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Introduction
Lithium is the main treatment of bipolar disorder and is also frequently used to treat 
other mental diseases such as schizoaffective disorders and depression. Lithium is 
prescribed to 0.1% of the western population (1, 2). However, 20% of the patients that 
receive lithium develop nephrogenic diabetes insipidus (NDI), which is characterized
by an impaired response of the kidney to vasopressin (AVP) leading to polyuria and 
polydipsia (3-5). Therewith, lithium-induced NDI is the most common form of NDI. 
Patients with lithium-NDI are at risk for dehydration and hypernatremia. Moreover 
prolonged lithium treatment might lead to metabolic acidosis and collecting duct 
remodeling (1).
From studies in rodents, it became clear that lithium-NDI develops in two stages. At 
short term, lithium-NDI coincides with downregulation of aquaporin-2 (AQP2) water 
channels (6-8). Despite an increased proliferation of the AQP2-expressing principal
cells of the collecting duct, long-term lithium treatment also results in a severe loss in 
the fraction of principal cells, which might be partially attributed to a lithium-induced
G2/M phase cell cycle arrest (9, 10). This principal cell loss is ‘compensated’ by an 
increased number of intercalated cells, which are involved in acid/base homeostasis
(9). Interestingly, lithium treatment is known to cause metabolic acidosis, which might 
be the trigger for intercalated cells to divide to remove excess acid (11-13).
To reduce polyuria in patients receiving lithium, a low-sodium diet together with 
thiazide and amiloride diuretics is prescribed (14). Amiloride acts on the principal cell
epithelial sodium channel (ENaC) and others and we found that amiloride blocks
principal cell lithium entry through ENaC, thereby attenuating polyuria in rodents and
humans (15-17). Kortenoeven et al. showed that amiloride prevented lithium-induced 
AQP2 downregulation and collecting duct remodeling in the kidneys of rats (18). 
However, the effect of amiloride on lithium-induced metabolic acidosis and lithium-in-
duced cell proliferation are not known. Therefore, in this study we investigated whether 
amiloride, besides the attenuation of Li-NDI and collecting duct remodeling, also 
prevents metabolic acidosis development and proliferation of principal cells.
Material and Methods
Animal experiments
The animal protocols were approved by the Animal Experiments Inspectorate, Ministry 
of Environment and Food of Denmark. Male Wistar rats were obtained from Janvier 
LABS (France). Lithium chloride and amiloride containing food was prepared as
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described (18, 19). The control group (n=6) of rats received normal rodent diet during
the entire experiment. Two other groups of rats received the same diet supplemented
with 40 mmol LiCl/kg of dry food for the first 7 days, followed by 60 mmol LiCl/kg of 
dry food the next 3 weeks in the presence (group 2; n=6) or absence (group 3; n=6) of 
amiloride (200 mg/kg dry food). All rats had free access to water and a NaCl block. 
During the last 3 days of the experiments, the animals were housed in metabolic cages
to measure daily urine output and water intake. Rats were anesthetized by isofluoran.
One kidney was removed and divided in two parts. One part was dissected into cortex, 
outer medulla and inner medulla then subjected to homogenization for immunoblotting. 
The other part of the kidney was stored in -80°C. The other kidney was washed by 
retrograde perfusion via the abdominal aorta by 0.01 M PBS (pH 7.4) and then fixed by
3% paraformaldehyde for Immunohistochemistry.
Urine analysis
Urine samples were centrifuged at 2000xg for 5 minutes to remove any sediment
precipitated. Then the urine was decanted and stored in eppendorf tubes. Urine
osmolality was measured using a Micro-Osmometer Model 3320 (Advanced Instruments,
Inc., Norwood, MA). 
Immunohistochemistry 
Immunohistochemistry was performed as described (20). In short, one kidney was
immersion fixed in 3% paraformaldehyde before dehydration in a graded series of 
ethanol (2 h in 70, 96, and 99%, respectively) and xylene (overnight). This was followed
by embedding in paraffin. Paraffin sections (2 μm) were cut on a Leica RM 2126 
microtome and dried overnight at 37°C.
Double-labeling: Sections were incubated with anti-AQP2 antibody (7661AP, dilution, 
1:2,000) followed by incubation with goat anti-rabbit peroxidase (HRP)-conjugated
secondary antibody and 3’-Diaminobenzidine (DAB; brown color). The potential
remaining peroxidase from the first staining was removed by incubating the sections
in 3.5% H2O2. After blocking for endogenous biotin (Biotin Blocking System; Dako,
Glostrup, Denmark), sections were incubated with biotinylated H+-ATPase antibody 
(7659AP; dilution 1:10) and labeling was visualized by HRP-conjugated streptavidin 
(Dako) and Vector SG substrate (blue-gray color). For single labeling, sections were 
incubated with PCNA (1:16000 dilution) and labeling was visualized by use of a 
HRP-conjugated secondary antibody and 3,3-diaminobenzidine (DAB). Cell counting
was performed on kidney sections labeled with antibodies against PCNA or H+-ATPase/
AQP2. Counting was performed directly under the microscope as described for 1
section per rat (n = 6) (21). 
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Immunoblotting 
The dissected cortex, outer medulla en inner medulla were homogenized in dissecting 
buffer as described (19). This homogenate was centrifuged at 4000 g for 15 min at 4°C.
Laemmli sample buffer was added to the supernatant and samples were stored at -20°C. 
Before running the gels, laemmli samples were denatured for 30 minutes at 37°C. 
SDS-PAGE, blotting, and blocking of the PVDF membranes was done as described (22).
Membranes were incubated for 16 hours at 4°C with 1:1000 affinity–purified rabbit (Rb2) 
C-tail AQP2 antibody in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% 
nonfat dried milk (23). After washing in TBS-T, all blots were incubated for 1 hour in TBS-T 
containing 1:10000-diluted goat anti–rabbit IgGs (Sigma-Aldrich, St. Louis, USA) coupled
to horseradish peroxidase. Proteins were visualized using enhanced chemiluminescence
(ECL; Pierce, Rockford, USA). Densitrometric analyses were performed using Bio-Rad 
quantification equipment (Bio-Rad 690c Densitometer; Chemidoc XRS) and Image 
studio software (LI-COR, Nebraska, USA). Equal loading of the samples was confirmed by
staining of the blots with coomassie brilliant blue R-250 (BioRad, Hercules, USA).
Urinary ammonium assay
Urinary ammonium was determined using a Pointe Scientific kit (A7553; Canton, USA)
modified for small volumes as described (24).
Statistics 
One-way ANOVA with Bonferroni correction was applied. A p value of less than 0.05 was 
considered significant. Data are presented as mean and standard error of the mean (SEM).
Results 
Effect of amiloride on electrolyte levels and lithium-induced NDI 
development 
To investigate whether amiloride attenuates development of Li-NDI, rats were 
maintained on normal rodent diet, lithium-containing diet or on a diet that containing 
lithium and amiloride for 4 weeks. As reported (15, 25), rodents treated with lithium 
developed severe polyuria and polydipsia, combined with a significantly reduced 
urine osmolality (Figs. 1A-B). Moreover, as shown before (18), amiloride treatment 
induced a significant antidiuresis and increased urine osmolality. Consistent with the 
antidiuresis, water intake was significantly reduced with amiloride treatment as 
compared to lithium only (Fig. 1C). Lithium treatment did not affect blood calcium, 
sodium and potassium levels nor did it change blood pH and other blood gases (Table 1). 
Urinary ammonium, however, was significantly increased with lithium and significantly 
attenuated again with amiloride. 
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Segment-specific effects of amiloride therapy on AQP2 abundance
To examine segment-specific effects of amiloride therapy, immunoblotting for AQP2
was performed. Immunoblot analysis revealed that lithium reduced AQP2 abundance 
in the cortex, outer medulla and the inner medulla (Figs. 2A-D). Consistent with earlier 
Figure 1. Amiloride attenuates lithium-induced NDI. One group of the rats received normal
rodent diet while the other rats received the same diet supplemented with lithium or lithium and 
amiloride for 4 weeks and individually housed in metabolic cages for the last 48 hours. Urine
production (A), urine osmolality (B) and water intake (C) were determined for the last 24h. 
A significant difference (P<0.05) from CTR is denoted by an asterisk. Abbreviation: CTR, control;
Li+, lithium and AM, Amiloride.
Table 1. Metabolic parameters of rats treated for 4 weeks with standard chow only 
(CTR) or together with lithium (Li+). Lithium + amiloride (Li+ + Am).
CTR Li+ Li++ AM
Blood pH 7.30 ± 0.01 7.24 ± 0.03 7.27 ± 0.02
pCO2 (mmHg) 8.446 ± 0.2 9.092 ± 0.5 8.33 ±0.3
PO2 (mmHg) 1.4 ± 0.2 1.84 ± 0.5 1.8 ±0.3
HCO3 (mmol/L) 31.44 ± 0.3 29.24 ± 0.9 28.56 ±1.4
TCO2 (mmol/L) 32.5 ± 0.5 31.2 ± 1.0 30.4 ±1.5
Serum Sodium (mmol/L) 137.4 ± 0.9 138 ± 0.9 137.4 ±1.5
Serum Potassium (mmol/L) 4.82 ± 0.10 4.92 ± 0.07 5.26 ±0.14
Serum lithium (mmol/L) / 1.045 ±0.08 1.372 ±0.09
Blood Ionized Calcium (mmol/L) 1.444 ± 0.05 1.452 ±0.01 1.476 ±0.03
Urinary ammonium (mmol/24h) 0.102±0.05 0.940 ±0.09* 0.554 ±0.09
Values are means ± s.e.m.
*P<0.05 Compared with lithium treatment.
/ Below detection limit
A B C
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data (18), amiloride fully rescued AQP2 downregulation in the inner medulla, partially 
rescued AQP2 abundance in the outer medulla but, in contrary to earlier findings, had
no effect on AQP2 levels in the cortex. 
Figure 2. Amiloride attenuates AQP2 mainly in the inner medulla of the collecting duct. Rats 
were treated for 4 weeks with a control, lithium or lithium and amiloride containing diet. After 
sacrifice, kidneys were rapidly isolated, one part of the kidney was dissected into cortex, outer 
medulla and inner medulla then snap frozen in liquid nitrogen and stored at -20°C. Immunoblot
analysis (A) on lysates was performed to determine protein abundance of AQP2. Unglycosylated
AQP2 bands were quantified for cortex (Cx; B), outer medulla (OM; C) and inner medulla (IM; D).
A significant difference (P<0.05) from CTR is denoted by an asterisk. CTR, control; Li+, lithium; 
AM, Amiloride and Cm, coomassie blue staining.
A B
C
D
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Effect of amiloride on lithium-induced collecting duct remodeling
Earlier, it has been shown that 4 weeks lithium treatment leads to collecting duct 
remodeling with a loss of principal cells and increased intercalated cells, which was 
rescued by the use of amiloride (18, 19). The data of figure 2 indicated that amiloride 
mainly attenuated Li-NDI development in the inner medulla, we investigated whether 
this coincided with a similar segment-specific protection against remodeling. For this,
immunohistochemistry was performed. As shown before (18), lithium significantly
increased the fraction of H+-ATPase-labeled intercalated cells and decreased the 
fraction of AQP2-labeled principal cells in the cortex and the medulla (Fig. 3), 
underscoring collecting duct remodeling with lithium. Amiloride treatment partially
Figure 3. Amiloride attenuates lithium-induced collecting duct remodeling. Immunocyto-
chemistry using whole kidney sections from control (A-B), lithium-treated (C-D) and lithium and
amiloride (E-F) treated rats. Sections were incubated with anti-H+-ATPase and anti-AQP2
antibodies. Average fraction of AQP2 positive principal cells and H+-ATPase positive intercalated 
cells is shown for cortex (G) and the medulla (H). A significant difference (P<0.05) from CTR is 
denoted by an asterisk. CTR, control; Li+, lithium; AM, Amiloride; PC, Principal cells; IC,
Intercalated cells; Cx, cortex and Md. Medulla.
G H
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prevented collecting duct remodeling as shown by a lower fraction of H+-ATPase 
positive cells compared to lithium in the cortex and the medulla. Earlier, others and we 
have shown that lithium initiates proliferation of principal cells in vitro and in vivo (10, 
26). Here, we found that lithium also increased the fraction of proliferating cells, as 
shown by the increase in PCNA staining. Importantly, amiloride treatment reduced the 
increase in PCNA staining, indicating that amiloride treatment also attenuated lithi-
um-induced cell proliferation (Fig. 4).
Figure 4. Amiloride treatment reduces lithium-induced proliferation. Immunohistochemistry
using whole kidney sections from control (A), lithium-treated (B) and lithium and amiloride (C)
treated rats. Sections were incubated with an anti-PCNA antibody and labeling was visualized 
by use of a HRP-conjugated secondary antibody and DAB. A significant difference (P<0.05) from 
CTR is denoted by an asterisk. CTR, control; Li+, lithium; AM, Amiloride; Cx, cortex and Md,
Medulla.
D
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Discussion
Amiloride attenuates lithium-induced collecting duct AQP2 expression,
cell proliferation, and remodeling.
Earlier, others and we have shown in vitro and in vivo that lithium downregulates AQP2 
and initiates proliferation, but that this is for a fraction of principal cells halted in the
G2/M cell cycle phase, which may at least partially explain the overall loss of principal
cells observed in Li-NDI (10, 26). Furthermore, lithium treatment also caused metabolic 
reprogramming towards aerobic glycolysis in principal cells (27). Here, we show that 
blocking lithium entry into principal cells with amiloride did not only attenuate lithi-
um-induced AQP2 downregulation but also prevented cell proliferation and collecting
duct remodeling. This is in line with our earlier in vitro findings in mpkCCD cells where 
amiloride, in addition to the rescued AQP2 abundance, prevented proliferation and
aerobic glycolysis (27).
Amiloride attenuates development of metabolic acidosis
As the G2-phase arrest of principal cells with lithium only affects a fraction of principal
cells, it may well not ne the sole factor leading to collecting duct cell remodeling. 
Earlier studies demonstrated that lithium treatment of rats also induced an increase in 
collecting duct intercalated cells(28-30). An important stimulus for this could be the
development of metabolic acidosis, which is often, but not always, observed with
lithium treatment in rodents and man (31, 32), because a state of metabolic acidosis
increases the numbers of a-intercalated cells as an adaptive response (33, 34). In our 
recent study, we proposed that lithium-induced aerobic glycolysis in principal cells,
therewith acidifying the micro-environment, could be a cause of acidosis and lead to 
increased numbers of intercalated cells instead of the earlier suggested hypothesis of a
direct inhibition of intercalated cell H+-ATPase and H+/K+-ATPase by lithium (27, 35, 36). 
Here, we provide evidence that aerobic glycolysis of principal cells may indeed be 
a trigger for intercalated cell proliferation. With lithium, we did not find observe a
change in plasma pH, HCO3- or pCO2 levels indicating that our mice did not show 
metabolic acidosis with lithium.  However, a crucial renal mechanism to eliminate acid
is the production and tubular release of NH3, which, by acceptor H+, becomes
ammonium. Indeed, urinary ammonium was significantly elevated in our lithium-treat-
ed rats. Moreover, urinary ammonium was again strongly reduced with amiloride. As 
we showed here and before that amiloride also attenuated collecting duct remodeling
(18), our present data support the view that lithium entry of principal cells through
ENaC induces aerobic glycolysis. The aerobic glycolysis acidifies the micro-environ-
ment of the intercalated cells which stimulates them to proliferate. With blocking 
lithium entry through ENaC, amiloride prevents all these steps.
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Interestingly, approximately 1.5% of the lithium-users develop end stage renal disease,
which is the final stage of chronic kidney disease (Li-CKD). A hallmark of Li-CKD is the 
development of renal interstitial fibrosis and a recent study revealed that administration
of amiloride to rats that had already developed NDI also limited the progressive
development of cortical fibrosis resulting from the chronic lithium exposure (37). 
Taken together, we have shown that amiloride does not only attenuate lithium-induced 
NDI, but also prevents lithium-induced cell proliferation, acidification and collecting 
duct remodeling. Together with the discovery that amiloride also limits fibrosis 
formation in rats, amiloride seems an excellent prophylactic medication for the
development of the renal side effects of lithium.
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Abstract
Lithium is the main treatment of bipolar disorder. Unfortunately, approximately 1.5% of 
the lithium-users develops end stage renal disease, which is the final stage of chronic
kidney disease (Li-CKD). A hallmark of Li-CKD is the development of renal interstitial 
fibrosis. To prevent Li-CKD, it is essential to understand the etiology of lithium-induced 
renal fibrosis, but convenient animal models have not been described. Therefore, to 
establish this model, C57Bl/6 mouse mothers and subsequent pups were fed either a 
normal diet or a diet supplemented with 40 mmol lithium chloride/kg food for 40 
weeks. Histological analysis revealed interstitial fibrosis development and increased
т-SMA staining in the cortico-medullary region of lithium-treated mice. Staining with
the anti-heparan sulfate (HS) antibody, which defines an inflammatory HS domain, 
revealed an increased expression in peritubular capillaries. In addition, mRNA
expression of the cytokine TNFт and the macrophage marker F4/80 was increased in
both the cortex and the medulla while mRNA expression of the fibrotic factor CTGF was
only increased in the medulla. In conclusion, we show that 40 weeks lithium treatment
of mice resulted in the development of renal interstitial fibrosis, which may serve as an
experimental model to investigate renal interstitial fibrosis development.
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Introduction
Bipolar disorder is a severe mental illness that affects about 2% of the world’s 
population (1, 2). Patients suffer from a disturbance of mood with periods of depression
or elation. This has a severe impact on the lives of most patients, demonstrated by the 
fact that more than 30% of bipolar patients attempt suicide during their lifetime (3, 4). 
Moreover, the annual direct and indirect economic burden of bipolar disorder was 
estimated to be 151 billion American dollars in the USA only (5). Lithium is the best-es-
tablished long-term treatment for bipolar disorder and it has been shown to reduce the 
risk of manic relapses by 38%, depressive relapse by 28% and the risk of suicide by
more than 50% (6, 7). At least 1 per 1000 people in western countries uses lithium and,
as such, lithium usage saves our society huge amounts of health costs (8, 9).
Unfortunately, lithium treatment leads to various renal side effects (10). The majority of 
lithium users experience loss in urine concentrating ability while 20% develops lithi-
um-induced nephrogenic diabetes insipidus (Li-NDI), in which the vasopressin-depen-
dent concentration of urine is affected, leading to polyuria, dehydration, thirst, and 
compensatory polydipsia (11, 12). Besides the effect on the urinary concentrating 
ability, long-term lithium treatment results in the development of renal interstitial 
fibrosis that is a hallmark and common outcome in the development of chronic kidney 
disease (CKD). The final stage of CKD is end stage renal disease (ESRD), which is 
defined by a complete loss of kidney function. Such patients can only be treated by 
either dialysis or transplantation (13). The affection of renal function is highly 
dose-dependent and can be ameliorated by close monitoring of serum Li-concentra-
tions in patients (14, 15). Approximately 1.5% of lithium-users develop ESRD, which is 
six to eight times more frequent than in the general population (10, 13, 16). Renal
biopsies of patients with lithium toxicity revealed a chronic tubulointerstitial 
nephropathy in all patients associated with cortical and medullary tubular cysts
(62.5%), tubular dilatation (33.3%) and segmental/global glomerulosclerosis (17-20).
To fully understand the development of lithium-induced renal fibrosis, the use of 
animal models is essential. Mice developing Li-CKD would be advantageous, 
considering the availability of many transgenic mice and the extensive existing 
knowledge of Li-NDI in mice (21-28). However, a Li-CKD mouse model has not yet been 
developed. Studies by Christensen et al. (1981) and Ottosen et al. (1984) demonstrated 
that newborn rats were more susceptible to develop interstitial fibrosis with lithium 
treatment than adult mice (29, 30). Therefore, we here wanted to perform a proof of 
principle experiment to determine whether, upon administration of diet-contained
lithium to pregnant mice and to pups after weaning, would lead to renal fibrosis after 
40 weeks of lithium treatment.
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Materials and methods
Animal experiments
Male and female C57BL/6 mice were housed in a climate-controlled facility with a 12-
hour:12-hour light-dark cycle. All mice had free access to food, water and a sodium
chloride block throughout the experiment. It has been shown in humans and rodents
that lithium passes into breast milk (31, 32). Therefore, four days after birth, one group 
of the mothers received normal rodent diet (7013, NIH-31 Modified, Harlan Laboratories, 
Inc., Madison, WI, USA), while other mothers received the same diet supplemented
with 40, 60 or 80 mmol lithium chloride/kg food for 3 weeks. After weaning, groups of 
7 pups/group received the same diet as their mothers. For controls, a group of 6 mice
was taken. It has been shown that treatment of adult mice with 40 mmol lithium
chloride/kg food results in lithium plasma concentration of 0.61 ± 0.16 mM, which 
represents the lowest value in the therapeutic range of patients with bipolar disorder 
(33). To increase the chance of obtaining interstitial fibrosis, other groups of 6 mice 
were given 60 and 80 mmol lithium chloride/kg food (i.e.1.5 and 2.0 times more). After 
three weeks, mice that received 40 mmol lithium chloride /kg food were weaned, while
those receiving 60 and 80 mmol lithium chloride/kg food were sacrificed, as they
showed paralysis of their rear legs and hardly responded to touch, indicating that 
these latter dosi were toxic for the mice. During the experiment, the appearance and 
behavior of the mice in addition to their weight was monitored. As per protocol of the
animal welfare regullations, animals that showed signes of pain or that had a 10% 
weight reduction were euthanaised after consultation with the veternerian. The
experment was continued with the group that received 40 mmol lithium / kg food for 
40 weeks. Then the mice were killed by cervical dislocation, followed by rapid isolation
of the kidneys. One kidney was fixed for immunohistochemistry by immersion in 4%
(wt/vol) paraformaldehyde (PFA) in PBS overnight. The second kidney was divided in
two, one half was snap frozen directly while the other half was dissected into cortex 
and medulla, snap frozen in liquid nitrogen, and stored at -20°C. The animal experiment
was approved by the Animal Experiments Committee of the Radboud University 
Nijmegen Medical Center and all experiments were performed in accordance with
relevant guidelines and regulations.
(Immuno)histochemistry 
In general, Immunofluorescence staining was performed on paraffin-embedded 
sections as described (34). In short, kidney sections were incubated with blocking
reagent (NEN Life Science Products, Zaventem, Belgium) and incubated overnight with
primary antibodies diluted in Tris-BSA-Triton buffer at 4°C. Antibodies used were rabbit 
anti-CD31 (ab28364) antibody (1:50; Abcam, Cambridge, UK) to mark endothelial cells, 
mouse monoclonal (A5228) antibody against alpha smooth muscle actin (т-SMA;
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1:200; Sigma-Aldrich, St Louis, USA), and guinea pig anti-aquaporin 4 (AQP4; 1:200; 
(35)) to mark (medullary) principal cells of the collecting ducts. Incubation with 
secondary antibodies labeled with Alexa488, -594 and/or -647 dyes (1:1000) was 
done for 60 minutes at room temperature. Sections were then incubated in DAPI 
(1:10000; ITK Diagnostics; Uithoorn, Netherlands) for 60 minutes for nuclear count-
er-staining. The sections were mounted in Fluoromount-G (Southern Biotech 
Associates, Birmingham, AL, USA) and stored in the dark at 4°C until microscopic 
analysis. Images were acquired using a Zeiss AX10 digital fluorescent microscope and 
ZEN lite software.
For the heparan sulphates, immunofluorescence staining was performed on 2-μm 
renal cryosections as described (36). Heparan sulfate (HS) domains were visualized
with the VSV-tagged anti-HS scFv antibodies EW3D10 (N- and 6-O sulfation) and 
HS4C3 (N-, 2-O, 3-O and 6-O sulfation) (37-40). The exact sequences within HS that are 
recognized by these anti-HS scFv antibodies are not known. However, they recognize 
distinct domains. The HS domains recognized by EW3D10 are upregulated under 
inflammatory conditions, in contrast to the domain recognized by HS4C3 (36, 41, 42). 
Anti-VSV-Cy3 antibody (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) was
applied to detect VSV-tagged antibodies. Sections were post-fixed with 1% parafor-
maldehyde–PBS and embedded in VectaShield mounting medium H-1000 (Brunschwig
Chemie, Amsterdam, The Netherlands). The fluorescence intensity in peritubular 
capillaries was quantified with Image-J software and normalized for staining intensity 
of tubular basement membranes (TBM). Pictures were loaded into the ImageJ software, 
and by using a fixed area, the mean fluorescence intensity of peritubular capillaries
was determined at 25 areas per picture on at least 3 representative pictures per mouse. 
The individual results per picture were corrected for possible variations in staining 
efficiency by measuring the mean fluorescence intensity in tubular basement
membranes, which were not affected by the treatment.
Immunohistochemistry for CD68 (clone KP1, dilution 1:100, DAKO, Glostrup, 
Denmark) was performed on the Ventana automated staining platform (Ventana 
Medical Systems, Tucson, AZ, USA) according to the manufacturer’s instructions.
Chromotrope aniline blue (CAB) histochemistry was performed to detect collagen 
deposition in the kidney. 4-μm thick sections were de-paraffinized in xylene for 10 
minutes followed by rehydration with a short rinse in 100% ethanol and two short 
rinses in 96% ethanol, followed by rinsing in water for 10 minutes. Sections were then 
incubated in Bouin’s solution (Klinipath, Duiven, the Netherlands) at 60ºC for 1h. After 
rinsing with water for 5 minutes and 10 min incubation in Weigert’s hematoxylin, 
sections were again rinsed with water and incubated for 6 min in 1% phosphomolybdic 
acid (Merck, Darmstadt, Germany). After rinsing in water, chromotrope aniline blue 
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solution (0.5% aniline blue (BDH, Poole, UK), 15% hydrochloric acid and 2% 
chromotrope 2R (Sigma, Steinheim, Germany) was added for 8 minutes. After a short 
rinse with demineralized water, sections were dehydrated with two short rinses in 96%
ethanol, followed by a short rinse in 100% ethanol, two short rinses in xylene and
placement of a coverslip. Periodic acid-methenamine silver (MZ) staining was 
performed according to the method described (43).
RT-qPCR
Samples from control and lithium kidney cortex and medulla were transferred from
-80°C to liquid nitrogen. Each sample (50-100 mg) was homogenized with a Warton
Tissue homogenizer in a glass tube with 1mL TRIzol (Invitrogen, Bleiswijk, the
Netherlands). Total RNA was isolated using TRIzol extraction reagent according to the 
manufacturer’s instructions. RNA was then precipitated in ethanol, washed, and 
dissolved in nuclease-free water. Next, RNA was subjected to DNase treatment
(Promega, Fitchburg, WI, USA) to prevent genomic DNA contamination according to 
the manufacturer’s instructions. Subsequently, RNA was measured using NanoDrop
2000c UV-Vis spectrophotometer (Thermo Scientific, Wilmington, USA) then reverse-
transcribed into cDNA using Moloney murine leukemia virus reverse transcriptase 
(Invitrogen, Bleiswijk, the Netherlands). During cDNA production, a negative control
without reverse transcriptase was included. Subsequent RT-qPCR assays were
performed using SYBR Green kit (Bio-Rad, Veenendaal, the Netherlands) and the
primers used (Table 1) were designed using the Primer-BLAST tool (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/). 36B4, which encodes an acidic ribosomal phospho-
protein P0 (RPLP0), was used as the housekeeping gene. This gene has been proven
to be a reliable and consistent standard for use in gene expression analysis (44). Gene
expression data were calculated by using the Livak (2-ΔΔCt) method and they represent
the mean fold difference from the calibrator/control group. For primer validation,
standard curves with serially diluted cDNA were generated, and primer concentration
was optimized to ensure highly efficient qPCR reactions. Construction of SYBR green
dissociation curves after completion of 40 PCR cycles revealed the presence of single 
amplicons.
Statistical analysis
Student’s unpaired t-test was performed using GraphPad Prism 5 (GraphPad Software
INC, La Jolla, USA) to compare between two groups. A P value of <0.05 was considered
significant. Data are presented as means ± SE unless indicated otherwise.
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Results
Lithium induces renal fibrosis and tubular atrophy in mice.
We investigate whether C57BL/6 mice would develop renal interstitial fibrosis when
long-term (40 weeks) treated with 40 mmol lithium/kg food starting with the pregnant
mother mice. After this 40 weeks, the mice were sacrificed and the presence of fibrosis 
was assessed using CAB staining (Fig 1). In control mice, only the collagen-containing 
basement membranes of glomeruli and brush borders of proximal tubules were 
positively stained (Fig 1A and Fig. S1), while the outer and inner medulla did not show
any positive staining (Figs 1C and E). In lithium-treated mice, however, fibrotic foci were 
present in the cortex as well as in the outer medulla, but not in the inner medulla (Figs 
1B, D and F). Lithium treatment resulted in a increase in the the presense of fibrotic foci 
Table 1. Primers used in real-time polymerase chain reaction
Target gene F/R Primer sequence
36B4 F AGCGCGTCCTGGCATTGTGTGG
R GGGCAGCAGTGGTGGCAGCAGC
IL-6 F CAAGTCGGAGGCTTAATTACACATG
R ATTGCCATTGCACAACTCTTTTCT
TNFт F CATCTTCTCAAAATTCGAGTGACAA
R TGGGAGTAGACAACGTACAACCC
IFNф F GGTGACCTTGTGACAAGCTC
R TGCTGTGTGGTCTGTCTGTC
IL-1Ra F AAATCTGCTGGGGACCCTAC
R TGAGCTGGTTGTTTCTCAGG
MCP1 F CCCAATGAGTAGGCTGGAGA
R TCTGGACCCATTCCTTCTTG
F4/80 F CTTTGGCTATGGGCTTCCAGTC
R GCAAGGAGGACAGAGTTTATCGTG
TGFу1 F CTGGAGTTGTACGGCAGTGG
R TGGGGCTGATCCCGTTGA
CTGF F GTCCAGACCACAGAGTGGAG
R CTCCAGGTCAGCTTCGCAG
F, forward; R, reverse; 36B4, housekeeping gene; IL-6, interleuking-6; TNFт, tumor necrosis factor-alpha,
INFф, interferon-gamma; IL-1Ra, interleukin-1 receptor antagonist; MCP1, Monocyte chemotactic protein 1; 
TGFу1, transforming growth factor-beta 1; CTGF, connective tissue growth factor.
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(Fig 2A). Moreover, and consistent with the observed polyuria in Li-NDI, many proximal
and distal tubuli, and collecting ducts were dilated (Fig 2B) and the brush border was
lacking in most tubuli (Fig. S1). In the collecting duct of Li-treated mice, cells were also 
protruding into the lumen (Fig. S1). Besides renal fibrosis, the diameter of the glomeruli 
in lithium-treated animals was decreased by ca. 24% (Fig 2C). Scoring of the extent of 
segmental glomerular sclerosis revealed that 5% of the glomerulri in lithium treated
mice were affected. In control mice, no segmental sclerosis was observed (Fig 2D and E). 
Figure 1. Lithium induces interstitial ﬁbrosis in the renal cortex and the medulla. Newborn
mice were treated with 40 mmol lithium chloride/kg food for 40 weeks or regular chow. Kidneys 
were harvested and stained for fibrosis using CAB staining. Shown are the cortex (A, B), outer 
medulla (C, D) and inner medulla (E, F) of control (A, C, E) and lithium-treated (B, D, F) mice.
Scale bar represents 30 μm, white arrows indicate collagen deposition, yellow arrows indicate 
brush border and the asterisk symbol indicates dilatated tubules. Number of animals: CTR = 6, 
Li = 7.
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Lithium increases alpha smooth muscle actin expression in cortex  
and outer medulla.
The recruitment, proliferation and differentiation of extracellular matrix–producing 
myofibroblasts is an essential step in the development of interstitial fibrosis (45-47). To
test for their presence, we stained kidney sections for т-smooth muscle actin (т-SMA),
a marker for myofibroblasts, in combination with markers for blood vessels (CD31) and
collecting duct cells (AQP4). In control animals, т-SMA staining was only detected 
around cortical blood vessels (Figs 3A, C and E). In lithium-treated mice, however,
т-SMA staining was observed around tubuli in the cortex and outer medulla (Figs 3B
and D), but not in the inner medulla (Fig 3F). The CD31 staining did specifically stain 
capillaries, but showed a non-specific green background staining, therewith visualizing 
the tubuli. In line with earlier stainings, the yellow staining for AQP4 was only visible in 
the basolateral side of principal cells in the inner medulla (48). 
Figure 2. Lithium induces renal tubular abnormalities after 40 weeks treatment. Newborn 
mice were treated with 40 mmol lithium chloride/kg food for 40 weeks or regular chow. Kidneys 
were harvested and fibrotic foci (A), tubular dilatation (B) and glomerular size (C) were
determined in the images obtained from the CAB staining. The extend of glomerular sclerosis 
was determined in images obtained from the methenamine silver staining (D and E). Scale bar 
represents 30 μm and the asterisk symbol indicates dilatated tubules. Number of animals: 
CTR = 6, Li = 7.
A B C
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To get an indication of factors contributing to the increase in the number of 
myofibroblasts, we assessed the mRNA expression of transforming growth factor beta
1 (TGFу1) and connective tissue growth factor (CTGF), two growth factors critically 
involved in stimulation of conversion of fibroblasts into myofibroblasts (46). RT-qPCR 
analysis revealed that TGFу1 mRNA levels were not changed by lithium-treatment, but
that the CTGF mRNA expression was significantly higher in the medulla, but not the 
cortex, of lithium treated mice (Figs 4A-D).
Lithium treatment causes a pro-inflammatory response.
The migration of mononuclear cells into the interstitium where they mature into 
macrophages is a hallmark in the pathology of tubulo-interstitial fibrosis (47, 49, 50). 
Monocytes and macrophages contribute directly to the fibrogenic process by releasing
S1 Figure. Lithium treatment results in loss of brush border in the cortex and tubular atrophy
of the inner medullary collecting duct. Magnification of the cortex and the inner medulla of 
control (A and C) and lithium treated (B and D) mice. Kidney sections were stained with CAB 
staining. Lithium treatment resulted in loss of brush border in the cortex and tubular atrophy of 
the inner medullary collecting duct cells with that showed enlarged nuclei and protruded into 
the lumen. Scale bar represents 30 μm.
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inflammatory and profibrotic molecules (50). Therefore, we determined the mRNA
expression of monocyte chemotactic protein 1 (MCP1), a chemokine that recruits 
monocytes to the sites of inflammation, F4/80, a macrophage marker, tumor necrosis 
factor alpha (TNFт), interleukin-6 (IL-6), interferon gamma (IFNф) and interleukin-1
receptor antagonist (IL-1Ra) in renal cortex and medulla (51, 52). Although the MCP1
mRNA expression was not higher in lithium groups (Figs 5A and B), F4/80 was 
significantly increased in both cortex and medulla of lithium-treated animals (Figs 5C 
and D), indicating an increased presence of macrophages. Furthermore, kidney 
sections of control and lithium-treated mice were stained immunohistochemically for 
the macrophage marker CD68. This confirmed the increase of macrophages after 
lithium treatment in comparison to control mice (Figs 5E and F). Furthermore, we also 
Figure 3. Lithium increases ʸ-SMA staining in the renal cortex and the medulla. Immunofluores-
cence staining for т-SMA (red), CD31 (green), AQP4 (yellow) and DAPI (blue) was performed on 
kidneys of mice that received lithium for 40 weeks. Shown are the cortex (A, B), outer medulla 
(C, D) and inner medulla (E, F) of control (A, C, E) and lithium-treated (B, D, F) mice. Scale bar 
represents 20 μm. Number of animals: CTR = 6, Li = 7. Abbreviation: alpha smooth muscle actin
(т-SMA), cluster of differentiation 31 (CD31), aquaporin-4 (AQP4) and 4’,6-Diamidino-2-Phenylin-
dole, Dihydrochloride (DAPI).
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assessed the mRNA expression of several inflammatory markers. After lithium 
treatment, mRNA expression of TNFт was significantly increased in both segments
(Figs 6A and B). No significant changes were observed for IL-6 (Figs 6C and D), IFNф
(Figs 6E and F), and IL-1Ra (Figs 6G and H).
For recruitment of inflammatory cells to injured tissue, immune cells in the circulation 
attach to the endothelium of blood vessels at the site of injury, for which the endothelial 
cells must have undergone several changes, such as increased expression of adhesion 
molecules and particular changes in heparan sulfate (HS) domains of the endothelial 
glycocalyx. Upon pro-inflammtory stimuli, such as the activation of the endothelium 
by the cytokines TNFт or IL-1у, heparan sulfate is changed to express specific highly
sulfated domains. Some of these domains were identified with specific anti-HS
Figure 4. Lithium induces CTGF mRNA expression in the renal medulla. RT-qPCR analysis was 
performed on cortex and medulla samples from control and 40 weeks lithium treated mice. (A)
TGFу1 cortex, (B) TGFу1 medulla, (C) CTGF cortex, (D) CTGF medulla. Results were normalized for 
36B4 mRNA expression and a significant difference (P<0.05) from CTR is denoted by an asterisk.
Number of animals: CTR = 6, Li = 7. Abbreviation: TGFу1; Transforming growth factor beta 1,
CTGF; connective tissue growth factor.
A
C
B
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antibodies on activated mouse glomerular endothelium. The expression of these
domains was increased upon TNFт or IL-1у activation, and leukocyte adhesion could
be inhibited by specifically blocking these domains, while targeting of other HS 
domains had no effect. Increased HS N-sulfation was shown to be a major determinant 
in this process since the inflammatory processes in a mouse model of experimental 
glomerulonephritis were decreased by specific knock-out of N-deacetylate/N-sulfo-
transferase-1 (Ndst-1), the major enzyme responsible for HS N-sulfation (41, 42, 49, 53).
To test the changes in heparin sulphate domains, we performed semi-quantitative 
immunohistochemistry with the EW3D10 antibody, which recognizes a pro-inflammatory 
HS form and mediates binding of leukocytes and chemokines. The expression of the 
HS domain recognized by the anti-HS antibody EW3D10 was increased 2-fold on 
Figure 5. Lithium induces macrophage accumulation in the renal cortex and medulla.
RT-qPCR analysis was performed on cortex and medulla samples from control and 40 weeks 
lithium treated mice. (A) MCP1 cortex, (B) MCP1 medulla, (C) F4/80 cortex, (D) F4/80 medulla. 
Results were normalized for 36B4 mRNA. kidney sections of control (E) and lithium-treated (F) 
mice were stained immunohistochemically for the macrophage marker CD68.  The scale bar 
represents 30 μm and the asterisk denotes a significant difference (P<0.05) from CTR. Number 
of animals: CTR = 6, Li = 7. Abbreviation: MCP1; monocyte chemotactic protein 1.
A B C D
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Figure 6. Minimal inﬂammatory reaction after long-term lithium treatment. RT-qPCR analysis 
was performed on cortex and medulla samples from control and 40 weeks lithium treated mice. 
(A) TNFт cortex, (B) TNFт medulla, (C) IL-6 cortex, (D) IL-6 medulla, (E) IFNф cortex, (F) IFNф
medulla, (G) IL-1Ra cortex, (H) IL-1Ra medulla. Results were normalized for 36B4 mRNA 
expression and the asterisk denotes a significant difference (P<0.05) from CTR. Number of 
animals: CTR = 6, Li = 7 Abbreviation: IL-6; Interleuking-6, TNFт; Tumor necrosis factor alpha, 
IFNф; Interferon gamma and IL-1Ra; interleukin-1 receptor antagonist.
Figure 7. Inﬂammatory changes in the peritubular endothelial glycocalyx after lithium
treatment. Pro-inflammatory changes in the glycocalyx were analyzed with anti-heparan
sulphate antibody EW3D10 (red) that detects inflammatory HS domains that are involved in
leukocyte trafficking and chemokine binding. The sections were also stained with AQP4 (green) 
to detect collecting ducts. (A) control, (B) lithium, (C) EW3D10 fluorescence intensity. The 
asterisk denotes a significant difference (P<0.05) from CTR.
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peritubular capillaries of lithium chloride fed mice as compared to control mice (Fig 7). 
No differences in staining intensity was found with the HS4C3 antibodies, which 
recognize a HS domain that is not affected by inflammation (Fig. S2).
Discussion
Lithium induces renal interstitial fibrosis in mice. 
Long-term lithium treatment in humans has been correlated with the development of 
chronic tubulointerstitial fibrosis (54-56). In this study, we investigated whether mice 
are a suitable model to study lithium-induced interstitial fibrosis. Based on our earlier 
(unpublished) data, we know that long-term lithium treatment of adult mice does not
lead to interstitial fibrosis within a time frame of 8 months. In addition, studies by 
Christensen et al. (1981) and Ottosen et al. (1984) demonstrated that newborn rats
were more susceptible to develop interstitial fibrosis after lithium treatment than adult 
mice (29, 30). Therefore, pregnant mice received several lithium concentrations in diet
and after weaning, these diets were directly administered to the pups. Only the group 
that received 40 mmol lithium chloride/kg survived the study of 40 weeks lithium 
chloride treatment, while mice that received higher lithium concentration died at an 
earlier age. Lithium poisoning can affect multiple organs including the central nervous 
system and the cardiovascular system, in addition to the adverse effects on water 
homeostasis (57, 58). Although the cause of death and serum lithium levels were not 
determined here, their early death is likely due to lithium poisoning. 
In this study, we found that treatment of newborn male and female C57Bl6 mice 
with 40 mmol lithium chloride/kg food for 40 weeks induced renal interstitial fibrosis 
S2 Figure. No differences in expression of the HS domain deﬁned by HS4C3. HS4C3 (red) was 
used as a non-inflammatory control in the detection of the endothelial glycocalyx and revealed 
no differences in expression in the peritubular endothelial glycocalyx between control (A) and
lithium-fed groups (B). The sections were also stained with AQP4 (green) to detect collecting 
ducts.
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in the cortex and outer medulla (Fig 1). This coincided with a  remarkable increase in
collagen deposition in the cortex and the outer medulla. Walker et al.  treated rats with
lithium (60 mmol lithium chloride/kg food) for 1, 3 and 6 months and reported, in line 
with our findings, a progressive interstitial fibrosis that was characterized by increased 
numbers of myofibroblasts, interstitial collagen deposition and a minimal inflammatory 
cellular response (59). We, nor they, observed any microcysts, which may be partially 
due to our 2D way of analysis, which complicates proper identification of cysts. It is at
present unclear why long-term lithium treatment yields renal cysts in humans, but not 
in rodents. Moreover, Ottosen et al. showed that young male rats being more affected
than females by lithium (60). However, the number of included animals from each
gender in this study was not enough to determine whether gender is an important 
aspect in the developmeant of interstitial fibrosis after lithium treatment. 
Classical activation of the fibrogenic pathway by lithium
A key feature in fibrosis is the activation of extra cellular matrix (ECM)-producing
myofibroblasts, which mediate the fibrogenic process (45, 47). Here, we demonstrated 
that lithium also induces the generation of myofibroblasts in the renal cortex and outer 
medulla of mice (Fig 3). Earlier findings in rats showed thatт-SMA staining was present 
throughout the whole kidney after 6-month lithium treatment (59, 61). In our study, 
renal TGFу1 mRNA expression was not increased after lithium treatment (Figs 4A and 
B), while it was increased in lithium-treated rats (59, 61). This difference can be
explained by the fact that serum lithium levels in the rats were higher (± 1.0 mM) than 
the expected serum lithium concentrations in our experiment (0.6 mM) after long term
lithium treatment. TGFу is considered as the major factors driving the development of 
fibrosis, as it stimulates interstitial generation of myofibroblast (46, 62). However, 
CTGF was significantly increased in the medulla of lithium treated mice (Fig 4D) and it 
antagonizes bone morphogenetic protein (BMP) signaling by preventing BMP binding 
to BMP receptors, thereby enhancing TGFу signaling (46, 63).
Moreover, lithium might also directly induce the conversion of resident fibroblasts
into myofibroblasts as Caraci et al. have shown that lithium treatment of human lung
fibroblasts increased total у-catenin levels, т-SMA expression and collagen production 
(64). However, Michalik et al. found contradictory results where lithium attenuated the 
transition of TGFу1-stimulated bronchial fibroblasts to myofibroblasts (65). Moreover, 
we have shown previously that lithium caused G2 phase cell cycle arrest in principal
cells (66). Under specific stress conditions, G2 arrested cells are also known to produce 
inflammatory cytokines and profibrotic proteins such as TGFу1 and CTGF, mediating 
the fibrogenic process and increase myofibroblasts (67). Taken together, the direct 
effect of lithium on renal fibroblasts remains unclear and more research is required to
elucidate the cellular and the molecular mechanisms responsible for the increase in
myofibroblasts in the kidney.
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The role of inflammation in lithium-induced renal fibrosis.
Previously we showed that specific HS domains within the endothelial glycocalyx, as
defined by specific anti-HS antibodies, are upregulated under inflammatory conditions, 
both in vitro and in vivo (36, 41, 42). Furthermore, we have provided in vitro and in vivo
evidence that these so called “inflammatory” HS domains are mediating leukocyte 
trafficking and chemokine binding (36, 41, 42). It appears that the expression of the 
inflammatory HS domain as defined by EW3D10 was upregulated in the lithium group 
(Fig 7). As such, this inflammatory state of the peritubular endothelial glycocalyx may 
have facilitated the migration of mononuclear cells into the interstitium after which
they matured into macrophages, as we found an increased abundance of macrophages 
based on F4/80 levels (Figs 5C and D). Moreover, we observed a significant increase of 
TNFт in the cortex and the medulla (Figs 6A and B), suggesting that the kidneys were 
in a pro-inflammatory state. However, this was a minimal inflammatory response since
other markers such as IL-6, IFNф and IL-1Ra were not altered by lithium. Walker et al.
also found a significant increase in the number of macrophages in the kidneys of 
6-month lithium-treated rats while inflammatory changes were minimal (59). Lithium 
might induce renal fibrosis without inducing an acute inflammatory response, as
Maarouf et al. demonstrated that activation of wnt1 caused interstitial fibrosis, while 
no inflammatory response was found (68). Wnt1 and lithium both target glycogen 
synthase kinase 3 beta (GSK3у) and a similar mechanism might underlie the observed
interstitial fibrosis. But lithium might also induce fibrosis that in turn results in an
inflammatory response that is inhibited by lithium, this response has been extensively 
reviewed by Nassar et al. (69).
In conclusion, we have shown that the most-commonly used mouse model C57BL/6, 
which is already extensively used to study Li-NDI, develops interstitial fibrosis when
mothers and subsequent pups are treated with a lithium dose that yields clinically-rel-
evant blood lithium levels. We furthermore showed that the histological and molecular 
changes with lithium-induced interstitial fibrosis formation is alike that found in lithium 
using patients, indicating that this approach allows the usage of C57Bl6 mice as a 
model to uncover the underlying mechanism, and to identify ways to prevent or treat,
human Li-induced renal fibrosis and, possibly, ESRD.
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Abstract
In SIADH, hyponatremia is limited by onset of vasopressin-escape, which is caused by 
loss of the water channel aquaporin-2 in the renal collecting duct (CD) despite high 
circulating vasopressin. Here, we use the methods of systems biology in a well-
established rat model of SIADH to identify signaling pathways activated at the 
onset of vasopressin-escape. Using single-tubule RNA-Seq, full transcriptomes were 
determined in microdissected cortical CDs of vasopressin-treated rats at time points 1, 
2, and 4 days after initiation of oral water loading (vs. time-controls without water 
loading). Time-dependent mRNA abundance changes were mapped to gene sets 
associated with curated canonical signaling pathways, revealing evidence of 
perturbation of TGFу signaling (and epithelial-to-mesenchymal transition [EMT]) on 
Day 1, simultaneous with the initial fall in Aqp2 gene expression. On Day 2, 
transcriptomic changes mapped to “notch signaling” and “transition from G0 to cell 
cycle”. There was no evidence of cell proliferation or altered principal or intercalated 
cell numbers. Exposure of vasopressin-treated cultured mpkCCD cells to TGFу resulted 
in a virtually complete loss of aquaporin-2. The data demonstrate a role for partial EMT 
in vasopressin-escape with a subsequent shift from quiescence to the cell cycle with 
arrest and loss of aquaporin-2.
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Introduction
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most
frequent cause of dilutional hyponatremia in hospitalized patients (1). In SIADH, high
levels of circulating vasopressin persist even when serum osmolality falls to levels 
that normally totally suppress neurohypophyseal vasopressin secretion. Consequently,
the kidney continues to reabsorb free water, leading to a progressive fall in serum 
osmolality (and sodium concentration). The extent of the fall is limited by the 
phenomenon of ‘vasopressin-escape’, which allows the kidneys to excrete free water 
despite sustained high levels of circulating vasopressin (2). Previous studies have 
demonstrated that vasopressin-escape is associated with a profound decrease in the 
expression of the Aqp2 gene (3), which codes for the vasopressin-regulated water 
channel, aquaporin-2 (AQP2) (4, 5). This results in markedly reduced water permeability 
of the collecting duct epithelium (6), increasing water excretion. 
The transcriptional regulatory mechanisms and signaling pathways responsible 
for vasopressin-escape are unknown. The chief limiting factor in the investigation of 
the vasopressin-escape phenomenon is the fact that collecting duct principal cells
make up only a small fraction of the renal cortex, where the suppression of AQP2 
expression in vasopressin-escape is most pronounced. Thus, standard biochemical
and systems biology techniques applied at a tissue level are not effective as a way of 
detecting responses in collecting duct principal cells. Recently, we have introduced
single-tubule RNA-Seq techniques that are capable of quantifying the entire 
transcriptome in samples of microdissected renal tubules from rat kidney consisting of 
less than 2000 cells (7). In this study, we used small sample RNA-Seq applied to 
microdissected renal cortical collecting ducts (CCDs) to identify transcriptomic
changes during onset of vasopressin-escape in a model of SIADH. The strategy was to 
carry out global measurements of transcript abundances to identify the changes that
occur at the earliest stages in the induction of vasopressin-escape (one, two and four 
days after initiation of water loading in vasopressin-treated rats). The central question 
that we addressed was, “What signaling pathways are activated or inactivated during 
development of vasopressin-escape?”  Based on the RNA-Seq results, we identified
elements of TGFу signaling, epithelial-to-mesenchymal transition (EMT), Notch 
signaling, and cell-cycle regulatory pathways as components of the cell signaling 
response during initiation of the vasopressin-escape phenomenon.
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Materials and Methods
The experimental design for this study (Animal Study Protocol No. H-0110R2, NHLBI)
was described previously (3) (Figure 1). Male Sprague-Dawley rats (120-160 g) were 
subcutaneously implanted with osmotic minipumps (Alzet) releasing dDAVP (Bachem)
at 5 ng/h. After 5 days of infusion, rats were divided into two groups (n=3 for each 
group for Day 1 and Day 4; n=4 for each group on Day 2). One group received a water 
load (“Escape”, 50 mL/day) in the form of a daily ration of gelled food containing 72%
water, 27% finely-ground rat chow, and 1% agar. The other group received only 25 mL/
day of water (“Control”) by feeding a gel containing 55% water, 43% chow, and 2%
agar. The level of water intake in the control animals was based on a prior estimate of 
insensible water losses and does not result in hyponatremia (8). Each Escape rat was
paired with a Control rat and both members of the pair were euthanized on the same
day for tissue processing, alternating the order. Plasma sodium concentration was 
measured in heparinized blood samples from tail-snips, using an iSTAT hand-held 
analyzer with a CHEM8+ cartridge.
Microdissection of CCDs. We followed our standard protocol for microdissection of 
rat renal tubule segments (9). Approximately four millimeters of CCD segments were
dissected per rat under a Wild M8 dissection stereomicroscope (Wild Heerbrugg) 
equipped with on-stage cooling.
RNA sequencing in microdissected tubules. The microdissected CCDs were processed 
for small sample RNA-Seq as described (6). The resulting cDNA libraries were
sequenced using an Illumina HiSeq2000 (Illumina, Inc.) to generate 50-bp paired-end 
nucleotide sequences. The FASTQ sequences were mapped to a rat reference genome
(Ensembl Rnor6.0) using STAR-2.4.0.1 (10). The read count data were summarized at 
the gene level and processed using factor analysis (11). DESeq2 (12) was used to 
generate Benjamini-Hochberg FDR-adjusted p-values for Log2(Escape/Control) values
for each transcript based on Wald tests. The FASTQ sequences and metadata
generated by this work have been deposited in NCBI’s Gene Expression Omnibus
(GEO)
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=axgfmcskxzmntep&-
acc=GSE69779).
Quantitative real-time PCR.  Quantitative real-time PCR was carried out from cDNA
libraries using a 7900HT PCR system (Applied Biosystems) (13). Gene expression was
compared using the ΔΔCT method (14). у-actin and glutaraldehyde-3-phosphate 
dehydrogenase were used as reference genes. Two-tailed Student’s t-test was used to
compare values in control versus escape animals.
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Identiﬁcation of gene groups over-represented. We used Chi-square analysis to ask
whether genes from a particular curated gene list were over-represented among genes
whose transcript abundances were changed in vasopressin-escape compared to 
genes whose transcript abundances did not change. Curated lists for various signaling
pathways were downloaded from KEGG (Kyoto Encyclopedia of Genes and Genomes) 
(http://www.genome.jp/kegg/) or from the literature (see Results). In addition, we 
used DAVID (14)  to identify Gene Ontology terms that were enriched in the set of genes 
whose transcripts changed relative to non-responding genes. 
Quantitative immunocytochemistry in microdissected tubules. Determination of 
the numbers of each cell type per unit length in microdissected CCDs from escape and
control rats was carried out using immunocytochemistry employing antibodies 
recognizing cell type specific markers, based on Purkerson et al. (15) The primary
antibodies used were goat anti-pendrin (G-19, sc-23779, Santa Cruz Biotechnology,
Santa Cruz, CA) and a previously characterized rabbit anti-H+-ATPase V1-B1 subunit 
(L615,(16)), each at 1:50 dilution. The secondary antibodies were Alexa Fluor 488
donkey anti-goat and Alexa Fluor 555 donkey anti-rabbit IgG (A11055 and A31572,
respectively, Invitrogen) each at 1:2000 dilution. Cell nuclei were also stained with 
DAPI.  Confocal fluorescence images were recorded with a Zeiss LSM780 confocal 
microscope using a 20x objective lens. Cell counting was performed on three-dimen-
sional reconstructed tubule images created by Imaris Scientific Image Processing & 
Analysis software (v7.7.1, Bitplane, Zurich, Switzerland). Counting was automated 
using Imaris “spot analysis” for nuclei and “surface analysis” to enumerate cells with 
apical pendrin or H+-ATPase labeling.   
Immunocytochemistry and Western blotting of rat kidney. Kidneys from vasopres-
sin-escape rats or control rats were perfusion fixed for immunocytochemistry following 
previously described procedures (17). Observations were made and recorded with a
Zeiss LSM780 confocal microscope. The right kidney from 2-day escape microdissec-
tion experiments was dissected into cortex, outer, and inner medulla, and prepared for 
Western blotting as previously described (13). Sources of primary antibodies for 
blotting and immunocytochemistry are found in Table 1 (18-20). 
Quantitative RT-PCR. Total RNA was isolated from the samples using TRIzol extraction
reagent according to the manufacturer’s instructions. RNA was then precipitated in 
ethanol, washed, and dissolved in nuclease-free water. Subsequently, RNA was re-
verse-transcribed into cDNA using Moloney murine leukemia virus reverse transcriptase
(Invitrogen, Bleiswijk, the Netherlands). RT-qPCR assays were performed using SYBR
Green kit (Bio-Rad, Veenendaal, the Netherlands). Primers were designed using the 
Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 36B4, which
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encodes an acidic ribosomal phosphoprotein P0 (RPLP0), was used as the reference 
(housekeeping) gene. Gene expression data were calculated using the Livak method 
(2−ΔΔCt) and they represent the mean fold difference from the control group. 
Cell culture. Mouse mpkCCD cells were cultured as described (21).
Statistics. The statistical methods used for each data type in this study are summarized 
in Table 2.
Results
Using a standard animal model of SIADH (3, 6, 8, 22-24) (Figure 1A), we confirmed the 
marked decrease in AQP2 protein abundance in vasopressin-escape kidneys (dDAVP
infusion plus water loading) relative to controls that received dDAVP and low water 
intake (Figure 1B and C). In a parallel set of vasopressin-escape rats, the plasma 
sodium decreased progressively from 137.2+0.4 on Day 1 to 124.3+1.5 on Day 2 to 
114.2+1.5 mM on Day 4 (all measured in the same animals, n=5).
RNA-Seq of microdissected CCDs: General features. We focused solely on the CCD to 
investigate transcriptomic changes occurring in vasopressin-escape rats as a function
of time following the increase in water intake (vasopressin infusion plus increase in 
water intake) versus control (vasopressin infusion with no increase in water intake),
employing single-tubule RNA-Seq (7). Among all RNA-Seq libraries, 81.3 to 85.3% of 
RNA-Seq reads were uniquely mapped to the reference genome (Rnor6.0), which
compares favorably to previous single-tubule RNA-Seq data (7) (Supplementary
Table 1. Antibodies Used for Immunocytochemistry and Western Blotting
in Native Tissue
Antibody Species Approach Dilution Source Reference
AQP2 Rabbit WB 1:1000 Knepper 41
AQP2 Chicken IC 1:300 Knepper 42
AQP3 Rabbit IC 1:100 Knepper 43
VDAC Mouse IC 1:500 Abcam ab14374
H-ATPase B/B2 subunit Mouse IC 1:50 Santa Cruz sc55544
PCNA Rabbit IC 1:100 Abcam ab18197
WB- western blotting, 
IC- immunohistochemistry
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 147
Single-tubule RNA-Seq reveals novel signaling mechanisms in SIADH | 147
Ta
bl
e 
2.
  S
ta
tis
tic
al
 M
et
ho
ds
D
at
a 
Ty
pe
M
ea
su
re
M
et
ri
cs
Pu
rp
os
e
Cr
it
er
io
n
RN
A-
Se
q
Fr
ag
m
en
ts
 p
er
 k
ilo
ba
se
 
ex
on
s 
fo
r m
ill
io
n 
m
ap
pe
d 
re
ad
s 
(F
PK
M
)
Pa
dj
; z
 v
al
ue
De
sc
rip
tiv
e;
 S
tre
ng
th
 o
f e
vi
de
nc
e
no
ne
Se
m
i-Q
ua
nt
ita
tiv
e 
Im
m
un
ob
lo
tti
ng
of
 K
id
ne
y 
Ti
ss
ue
 (F
ig
ur
e 
1)
N
or
m
al
iz
ed
 b
an
d 
de
ns
ity
P 
(u
np
ai
re
d 
t-t
es
t)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
Se
m
i-Q
ua
nt
ita
tiv
e 
Im
m
un
ob
lo
tti
ng
of
 C
ul
tu
re
d 
Ce
lls
 (F
ig
ur
es
 7
 a
nd
  1
2)
N
or
m
al
iz
ed
 b
an
d 
de
ns
ity
P 
(A
N
O
VA
; B
on
fe
rro
ni
)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
/n
En
ric
hm
en
t o
f G
en
es
 fr
om
 C
ut
at
ed
 L
is
ts
in
 V
as
op
re
ss
in
-e
sc
ap
e 
G
en
e 
Li
st
s
N
um
be
r o
f t
ra
ns
cr
ip
ts
P 
(C
hi
-s
qu
ar
e)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
En
ric
hm
en
t o
f G
en
e 
O
nt
ol
og
y 
Te
rm
s
in
 V
as
op
re
ss
in
-e
sc
ap
e 
G
en
e 
Li
st
s
N
um
be
r o
f t
ra
ns
cr
ip
ts
P 
(F
is
he
r E
xa
ct
; D
AV
ID
)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
Ce
ll 
Co
un
ts
 in
 Im
m
un
oc
yt
oc
he
m
ic
al
ly
 
La
be
le
d,
 M
ic
ro
di
ss
ec
te
d 
Tu
bu
le
s
N
um
be
r o
f c
el
ls
P 
(u
np
ai
re
d 
t-t
es
t)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
Ce
ll 
Co
un
ts
 o
f P
CN
A 
po
si
tiv
e 
ce
lls
 
N
um
be
r o
f c
el
ls
P 
(C
hi
-s
qu
ar
e)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
Ce
ll 
Co
un
ts
 o
f h
ig
h 
de
ns
ity
 
DA
PI
-la
be
le
d 
nu
cl
ei
N
um
be
r o
f c
el
ls
P 
(F
is
he
r E
xa
ct
)
Te
st
in
g 
nu
ll 
hy
po
th
es
is
P<
0.
05
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 148
148 | Chapter 8
Dataset 1 [Supplementary datasets at https://hpcwebapps.cit.nih.gov/ESBL/Database/
VasopressinEscapeData]). Overall, 12,951 to 14,357 transcripts were detected in the 
single-tubule RNA-Seq libraries (fragments per kilobase exons for million mapped 
reads [FPKM] > 0, Supplementary Dataset 1). All values are reported in Supplemental 
Dataset 2 and a summary is presented on a permanent web page (https://hpcwebapps.
Figure 1. Experimental model. A. The study design was adapted from Ecelbarger et al.(3).  Rats
were euthanized on day 1, 2, and 4. B.  Immunoblotting for AQP2 in the cortex, outer medulla, 
and inner medulla (n=4 per group) at day 2 of escape protocol. C. Densitometry shows a 
significant decrease in aquaporin-2 protein abundance in the cortex and inner medulla of the
escape animals, consistent with previous reports. For each lane, 10 μg (cortex), 5 μg (outer 
medulla), and 2 μg (inner medulla) of total protein was loaded. *p < 0.05 by unpaired t-test. 
(Coomassie-stained gels, run in parallel, showed equal loading.) Glyc-AQP2, glycosylated
aquaporin-2; non-Glyc-AQP2, nonglycosylated aquaporin-2.
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cit.nih.gov/ESBL/Database/VasopressinEscape/). The vast majority of transcripts 
(Figure 2) showed little or no change (Z* near zero). 
We focused first on RNA-Seq results for the water channels, AQP2 and AQP3 (Figure 3). 
Mapped reads (Figure 3A) coincide with the exons of the Aqp2 and Aqp3 genes. The 
reads mapped to the Aqp2 and Aqp3 genes were decreased in vasopressin-escape 
relative to the control (Figure 3A-B). The changes at Day 2 were confirmed by 
quantitative real-time PCR (AQP2: mean escape-to-control ratio 0.55, p = 0.024 by 
unpaired t-test; AQP3: mean escape-to-control ratio 0.24, p = 0.0000052;
Supplementary Dataset 3). The decreases in AQP2 and AQP3 transcript abundances 
began on Day 1 and were most striking at Day 4 (Figure 3C).  Among all transporters 
and receptors, AQP2 and AQP3 were the only ones with demonstrable changes (Table 3). 
Thus, the vasopressin-escape process selectively targets the two water channels.  
Canonical signaling pathways. To interpret the RNA-Seq data at a systems level, we
began by mapping up- and down-regulated transcripts to a set of known signaling 
pathways annotated in the KEGG Database. Table 4 summarizes the receptors, ligands
and transcription factors (TFs) associated with each KEGG Pathway. The hypothesis is 
that transcripts coding for elements of one or more of these pathways will be perturbed 
during the development of the vasopressin-escape phenomenon.
Figure 2. Distribution of Z* values for Log2(Escape/Control) across all genes. Z* is estimated 
as mean value for all replicates divided by the standard deviation across means for all genes.
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Mapping RNA-Seq data to canonical signaling pathways. Figure 4 shows a summary 
of the RNA-Seq results with values presented as the mean Log2(Escape/Control) for 
the relevant TFs for the canonical signaling pathways on Days 1, 2 and 4. Most were 
either unchanged or not detectable throughout the time course (yellow boxes). 
However, a few key TFs in some of the signaling categories were seen to change, viz.
TGFу signaling/EMT (Snail3 and Smad3 increased on Day 1; Smad2 and Tgif1 increased 
on Day 4), MAPK signaling (Elk1 increased on Days 2 and 4; Nr4a2 decreased on Day 
1), signaling associated with transition from G0 (quiescence) into the cell cycle (E2f1 
and Foxm1 increased on Days 2 and 4; E2f2 increased on Day 2; E2f4 increased on Day
1), cyclic AMP signaling (Jun decreased on Day 2; Sox17 decreased on Day1; Nfatc3,
increased on Day 4), and Notch signaling (Hes1 decreased on Days 2 and 4). Thus, we
hypothesize that one or more of these pathways could be responsible for vasopres-
sin-escape. We consider them in turn.
Table 3. Transcript abundance changes in transporters and receptors expressed in
principal cells of the rat renal CCD during the onset of vasopressin-escape.
Values with P<0.05 in bold (Wald test). 
Log2(Escape/Control)
Gene Symbol Annotation Day  1 Day 2 Day 4
Aqp2 Aquaporin-2 -0.70 -0.89 -1.11
Aqp3 Aquaporin-3 -1.31 -1.62 -1.59
Aqp4 Aquaporin-4 -0.75 0.21 0.26
Atp1a1 Na/K-ATPase subunit alpha-1 0.02 0.43 0.08
Atp1b1 Na/K-ATPase subunit beta-1 -0.41 -0.14 -0.09
Avpr2 Vasopressin receptor V2 0.22 -0.39 -0.23
Clcnka Chloride channel ClC-Ka -0.22 -0.69 -0.03
Clcnkb Chloride channel ClC-Kb 0.14 0.20 0.20
Fxyd2 Na/K-ATPase subunit gamma subunit -0.26 0.57 0.46
Kcnj1 Inward rectifier potassium channel 1 (ROMK) 0.05 0.00 0.05
Nr3c2 Mineralocorticoid receptor 0.46 -0.51 -0.03
Scnn1a Epithelial Na channel alpha subunit -0.09 0.17 -0.06
Scnn1b Epithelial Na channel beta subunit -0.07 -0.12 0.00
Scnn1g Epithelial Na channel gamma subunit -0.15 -0.47 0.24
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Figure 3. Abundances of aquaporin-2 (AQP2) and aquaporin-3 (AQP3) transcripts in the CCD 
are decreased in vasopressin-escape animals. A. RNA-Seq reads are mapped to the RefSeq 
transcript models of for rat Aqp2 gene (top) and Aqp3 gene (bottom). For each RefSeq transcript,
exons are shown as red rectangles and introns as blue lines connecting the exons. Barbs
indicate direction of transcription. The coverage was calculated as the number of reads per 
million nucleotides in the whole genome. B. Normalized RNA-Seq read counts for Aqp2 and 
Aqp3 in the CCD segments obtained from four pairs (control versus escape animals) at day 2.  C.
Change in AQP2 and AQP3 transcript abundances in the microdissected CCDs on different days 
relative to time controls (*Padj < 0.05 for escape vs control at each time point, paired t-test).
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Figure 4. Changes in transcript abundances for TF genes associated with annotated KEGG 
pathways during the onset of vasopressin-escape.
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TGFʹ signaling and epithelial-to-mesenchymal transition. TGFу signaling plays a
central role in the induction of epithelial-to-mesenchymal transition (EMT) (25), so we 
considered the two together. The increases in transcript abundances of Smad3 (a 
TGFу-signaling mediator) and Snail3 (an EMT-mediator) occur at the earliest time point
studied, pointing to the possibility that a change in TGFу signaling or induction of an
EMT could be an early event in vasopressin-escape. Looking at other mediators of 
TGFу signaling (Figure 5 and Table 5), there were coordinate increases in Smad3 and 
downstream TFs E2f4 and Snai3 on Day 1, as well as Smad2 and downstream TF Tgif1 
on Day 4. Thus, the weight of the evidence is in favor of downstream activation of TG-
Fу-BMP-activin-dependent signaling. 
A recent study has presented a meta-analysis listing 130 consensus “EMT-genes” that
are consistently altered in EMT (26). We use this list to ask, “Are the consensus 
EMT-genes statistically over-represented among genes whose transcript abundances 
are altered on Day 1 of vasopressin-escape versus genes whose transcripts are not 
altered?” The answer is that transcripts corresponding to consensus EMT genes are 
indeed over-represented (Table 6).   Looking at the time courses of change of some of 
these EMT-marker genes (Figure 6A), transcripts associated with mesenchymal cells
(collagen type I т-1, collagen type VI т-1, matrix metallopeptidase 2 and vimentin)
show a similar trend with no change or a decrease on Day 1 of vasopressin-escape 
Figure 5. Ofﬁcial gene symbols of transcripts associated with TGFʹ-activin-BMP signaling 
undergoing changes during onset of vasopressin-escape. Increased, green; decreased, red. See 
Table 4 for annotations of these genes. Specific values are available in Supplemental Dataset 2.
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Table 5. List of TGFу signaling genes whose transcript abundances were seen to 
change significantly during onset of vasopressin-escape. See Figure 5 for 
day and direction of changes.
Gene Symbol Protein Name Function
Acvr1 activin receptor type-1 
(serine/threonine-protein
kinase receptor R1)
On ligand binding, forms a receptor complex 
consisting of two type II and two type I
transmembrane serine/threonine kinases. Type
II receptors phosphorylate and activate type I
receptors which autophosphorylate, then bind and 
activate SMAD transcriptional regulators.
Acvr2a activin receptor type-2A On ligand binding, forms a receptor complex 
consisting of two type II and two type I
transmembrane serine/threonine kinases. Type
II receptors phosphorylate and activate type I
receptors which autophosphorylate, then bind and 
activate SMAD transcriptional regulators. Receptor 
for activin A, activin B and inhibin A.
Bmp7 bone morphogenetic 
protein 7 precursor
Belongs to the TGF-beta family. Secreted ligand.  
Involved in renal development.
Bmpr1b bone morphogenetic 
protein receptor type-1B 
(serine/threonine-protein
kinase receptor R6)
On ligand binding, forms a receptor complex 
consisting of two type II and two type I
transmembrane serine/threonine kinases. Type
II receptors phosphorylate and activate type I
receptors which autophosphorylate, then bind and 
activate SMAD transcriptional regulators. Receptor 
for BMP7.
Dcn decorin Binds to type I and type II collagen, fibronectin 
and TGF-beta.  Belongs to the small leucine-rich 
proteoglycan (SLRP) family.  Secreted.
E2f4 TF E2F4 Transcription activator that binds DNA 
cooperatively with DP proteins through the E2 
recognition site.  Found in the promoter region of 
a number of genes whose products are involved 
in cell cycle regulation or in DNA replication. E2F4
binds with high affinity to RBL1 and RBL2.
Id4 DNA-binding protein
inhibitor ID-4
Transcriptional regulator (lacking a basic DNA 
binding domain) which negatively regulates the
basic helix-loop-helix (bHLH) TFs by forming
heterodimers and inhibiting their DNA binding and
transcriptional activity.
Ppp2r1b serine/threonine-protein
phosphatase 2A 65 kDa 
regulatory subunit A beta 
isoform
Scaffolding molecule to coordinate the assembly 
of the catalytic subunit and a variable regulatory
B subunit.  PP2A consists of a common 
heterodimeric core enzyme, composed of a 36
kDa catalytic subunit (subunit C) and a 65 kDa 
constant regulatory subunit (PR65 or subunit A), that
associates with a variety of regulatory subunits.
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followed by large increases on Days 2 and 4. In contrast, transcripts associated with
differentiated epithelial cells (occludin and E-cadherin) show no substantial change. 
Thus, during the induction of vasopressin-escape, collecting duct cells show some 
characteristics of EMT, but do not manifest full-blown conversion to mesenchymal 
cells, a state that has been described by Kalluri and Weinberg as a ‘partial EMT’ (27).
AQP3 labeling remained on the basal and lateral aspects of the cell, while AQP2 
labeling continued to be apically oriented (Figure 6B), although labeling for both was 
less intense. Thus, it appears that epithelial polarity is not lost in early stages of vaso-
pressin-escape and that the reduction in water channel expression does not require
loss of polarity. 
Table 5. Continued
Gene Symbol Protein Name Function
Smad2 mothers against
decapentaplegic homolog 2
Intracellular signal transducer and transcriptional
modulator activated by TGF-beta (transforming 
growth factor) and activin type 1 receptor kinases.
Binds the TRE element in the promoter region of 
many genes that are regulated by TGF-beta and, 
on formation of the SMAD3/SMAD4 complex, 
activates transcription. Also, can form aSMAD3/
SMAD4/JUN/FOS complex at the AP-1/SMAD site 
to regulate TGF-beta-mediated transcription.
Dephosphorylated by phosphatase PPM1A,
resulting in nuclear export.
Smad3 mothers against
decapentaplegic homolog 3
Intracellular signal transducer and transcriptional
modulator activated by TGF-beta (transforming 
growth factor) and activin type 1 receptor kinases.
Binds the TRE element in the promoter region of 
many genes that are regulated by TGF-beta and, 
on formation of the SMAD3/SMAD4 complex, 
activates transcription. Also, can form aSMAD3/
SMAD4/JUN/FOS complex at the AP-1/SMAD site 
to regulate TGF-beta-mediated transcription.  
Dephosphorylated by phosphatase PPM1A,
resulting in nuclear export.
Snai3 zinc finger protein SNAI3 Transcriptional repressor of E-box-dependent
transactivation of downstream basic-Helix-Loop-
Helix genes. 
Tgif1 homeobox protein TGIF1 Binds to RXR element and inhibits the 9-cis-
retinoic acid-dependent RXR alpha transcriptional 
activation. Interacts with CTBP, SMAD2, SMAD3
and HDAC1.
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If activation of TGFу signaling is critical for loss of Aqp2 gene expression in vasopres-
sin-escape, then it might be expected that triggering of TGFу-signaling in another 
manner, namely by exposure of CCD cells directly to TGFу, would reduce the abundance 
of AQP2 protein. Indeed, in AQP2-expressing mouse mpkCCD collecting duct cells (28),
addition of TGFу to vasopressin-treated cells for 48 hrs produced a profound decrease 
in AQP2 protein and mRNA abundance (Figure 7). The transepithelial resistance of 
these cells did not fall, but rather increased, indicating that the junctional barrier 
remained intact (Supplemental Figure 1).  
Notch signaling and collecting duct remodeling. Notch signaling is an important
factor in collecting duct remodeling, a process in which the relative abundances of the 
three major cell types in the CCD (principal cells [PCs], т-intercalated cells [т-ICs], and
у-intercalated cells [у-ICs])  can undergo adaptive changes (29). The demonstrated 
decreases (Days 2 and 4) in the transcript abundance of the TF, Hes1, a mediator of 
Notch signaling, raise the possibility that Notch-related collecting duct remodeling is 
involved in vasopressin-escape (Figure 4).   Accordingly, we used immunocytochemis-
try in microdissected CCDs to count the cell types using standard markers (pendrin
([у-IC marker] and Atp6v1b1 [total IC marker]; DAPI [total cell marker]) (Figure 8 and 
Supplemental Figure 2). (In this analysis, principal cell counts are estimated as the
Table 6. Epithelial-to-mesenchymal transition (EMT) signature genes are more 
frequently represented among transcripts regulated in vasopressin-escape
than among non-regulated transcripts (Chi-square analysis).
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* For this analysis, ‘Regulated transcripts’ are those with Padj <0.10 and |z*|>2.
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transcripts. 
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transcripts.
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 158
158 | Chapter 8
Figure 6. Onset of vasopressin-escape is associated with a partial epithelial-to-mesenchymal 
transition in rat CCD cells. A. Time course of transcript abundance changes for selected EMT 
marker genes during onset of vasopressin-escape in microdissected rat CCDs shows increase in
mesenchyme-associated transcripts (Col1a1, Col6a3, Mmp2 and Vim) without loss of epithelium-
associated transcripts (Cdh1 and Ocln). Asterisk indicates Benjamini-Hochberg FDR-adjusted
P value <0.05. B. Immunocytochemical labeling for AQP2 and AQP3 in renal cortex of rats 
undergoing vasopressin-escape shows retention of normal epithelial polarity. VDAC labeling of 
mitochondria was also carried out to reveal presence of intercalated (‘mitochondria-rich’) cells. 
DAPI labeling of nuclei facilitates recognition of apical versus basal aspects of cells.
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total cell count minus the intercalated cell count.) Table 7 shows that there were no
significant differences in any cell type. We conclude that the decreases in AQP2 and 
AQP3 abundances were not likely to be due to a loss of PCs. Thus, there was little or no 
remodeling of the CCD in the vasopressin-escape rats. 
Figure 7. TGFʹ exposure decreases AQP2 protein and mRNA abundance in mpkCCD cells.
A. Representative immunoblot showing relative AQP2 abundances in control (CTR) cells and 
cells exposed to TGFу (1, 5 or 10 ng/ml) for 2 days in serum-free medium.  The cells were 
pretreated with 1 nM dDAVP on the basolateral side for 4 days to induce AQP2 expression.
Bottom panel shows a Coomassie-stained gel to demonstrate equal loading. B. AQP2 band 
density was significantly decreased both for glycosylated and nonglycosylated AQP2 (n=3). C.
SYBR Green™ fluorescence curves for RT-qPCR experiments quantifying AQP2 mRNA under the 
control (CTR) condition, after 1 ng/ml TGFу (2 days) and after 1 ng/ml TGFу plus amiloride at 10 
μM (2 days).  Cells were pre-treated with dDAVP at 1 nM for 4 days.  Horizontal green line is the 
threshold used to calculate Ct. The relative AQP2 abundances (normalized to the housekeeping
gene RPLP0) are shown as a bar graph.
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Signaling associated with transition from G0 to cell cycle. The increases in transcript
abundances of E2f1 and Foxm1 (Figure 4) on Day 2 and Day 4 of vasopressin-escape
point to a possible role for the signaling process that shifts cells from the quiescent
state (G0) into the cell cycle. The E2f family of winged-helix TFs are classical regulators
of this transition (30) and Foxm1 also plays key roles in transcriptional regulation of 
cell-cycle genes (31). Thus, we hypothesized that vasopressin-escape is associated
with a shift from G0 to cell cycle progression in CCD cells. To test this, we identified 
Gene Ontology Biological Process terms enriched among transcripts altered in 
abundance on Day 2 of vasopressin-escape relative to unregulated genes (Table 8).
The four Biological Process terms with the lowest false discovery rates were all 
associated with the cell cycle and cell division. The 49 regulated transcripts with the 
term ‘cell cycle’ are listed in Table 9. Remarkably, 46 of the 49 cell-cycle genes showed
increases in transcript abundance (Log2[Escape/Control] > 0). The striking changes are 
further illustrated in Figure 9 and Supplemental Figure 3. Thus, the analysis showed a 
dramatic increase in most mRNA species coding for cell cycle proteins at Day 2 of va-
sopressin-escape.  A similar analysis for Day 1 revealed a lack of a significant over-rep-
Table 7. Comparisons of cell populations in microdissected CCDs from rats
undergoing vasopressin-escape compared with control rats.
# Nuclei % Pendrin- % Pendrin- % Ratio Ratio
per mm length positive ICs negative ICs Total ICs PCs:ICs т-ICs: у-ICs
Control 1 547 21 15 37 1.69 0.75
Control 2 575 27 16 44 1.30 0.57
Control 3 479 22 19 41 1.45 0.84
Control 4 453 17 29 46 1.16 1.80
Mean ± SE 514 ± 29 22 ± 2 20 ± 3 42 ± 2 1.40 ± 0.11 0.99 ± 0.27
Escape 1 449 20 21 41 1.40 1.16
Escape 2 583 19 16 36 1.99 0.86
Escape 3 555 21 16 39 1.55 0.77
Escape 4 451 14 22 42 1.45 2.06
Mean ± SE 509 ± 35 19 ± 1 19 ± 2 40 ± 1 1.60 ± 0.13 1.21 ± 0.29
p-Value 0.93 0.26 0.82 0.33 0.30 0.60
A total of 35 microdissected CCDs were analyzed, 13 from Control rats and 22 from Escape rats.  There were
no statistically differences between two groups of animals (unpaired Student’s t-test, n=4).  Percent of 
principal cells (PCs) may be estimated as 100 minus the percent of total ICs.  IC, intercalated cell.
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Figure 8.  Cell counting in immunoﬂuorescently labeled CCDs microdissected from rats. After 
micro- dissection, tubules were fixed with paraformaldehyde followed by immunofluorescence 
staining for intercalated cells (using pendrin and H+-ATPase antibodies) and nuclei (DAPI). 
A. Standard confocal fluorescence image of a microdissected CCD from a control vasopressin-
treated rat. Pendrin, green; B1 H+-ATPase, red; DAPI labeling of nuclei, blue.  Examples of 
identified  т-intercalated cells (т-IC) and у-intercalated cells (у -IC) are pointed out. Asterisks 
indicate cells that appear to lack pendrin labeling in confocal image but are revealed to be 
у-intercalated cells in the 3D reconstruction. B. Maximum intensity projection of 3-D reconstructed
tubule image generated by IMARIS image analysis software. Colors are the same as in Panel A.
Asterisks mark the same cells indicated in Panel A. C. IMARIS-generated analytical image. The 
pendrin-positive IC cells and non-pendrin IC cells were labeled in green and red, respectively, 
based on IMARIS surface and spot analysis tools. Nuclei are shown in cyan. For details, see 
Supplemental Figure 2.
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resentation of the transcripts with the Gene Ontology Biological Process term ‘cell 
cycle’. However, on Day 4 (like Day 2), there was a marked over-representation of ‘cell
cycle’ (Supplemental Datasets 4-6). Thus, the widespread induction of cell-cycle gene
expression is not seen until Day 2, i.e. after the initial fall in AQP2 transcript abundance.
The pattern of response is illustrated by Figure 10, which shows the time course for 
three key protein kinases involved in cell-cycle regulation (Cyclin-dependent kinase 1 
[Cdk1], Polo-like kinase 1 [Plk1], and Aurora B kinase [Aurkb]) and for three transcrip-
tional regulators involved in cell-cycle control (E2f1, Timeless, and Foxm1). These
transcripts showed similar time courses of change with no change or a decrease on 
Day 1 and increases on Days 2 and 4, contrasting with transcripts not involved in
cell-cycle regulation (Protein kinase A Catalytic т [Prkaca] and Homeobox B7 [Hoxb7]) 
shown in red).
We asked whether the frequency of cells in S phase is increased in vasopressin-es-
cape using immunocytochemical labeling of renal cortical sections with anti-prolifer-
ating cell nuclear antigen (PCNA) antibodies (Figure 11A). PCNA-positive cell nuclei 
were scarce in CCDs in under both conditions. Only 1 PCNA-positive cell nucleus was 
Table 8. Statistically over-represented Gene Ontology Biological Process terms
among transcripts with altered abundance on Day 2 of vasopressin-escape.^
GO Biological Process Term* Number
of Genes
Fold
Enrichment†
False
Discovery
Rate (%)
P
(Fisher
Exact)
cell cycle process 44 6.6 4.10E-20 4.60E-24
cell cycle 49 5.7 5.40E-20 7.10E-24
cell division 22 8 4.30E-10 3.80E-14
chromosome segregation 15 15.1 6.40E-10 2.60E-14
organelle organization 47 2.6 2.40E-06 7.50E-10
microtubule-based process 19 5.2 2.90E-05 4.30E-09
nitrogen compound metabolic process 62 1.6 1.40E-01 7.00E-05
negative regulation of biological process 50 1.7 3.00E-01 1.50E-04
DNA packaging 9 5.2 4.10E-01 6.00E-05
cellular response to stimulus 27 2.1 5.30E-01 2.00E-04
positive regulation of biological process 55 1.6 6.30E-01 3.30E-04
^ “Altered transcripts” were those with Benjamini-Hochberg FDR-adjusted P value < 0.1.
* Analysis used DAVID Functional Annotation tools (see (Methods) to identify all terms with False Discovery 
Rate (FDR) < 1%.
† “Fold Enrichment” is the fraction of genes with the given GO term in the “regulated” list divided by the
fraction of genes in full list (“regulated” + “unregulated”) with that term.
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identified in 45 CCD profiles in dDAVP-only control animals, and only 4 PCNA-positive
nuclei were detected in 89 CCD profiles observed in escape animals (p=0.67, Fisher 
Exact Test). To identify G2 phase and early M phase, we quantified the intensity of DAPI
labeling in CCDs (Figure 11B). The median per-nucleus DAPI fluorescence is similar in 
the two groups (Table 10). Nuclei with total DAPI fluorescence greater than the
indicated threshold (1.8 times median) were scarce in both escape (1.67% of total) and
control (0.48% of total) CCDs. However, these proportions were statistically
significantly different (P=0.005, Fisher Exact Test). This finding is compatible with a 
modest increase in the frequency of cells in G2/M. However, the previous observation 
that the total number of each cell type per total tubule length in microdissected CCDs 
does not change (Table 7) argues against a major increase in cell proliferation, and the 
Figure 9. Transcripts corresponding to most genes present in the KEGG Cell Cycle Pathway 
were increased in abundance in CCDs from rats on Day 2 of development of vasopressin-
escape. Values for all four Day-2 replicates are shown as individual blocks colored to show 
magnitude of change (red, increased; green, decreased) as generated by Bioconductor Pathview 
software (https://www.bioconductor.org/packages/devel/bioc/html/pathview.html) run on R. 
The specific values are available in Supplementary Dataset 1.
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entirety of the data could be viewed as consistent with arrest at G2/M. If a shift from
quiescence to the cell cycle is in part responsible for the loss of AQP2 expression in 
vasopressin-escape, it may be predicted that inducing such a shift in cultured CCD
(mpkCCD) cells by serum addition, with or without addition of agents that inhibit cell 
cycle progression at specific points, would reduce the abundance of AQP2 despite the 
continued presence of vasopressin. Indeed, in such experiments, AQP2 protein
appears to be maximally expressed only in cells grown in the absence of fetal calf 
serum, i.e.  in G0 (Figure 12). However, we cannot rule out the possibility that the
decrease in AQP2 could also be caused by addition of factors that inhibit Aqp2 gene 
transcription independent of changes in the cell cycle.
Figure 10. Time courses of abundance change for mRNAs coding for protein kinases (left) and 
TFs (right) involved in regulation of cell-cycle. All six cell-cycle related transcripts (black)
showed significant increases only on Days 2 and 4. Only Foxm1 was significantly changed on
Day 1, a decrease.  Abundant non-cell-cycle transcripts (Prkaca and Hoxb7), shown in red, are
included as controls.  Cdk1, Cyclin-dependent kinase 1; Plk1, Polo-like kinase 1; Aurkb, Aurora B
kinase, Prkaca, Protein kinase A catalytic т; E2f1, E2F TF 1; Timeless, timeless circadian clock;
Foxm1, Forkhead Box M1 ; Hoxb7, Homeobox B7.
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Table 9. Altered transcripts in CCD on Day 2 of vasopressin-escape with 
Gene Ontology Biological Process term ‘Cell Cycle’*
Gene
Symbol
Annotation Log2
(Escape/
Control)
Padj 
(Benjamini-
Hochberg)
Mlf1 myeloid leukemia factor 1 4.17 2.52E-13
Tacc3 transforming, acidic coiled-coil containing protein 3 3.57 2.39E-12
Tubb5 tubulin, beta 5 1.90 3.33E-12
Cenpf centromere protein F 3.75 4.17E-12
E2f1 E2F TF 1 3.68 2.80E-11
Uhrf1 ubiquitin-like with PHD and ring finger domains 1 3.43 1.80E-08
Ube2c ubiquitin-conjugating enzyme E2C 2.82 2.58E-08
Aurkb aurora kinase B 2.64 2.34E-07
Kifc1 kinesin family member C1 2.02 2.54E-07
Pole polymerase (DNA directed), epsilon 2.79 3.28E-07
Fancd2 Fanconi anemia, complementation group D2 2.96 1.92E-06
Dscc1 defective in sister chromatid cohesion 1 2.16 4.72E-06
Spc25 SPC25, NDC80 kinetochore complex component 2.43 7.80E-06
Cdca8 cell division cycle associated 8 2.61 2.02E-05
Plk1 polo-like kinase 1 (Drosophila) 2.46 4.09E-05
Mcm6 minichromosome maintenance complex component 6 1.83 6.77E-05
Id4 inhibitor of DNA binding 4 -2.15 7.41E-05
Brca1 breast cancer 1 2.52 1.93E-04
Ncaph non-SMC condensin I complex, subunit H 1.66 3.33E-04
Aurka aurora kinase A 1.61 1.33E-03
Racgap1 Rac GTPase-activating protein 1 1.87 1.45E-03
Mad2l1 MAD2 (mitotic arrest deficient, homolog)-like 1  1.98 2.44E-03
Stmn1 stathmin 1 1.56 3.30E-03
Cdc25b cell division cycle 25 homolog B (S. pombe) 1.57 3.61E-03
Birc5 baculoviral IAP repeat-containing 5 1.78 3.82E-03
Cdc5l CDC5 cell division cycle 5-like (S. pombe) 1.38 4.31E-03
Pttg1 pituitary tumor-transforming 1 2.09 4.89E-03
Cdc20 cell division cycle 20 homolog (S. cerevisiae) 1.64 4.97E-03
Kif2c kinesin family member 2C 2.07 5.96E-03
Katna1 katanin p60 (ATPase-containing) subunit A1 1.49 7.35E-03
Wee1 wee 1 homolog (S. pombe) 1.29 7.35E-03
Kif18a kinesin family member 18A 1.98 7.83E-03
Haus4 HAUS augmin-like complex, subunit 4 1.19 7.84E-03
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Table 9. Altered transcripts in CCD on Day 2 of vasopressin-escape with
Gene Ontology Biological Process term ‘Cell Cycle’*
Gene
Symbol
Annotation Log2
(Escape/
Control)
Padj 
(Benjamini-
Hochberg)
Pola1 polymerase (DNA directed), alpha 1 1.86 9.08E-03
Cenpa centromere protein A 1.82 9.69E-03
Nusap1 nucleolar and spindle associated protein 1 1.65 9.69E-03
Trip13 thyroid hormone receptor interactor 13 1.68 9.69E-03
Msh5 mutS homolog 5 1.57 1.17E-02
Ccna2 cyclin A2 1.82 1.49E-02
Cdca3 cell division cycle associated 3 1.57 3.32E-02
Rad51c Rad51 homolog c 1.55 3.62E-02
Calm2 calmodulin 2 1.21 3.95E-02
Cdkn1b cyclin-dependent kinase inhibitor 1B -1.16 4.57E-02
Txnl4b thioredoxin-like 4B 1.42 4.72E-02
Mdm2 Mdm2 p53 binding protein -1.16 4.73E-02
Timeless timeless homolog 1.57 5.35E-02
Dlgap5 discs, large homolog-associated protein 5 1.47 5.36E-02
Nuf2 NDC80 kinetochore complex component 1.54 7.70E-02
Ska2 family with sequence similarity 33, member A 1.49 9.01E-02
* Includes all transcripts for “cell cycle” Gene Ontology term in Table 8.
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Table 10. DAPI-Fluorescence per Nucleus in 4-Day Escape Versus Control Rats†
Median
Intensity
Standard
Deviation
Total Nuclei 
Counted
Number of 
High Intensity
Nuclei*
Percent
High Intensity
Nucleus
P
(Fisher
Exact)‡
Control 116 26 1038 5 0.48
Escape 111 33 1921 32 1.67 0.005
† Values (arbitrary units) represent summation of fluorescence levels in all voxels mapping to a given 
nucleus using Imaris software (See Methods).
* Number of nuclei above threshold of 200 arbitrary units (green vertical line in Figure 11B). 
‡ Probability of the null hypothesis that the proportion of high intensity nuclei is the same in CCDs from 
escape and control rats.
Figure 11. Cell cycle indices in renal CCDs from vasopressin-escape versus control rats.
A. Nuclei labeled with antibody to PCNA (S-phase marker) are scarce. Image shows section of 
renal cortex from rat undergoing vasopressin-escape (Day 2). Labeling for AQP2 (green) and 
the B1 subunit of the vacuolar proton-ATPase (red) identify collecting ducts (numbered). A single
collecting duct cell with PCNA labeling (cyan) is seen (red arrow). DAPI, blue. B. Distribution of 
integrated DAPI fluorescence signal in nuclei of microdissected CCDs from rats undergoing 
vasopressin-escape (Day 4 of escape protocol) versus control rats. See Table 10 for quantitation.
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Discussion
Vasopressin-escape is a safety-valve mechanism that limits dilutional hyponatremia 
in SIADH and possibly other hyponatremic disorders (2). It attenuates water retention 
through the loss of expression of the Aqp2 gene, which codes for the aquaporin-2
water channel (3). Here, we have adopted a systems-biology-based approach (32, 33)
to address the mechanism of vasopressin-escape. “Systems biology” uses large-scale
Figure 12. AQP2 protein is strongly expressed in cultured CCD cells in G0, but not when in the 
cell cycle. dDAVP-treated (1 nM) mpkCCD cells were grown on a semi-permeable filter and
synchronized in the different phases of the cell cycle (FCS withdrawal for G0 phase, PD0332991
for G1, Hydroxyurea for S and Nocodazole for G2/M phase), then immunoblotted for AQP2 and 
Cyclins D1, A, and B.
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 169
Single-tubule RNA-Seq reveals novel signaling mechanisms in SIADH | 169
data acquisition techniques (here, “single-tubule RNA-Seq”) to study a biological
process (here, “vasopressin-escape”) by investigating all genes or gene products 
together to understand biological mechanisms, rather than focusing on one or a few
selected genes (32). The data are interpreted, not on a gene-by-gene basis, but rather 
through detection of coordinate changes in curated groups of genes (here, genes
whose products are elements of the canonical signaling pathways listed in Table 4). 
In the present study, we found statistically significant overlaps between the set of 
genes whose transcripts changed in abundance in vasopressin-escape and the sets of 
genes associated with two biological processes, namely “epithelial-to-mesenchymal 
transition (EMT)/TGFу signaling” and “the cell cycle”. The earliest detectable changes
in the former process were seen on Day 1 of vasopressin-escape, coincident with the 
first detectable decreases in AQP2 and AQP3 proteins. The earliest statistically significant
response for the cell-cycle pathway was seen on Day 2. We discuss these responses in
turn. It is important to point out however, that the changes we observe in microdissected 
CCD include changes occurring in both intercalated and principal cells, thus it is 
premature to suggest they are unequivocally related to the fall in AQP2 or AQP3.      
TGFу signaling/EMT. The decrease of Aqp2 gene expression in the CCD during the
onset of vasopressin-escape is temporally associated with gene expression changes
resembling a partial EMT (27, 34). A recent study by Li et al. (35) has demonstrated a 
high degree of plasticity in collecting duct principal cells owing to a reversible EMT.
The authors isolated AQP2-expressing principal cells from mouse kidney and the cells 
underwent an EMT (associated with loss of AQP2 expression) under culture conditions, 
but when they were re-injected into the renal medulla, they integrated selectively into
the collecting duct and again expressed AQP2. This suggests that principal cells can 
lose AQP2 expression by EMT and then gain it back by mesenchymal-to-epithelial
transition (MET). That is, according to this model, principal cells can reversibly switch
between AQP2-expressing and AQP2-nonexpressing phenotypes. We speculate that 
the sort of partial EMT seen in the present study may represent a physiological 
mechanism, independent of vasopressin signaling, that may control AQP2 expression 
in response to decreases in serum sodium concentration or osmolality. Ureteral 
obstruction, another pathophysiological state accompanied by loss of AQP2
expression (36), has also been shown to be associated with induced EMT of collecting 
duct cells (37). Thus, the general picture of the CCD principal cell during the onset of 
vasopressin-escape appears to be consistent with a reversible state of ‘partial EMT’
(27). The fact that the cells maintained their normal polarity also suggests a limited 
form of EMT, since full blown EMT is normally associated with loss of apical/basolateral 
polarity (38). A further question is whether EMT-like transcriptional changes or TGFу
signaling can account for the loss of AQP2 mRNA and protein in vasopressin-escape. 
To address this, we exposed vasopressin-treated mouse mpkCCD collecting duct cells 
to TGFу, observing a profound decrease in AQP2 protein abundance in the cells. It is 
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unclear, however, whether TGFу or a similar extracellular mediator like BMP7, a key 
mediator in renal development (39) whose mRNA was markedly increased on Day 1 
(Figure 5), could play a role in vasopressin-escape.  
Induction of expression of cell-cycle genes.  The loss of AQP2 expression during
vasopressin-escape was associated with a widespread increase in the expression of 
genes associated with the cell-cycle, seen on Days 2 and 4. Most of the genes 
annotated in the KEGG Cell Cycle Pathway exhibited increases in transcript abundance 
on Day 2 of the development of vasopressin-escape.  Included were two TFs, E2f1 and 
Foxm1, which play critical roles in the regulation of the transition between quiescence 
and the cell cycle and were markedly increased on Days 2 and 4 of vasopressin-
escape. E2f1 is the classical regulator of the transition from G0 to the cell cycle (30).
In addition to E2f1, a second member of the E2F TF family, namely E2f4 also shows 
increased expression during vasopressin-escape (Figure 5).  E2f4 mediates some of 
the transcriptional effects of TGFу through binding interactions with Smad3 (40). Thus, 
it is possible that the increase in expression of cell-cycle genes in vasopressin-escape
is a downstream consequence of activation of TGFу related signaling via E2f4, and that
the EMT-like response and the induction of cell-cycle gene expression are parts of the 
same pathophysiological program. The Foxm1 TF, which like E2f1 regulates expression 
of cell-cycle genes critical for progression into S-phase (31), was also markedly 
increased in expression on Days 2 and 4 during vasopressin-escape (Figure 10).
Despite the broad increase in expression of cell-cycle genes, there is little evidence for 
a proliferative response in CCD cells in the early stages of vasopressin-escape.
A similar picture with cell cycle arrest at all stages is seen when mammalian cells are
challenged with hypertonicity (41). 
Relationship to vasopressin signaling.  Because of the strong, selective, down-
regulation of Aqp2 and Aqp3 in vasopressin-escape and the known action of vasopressin
to increase expression of these genes (3), an important question to ask is, “Is
vasopressin-escape just a simple reversal of normal vasopressin-mediated signaling
in the collecting duct?” There is considerable evidence in opposition to this idea. First,
the у- and ф-subunits of ENaC (Scnn1b and Scnn1g) are also transcriptionally 
upregulated by vasopressin (42), but were not found to be decreased in the current
study. Second, transcriptional and proteomic profiling of mpkCCD cells (13) showed a
response profile that has little similarity to the list of transcripts downregulated in 
vasopressin-escape in the present study. Thus, we conclude that the transcriptional
response in vasopressin-escape is not simply the mirror image of the response to
vasopressin, but represents a vasopressin-independent regulatory mechanism. 
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Abstract
Aquaporin-2 (AQP2) water channels are expressed in principal cells of the renal
connecting tubules and collecting ducts (CD). These proteins play key role in the fine 
tuning of water in the body. The absence or reduced expression of AQP2 underlies 
congenital and acquired Nephrogenic Diabetes Insipidus (NDI), a disorder characterised
by polyuria and polydipsia. Recently a hypothesis was proposed that AQP2 itself was 
involved in principal cell proliferation, and formation of renal microcysts. In this study, 
using mpkCCD cells, endogenously expressing AQP2, and MRI analysis of a kidney of 
an NDI patient lacking AQP2, we investigated whether AQP2 has a direct role in 
principal cell proliferation and renal cyst formation. We observed reduced AQP2 
expression in proliferating FCS/growth factor treated mpkCCD cells and no AQP2
expression in proliferating dDAVP stimulated mpkCCD cells. Additionally, flow-released
adenosine decreased AQP2 abundance in mpkCCD cells. Moreover, no microcysts 
were formed in the kidney of patient lacking AQP2. Our data thus reveal that 
proliferation affects AQP2 abundance, but that AQP2 itself does not affect the 
proliferative status of principal cells nor lead to renal microcysts development. In 
contrary, we propose that a high collecting duct pro-urine flow not only results in renal 
microcyst development as seen in Li-NDI patients, but also reduces AQP2 abundance
in the collecting duct.
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Introduction
Water is the main component of the human body and is essential to facilitate many 
enzymatic processes, but also to maintain blood volume and osmolality homeostasis.
Aquaporin-2 (AQP2) water channels expressed in principal cells of renal connecting 
tubules and collecting ducts (CD) are key in fine tuning of water in the body, because
the absence or reduced expression of AQP2 underlies congenital and acquired 
Nephrogenic Diabetes Insipidus (NDI), a disorder characterised by polyuria and 
polydipsia (1-3). With hypernatremia or hypovolemia, centrally-released vasopressin 
(AVP) binds its V2R receptor, which is expressed in the basolateral membrane of 
principal cells. This binding leads to an increase in intracellular cAMP levels and
redistribution of AQP2 from intracellular vesicles to the plasma membrane thereby 
allowing water reabsorption from pro-urine (4).
Based on findings in several mouse models with increased diuresis, it is generally 
thought that tubular abnormalities such as dilated tubules and cyst formation as 
found in AQP2 KO mice are secondary to polyuria and increased flow (5-7). Recently,
however, Chen et al. provided evidence and proposed that AQP2 itself was involved in 
principal cell proliferation and formation of renal microcysts (6). Chen et al., based 
their hypothesis on the observation that AQP1, AQP3 and AQP4 KO mice manifest with 
similar concentrating defects as AQP2 KO mice, but do not have renal microcysts or 
renal failure. For cell migration and proliferation, the binding of AQP2 with its second
external loop to integrin, present in the extracellular matrix, was of importance.
However, several arguments against those of Chen et al. can be brought forward. 
At first, there is a large difference in the extent of aquaresis between AQP2 on the one
side and AQP1/AQP3/AQP4 on the other side in mice and man (8). Whereas AQP2 KO 
mice die shortly after birth because of dehydration (9), AQP1/AQP3 and AQP4 KO mice
urinate much smaller volumes and survive (10-12). Similarly, in humans lacking the 
diverse aquaporins, those lacking AQP2 are born with NDI, while those born without AQP1,
AQP3 or AQP4, show subclinical ‘polyuria’ or no increased aquaresis at all (3, 13-16).
Furthermore, a role for AQP2 in principal cell migration and binding of beta-integrin,
which is part of the extracellular matrix, requires expression of AQP2 in the plasma 
membrane and during proliferation. This is the case for the cells used by Chen et al., 
but these cells are stably-transfected with a construct driving constitutive expression
of AQP2 (6). It is unclear, however, whether endogenous AQP2 is expressed in 
proliferating CD cells. A hint that this may not be the case comes from our recent
discovery that polarized mpkCCD cells, which endogenously express AQP2 in response 
to vasopressin, reduce their AQP2 abundance following stimulation with growth factor 
containing fetal calf serum (17). Moreover, we also showed that in proliferating 
epithelial MDCK cells exogenously expressed AQP2 as well as V2R are mainly intracel-
lularly localized (18).
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A consensus on whether AQP2 has a direct role in principal cell migration, proliferation
and whether it contributes to cyst formation is thus lacking. Employing mpkCCD cells 
and with the help of an NDI patient lacking AQP2, we here tested the potential link
between flow, cell proliferation and microcyst formation in relation to Aquaporin-2.
Materials and methods
Patient
Our 20-year-old male patient was diagnosed with congenital NDI in early infancy,
which was confirmed at age 1, by demonstrating a homozygous mutation in the AQP2
gene (559C->T; R187C) (3). Repeated renal ultrasound studies did not show any
abnormalities, apart from a mild dilatation of the renal pelvis and proximal ureters. 
The Committee on Research Involving Human Participants (CMO) of the region Arnhem
and Nijmegen, the Netherlands, approved the study. Participant provided informed
consent.
Cell culture assays 
Unless specified otherwise, mpkCCD cells were cultured as described (19). In short,
cells were cultured in a modified defined medium containing DMEM:Ham’s F12 1:1 vol/vol;
60 nM sodium selenate, 5 μg/ml transferrin, 2 mM glutamine, 50 nM dexamethasone,
1 nM triiodothyronine, 10 ng/ml epidermal growth factor (EGF), 5 μg/ml insulin, 28 mM
D-glucose, 2% fetal calf serum (FCS), and 20 mM HEPES (pH 7.4). Cells were seeded 
at a density of 1.5x105 cells/cm2 on semi permeable filters (Transwell, 0.4 μm pore
size, Corning Costar, Cambridge, MA). After 96 hours, cells were treated with 1 nM
1-deamino-8-D-arginine vasopressin (dDAVP) at the basolateral side to induce AQP2
expression. For the last 48 hours, cells were cultured in a FCS/EGF-free medium,
unless mentioned otherwise. Cells could be treated with 10 μM 8cyclopentyl1,3dipro-
pylxanthine (DPCPX; RBI, Poole, UK) at the basolateral and apical side under static or 
shaking conditions. The shaking condition was provided by an UltraCruz 2-dimensional 
rocker (Santa Cruz Biotechnology, Heidelberg, Germany) with a tilt angle of 30° and an 
oscillation frequency of 20 cycles/min. On day 8, cells were harvested and prepared
for immunoblotting as described (19). To determine the effect of cell polarity on AQP2 
abundance, cells were seeded as described above, but collected after 1, 2 or 4 days.
The cells were cultured in presence of 1nM dDAVP or 10  μM forskolin during the last 24 
hours. Cells were used for immunoblotting or immunocytochemistry.
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Immunoblotting 
Laemmli samples were denatured for 30 minutes at 37°C. SDS-PAGE, blotting, and 
blocking of the PVDF membranes was done as described (20). Membranes were 
incubated for 16 hours at 4°C with 1:1000 affinity–purified rabbit (Rb2) C tail AQP2 
antibody in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% nonfat dried
milk (3). In an identical way, other blots were incubated with 1:1000 Cyclin D1 antibody 
(Rabbit; cell signaling, Massachusetts, USA). After washing in TBS-T, all blots were 
incubated for 1 hour in TBS-T containing 1:10000-diluted goat anti–rabbit IgGs (Sigma-
Aldrich, St. Louis, USA) coupled to horseradish peroxidase. Proteins were visualized 
using enhanced chemiluminescence (ECL; Pierce, Rockford, USA). Densitrometric 
analyses were performed using Bio-Rad quantification equipment (Bio-Rad 690c 
Densitometer; Chemidoc XRS) and Image studio software (LI-COR, Nebraska, USA). 
Equal loading of the samples was confirmed by staining of the blots with coomassie 
brilliant blue R-250 (BioRad, Hercules, USA).
Immunocytochemistry
Immunocytochemistry was done as described (21). In short, after removal of culture 
medium, mpkCCD cells were washed 3 times with ice-cold PBS-CM and fixed for 30 
min at room temperature with 4% w/v paraformaldehyde in PBS. After washing twice
with PBS, cells were treated with a permeabilization buffer (0.5% v/v Triton X-100 and 
in PBS with 0.7% w/v gelatin) for 30 min. Then, cells were incubated at 4°C overnight
with AQP2 (Rb2 1:50; (3)), E-cadherin (rat; Sigma-Aldrich, St. Louis, USA) or acetylated 
alpha tubulin (rabbit; cell signaling, Massachusetts, USA) primary antibody in perme-
abilization buffer. After 3 washing steps, cells were incubated with anti-rabbit or 
anti-rat secondary antibody conjugated to an Alexa dye (Invitrogen, 1:500) for 2-3 
hours at 37°C. Finally, cells were mounted in Vectashield containing DAPI (Vector 
Laboratories, Burlingame, USA) and imaged by confocal microscopy (Olympus 
FV1000, Center Valley, PA, USA).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on a 3.0 T MR scanner (Skyra,
Siemens Healthcare, Erlangen, Germany) with a pelvic phased-array coil. The following
sequences were performed: coronal and axial T2-weighted half-Fourier single-shot 
turbo spin-echo (HASTE) with fat saturation, axial T1 volumetric interpolated
breath-hold examination (VIBE) in-phase and out-of-phase, coronal T1 volumetric 
interpolated breath-hold examination (VIBE) with fat saturation. Diffusion weighted 
imaging was performed with b-factors of 50, 400 and 800 s/mm2. Contrast enhanced
dynamic imaging was performed with coronal gradient-echo T1-weighted MR sequence
at 5 measurements, after administration of 15 ml Dotarem and contrast enhanced axial 
T1 VIBE was performed.
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Statistical analysis
Analysis of the difference between groups was performed with student t-test or one-way 
ANOVA corrected by the Bonferroni multiple-comparisons procedure. A p-value < 0.05
was considered statistically significant.
Results
In mpkCCD cells, flow-released adenosine decreases AQP2 abundance 
Epithelial cells in the kidney have non-motile cilia, which allows them to sense flow 
(22). This mechanic stimulus is the trigger for purinergic signaling cascades and gene 
transcription mediated by ATP and its degradation products, including adenosine,
binding to their respective receptors (7). To determine whether we could test the effect
of flow on the regulation of the abundance of endogenously-expressed AQP2 in 
mpkCCD cells, these cells were grown to confluence on transwell filter in the presence 
of dDAVP and stained for acetylated alpha tubulin, a marker for primary cilia. Confocal 
analysis revealed that mpkCCD cells indeed express primary cilia on their apical side 
(Fig. 1A).
To subsequently test whether endogenous AQP2 abundance is influenced by flow, 
mpkCCD cells were grown to confluence, treated with dDAVP, and placed on a rocking
shaker for the last two days. Anticipating an effect of shaking on AQP2 abundance, we
additionally treated the cells with or without the adenosine purinergic receptor 
antagonist DPCPX during the last two days. Subsequent immunoblotting revealed that
the abundance of AQP2 was significantly reduced with shaking, which was precluded
with DPCPX (Fig. 1B, C). This indicates that the adenosine receptor is involved in
flow-mediated reduction of AQP2 in mpkCCD cells.
Proliferation suppresses AQP2 expression in mpkCCD cells
To determine whether endogenous AQP2 abundance is affected by the proliferative
status of cells, mpkCCD cells were cultured to confluence in the presence of dDAVP
with or without fetal calf serum (FCS) for the last 48 hours. FCS contains growth factors
that stimulate cells to enter the proliferative cycle (23). Immunoblotting revealed that
the AQP2 abundance was lower in the cells cultured in the presence of FCS (Fig. 2). 
Immunoblotting furthermore showed that cyclin D1 abundance was increased with
FCS, which underscored that FCS stimulated proliferation. While these mpkCCD cells 
had already formed a monolayer and did not have extra 2D space to expand due to the
plastic borders of the transwells, we wanted to test the effect of unrestricted 
proliferation on AQP2 abundance. For this, mpkCCD cells were seeded on transwell 
filters and cultured for 1, 2 or 4 days in the presence of dDAVP during the final 24 hours 
after which they were subjected to immunoblotting and immunocytochemistry.
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Figure 1. AQP2 abundance in mpkCCD cells is reduced by ﬂow-mediated purinergic signaling. 
(A) To determine the presence of cilia on mpkCCD cells, cells were grown to confluence, treated 
with dDAVP, and immunostained for acteylated alpha tubulin. (B) To test whether endogenous 
AQP2 abundance is influenced by flow, mpkCCD cells were grown and treated as described
under (A) and placed on a rocking shaker for the last two days in the presence or absence of a 
adenosine receptor selective antagonist (DPCPX) and immunoblotted for AQP2. (C) The
unglycosylated AQP2 band were quantified. Coomassie blue staining of the blots (Cm) revealed 
loading of protein equivalents. Data presented are mean ± SEM of three independent
experiments. A significant difference (P<0.05) from the condition with no shaking and no
treatment is denoted by an asterisk.
Figure 2. AQP2 abundance is reduced the the presence of fetal calf serum. (A) MpkCCD cells
were cultured on filters for 8 days in the presence of dDAVP. During the final 48 hours cells were
cultured in absence (CTR) or presence (FCS) of fetal calf serum and collected and immunoblotted 
for AQP2 and cyclin D1, Loading of protein equivalents is shown by Coomassie blue staining of 
the blots (Cm). Quantification of unglycosylated bands revealed a decreased (B) and increased 
(C) abundance of AQP2 and cyclin D1 with FCS, respectively. Data presented are mean ± SEM of 
three independent experiments. An asterisk denotes a significant difference (P<0.05) from 
control condition.
A
A B C
B C
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Immunoblotting of protein equivalents showed that AQP2 was not detected on day 1, 
increased at 2 days of culturing and was most pronounced, after 4 days of culture (Fig.
3A-B). In line with these data, immunocytochemistry showed no AQP2 staining after 
one day of culturing, some apical AQP2 staining at day 2, and extensive apical
membrane AQP2 staining at day 4 (Fig. 3C). Despite the fact that the cells at day 1 and
2 could still expand, the clear basolateral expression of E-cadherin revealed that most
cells were already polarized.
Our data above reveal that the abundance and apical membrane expression of AQP2
is strongly attenuated in proliferating cells. Considering that in proliferating Madin
Darby Canine kidney (MDCK) cells stably expressing AQP2 the V2R is localized intra-
cellularly (24), the absence of AQP2 protein expression on day 1 could be due to a lack
of plasma membrane expression of the V2R. To test whether the lack of AQP2
expression was due to an intracellular expression of the V2R in mpkCCD cells, we 
Figure 3: polarization is essential for AQP2 expression. MpkCCD cells were grown for 1,2 or 4 
days on filters, of which the last day in the presence of dDAVP (A-C) or forskolin (D-F). Next, the 
cells were lysed and immunoblotted for AQP2 (A, D). Coomassie blue (Cm) staining of the blots
revealed loading of protein equivalents . (B, E) The AQP2 bands of A/D were quantified and 
presented relative to the AQP2 abundance at day 4. (C, F) To determine the localisation of AQP2, 
cells were fixed, subjected to immunocytochemistry for AQP2 (green) and the basolateral 
membrane protein E-cadherin (red), and analyzed by confocal microscopy. Data presented are
mean ± SEM of three independent experiments. A significant difference (P<0.05) from day 4 is
denoted by an asterisk.
A
D
B
E
C
F
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repeated the experiment above with the adenylate cyclase activator forskolin instead 
of dDAVP, thereby bypassing V2R. Immunoblot and immunocytochemical analysis, 
however, showed similar results as found for cells treated with dDAVP (Fig. 3D-F),
indicating that the influence of proliferation on the AQP2 abundance was independent
of V2R activation.
No renal microcysts in a patient lacking AQP2
Our data above revealed that in a cell model with endogenous expression of AQP2,
flow as well as proliferation attenuated its abundance. To get the ultimate proof of 
whether the lack of AQP2 would lead to principal cell proliferation and microcyst 
formation in humans during kidney development or later, we contacted congenital NDI 
patients to ask their participation in an MRI analysis of their kidneys. The patient that 
responded positively was a 20-year-old male patient who was homozygous for the 
559C->T AQP2 gene mutation, encoding AQP2-R187C (3). Importantly, R187 is a highly
Figure 4. MRI analysis on kidneys of a patient lacking AQP2. Magnetic resonance imaging 
(MRI) was performed on a 3.0 T MR scanner (Skyra, Siemens Healthcare, Erlangen, Germany) 
with a pelvic phased-array coil to investigate whether the lack of AQP2 leads to the development 
of renal microcysts. No microcysts were detected (A; coronal plane, B; transversal plane).
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conserved amino acid of AQP2 and cell biological analyses showed that AQP2-R187C 
is a misfolded non-functional AQP2 protein that is retained in the endoplasmic
reticulum (20, 25). The MRI images revealed that the length of the patient’s kidneys 
was approximately 12.5 cm and were normally located. The left pyelum appeared wider 
than the right pyelum. Critical scanning of both kidneys, however, revealed no lesions, 
nor any microcyst (Fig. 4).
Discussion
Proliferation reduces AQP2 abundance, but AQP2 does not influence
proliferation. 
Our data reveal that endogenous AQP2 abundance is strongly attenuated by the
proliferative state of the cells. We observed reduced AQP2 abundance in polarized
mpkCCD cells of which proliferation was stimulated (Fig. 2), and absent or reduced 
AQP2 expression in mpkCCD cells proliferating for one or 2 days, respectively, in the 
presence of dDAVP for the last day, (Fig. 3). ). Moreover, when expressed in proliferating
cells, AQP2 mainly localized in the apical membrane of our dDAVP-stimulated mpkCCD 
cells. In line with this, we have shown earlier in vitro and in vivo that the cell cycle
status of principal cells determines the abundance of AQP2 water channel (26). The 
AQP2 abundance was found to be highest in the G0 cell cycle phase and reduced in all
other phases. Moreover, although we have not investigated whether AQP2 affects
proliferation in vitro, renal microcysts were not developed in our patient lacking AQP2, 
indicating that AQP2 does not induce principal cell proliferation in vivo.
Our data are in contrast to the data of Chen et al (6). Although we cannot exclude 
that (a low level of) expression of AQP2 may influence proliferation of principal cells 
during kidney development, as our proliferating cells will likely express some AQP2, their 
data are likely due to the constitutive expression of AQP2 in their cell model and the fact 
that in their used transfected LLCPK cells, AQP2 is targeted to the basolateral membrane. 
Flow reduces AQP2 abundance
Besides the status of proliferation, our data provide further support that flow and the
connected purinergic signalling affects AQP2 abundance. Changes in tubular flow are
sensed by the primary cilia that have a crucial role in a number of cellular processes
that include mechano and chemo-sensation as well as the transduction of signaling
cascades critical for the development and maintenance of different tissues and organs
(27). Accordingly, cilia are cellular antennas that coordinate the balance between cells
and their environment. While our mpkCCD cells express primary cilia, we showed that 
flow reduced AQP2 abundance and that this effect was conferred by the adenosine 
receptor. Considering that our medium is not refreshed during 2 days, and that 
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degradation of flow-released ATP is mostly degraded fast to ADP, AMP and adenosine, 
it may well be that receptors for ATP, ADP and AMP may reduce AQP2 abundance with 
flow as well. This data is line with earlier ex-vivo findings in AVP-stimulated rat inner 
medullary collecting ducts that were (flow-)perfused with ATP and resulted in reduced
intracellular cAMP levels and subsequent reduced water permeability (28). In addition,
increased urine production in lithium-induced nephrogenic diabetes insipidus, and 
therewith collecting duct pro-urine flow, is also stimulated by ATP, because blockade 
of the ATP/UTP-activated P2Y2  receptor ameliorated Li-induced NDI in rodents (29). 
Besides ATP, TGFу may have an important role in flow-mediated attenuation of AQP2, 
because fluid shear stress activated the TGFу pathway in renal epithelial cells and we 
showed that TGFу downregulate AQP2 (26, 30). 
In this respect, flow might also be an advantageous factor in diseases such as the 
syndrome of inappropriate antidiuretic hormone secretion (SIADH). SIADH is marked 
by increased water retention due to high AQP2 abundance that is induced by high 
circulating AVP. Ecelbarger et al. showed that, due to an unknown mechanism, AQP2 
water channels were reduced in rats that received high water load, despite the high 
circulating AVP levels that were induced by the mini-pumps (31). The reduced AQP2 
abundance in this so-called vasopressin escape may be due to the increased a flow. 
These and earlier data thus indicate that flow is an important modulating factor for 
AQP2 abundance and that it may be an aggravating factor in diseases such as Li-NDI.
Differences in the extent of collecting duct flow might also explain why renal microcysts 
do develop in cNDI in mice but not in patients. At first, the extent of flow increase in 
mice in cNDI is higher than in humans. Whereas the urine volume increases about
30-fold (urine osmolality from 3000 to 100 mOsm) with mice, it ‘only’ increases about 
12-fold (1200 to 100 mOsm) with humans (32, 33). Moreover, whereas most patients 
have a reduced flow, because they are treated for their polyuria with diuretics, cNDI 
mice are not treated. In this respect, it is worth to mention that in the far past, when 
cNDI patients did not receive medication to reduce their voiding volume, the patients 
developed tubular dilations. Recent patients, who receive thiazide/amiloride treatment
and therefore have reduced polyuria, develop less renal deformation as e.g. seen in 
our patient (34, 35). As such it would be interesting to see whether kidney deformation 
and cyst formation in AQP2 knockout mice would be attenuated in conditions of 
reduced polyuria, as observed with diuretic treatment.
Taken together, we showed that the proliferation attenuates AQP2 abundance and that
the absence of AQP2 cannot be the cause for renal microcyst development in man. In
addition, we propose that a high renal flow not only results in renal microcyst 
development as seen in cNDI mice and Li-NDI patients, but also as an important factor 
modulating AQP2 abundance in the collecting duct.
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Introduction
Each day, the kidneys filtrate about 170–180 L of blood. If these large volumes of 
ultra-filtrate were excreted unchanged as urine, it would be necessary to ingest huge 
amounts of water and electrolytes to stay in balance. This is avoided by the selective 
reabsorption of water, essential electrolytes and other blood constituents from the 
filtrate along the nephron. The fine-tuning of water homeostasis takes place in the 
collecting duct principal cells that express AQP2 water channel. Considering the 
importance of AQP2 in water homeostasis, increase or decrease in the abundance of 
AQP2 on the cell surface directly affects the urine concentrating ability thus also the 
amount of water in the body resulting in diseases such as syndrome of inappropriate 
antidiuretic hormone secretion (SIADH) or nephrogenic diabetes insipidus (NDI). The 
most common form of NDI is acquired and is a side effect of lithium treatment that is
given to bipolar patients. This thesis aimed to gain insight into pathophysiological
mechanisms involved in the development of renal side effects of lithium and explored 
the possibility to introduce novel treatments for Li-NDI.
The impact of aerobic glycolysis in lithium-induced 
renal pathology
Lithium-induced metabolic reprogramming of principal cells 
Earlier, others and we have shown that, by entering via ENaC, lithium initiated
proliferation of principal cells in vitro and in vivo (1, 2). In chapter 4 of this thesis, we 
provided in vitro and in vivo data, which showed that lithium-induced principal cell
proliferation coincided with metabolic changes toward aerobic glycolysis and 
glutaminolysis. In the continuous presence of oxygen, lithium treatment induced an 
increased (in vitro) release and (in vivo) urinary excretion of lactate, which was absent 
in mice lacking ENaC in collecting ducts. Our NMR analysis furthermore revealed that
lithium treatment strongly increased urinary levels of succinate, fumarate and citrate, 
which are known to increase during glutaminolysis (3). With aerobic glycolysis,
glutaminolysis is typically upregulated as well, because glutamine provides the cell of 
nitrogen and citrate, needed for amino acid and lipid synthesis, respectively (4).
Moreover, during aerobic glycolysis, the increased intracellular acid production, such
as lactate, necessitates the cell to ignite pathways to buffer acid excess, besides 
secretion of lactate through MCT proteins. Cellular glutamine influx and glutaminolysis
serve this buffering function, as the two molecules of NH3 released from glutamine
and glutamate during glutaminolysis are effective H+ buffers (5). In line with this,
urinary ammonium (NH4+) was strongly increased with lithium (Figure 1).
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Our in vitro data on the carbonic anhydrases (CAs) involved in the acetazolamide-
induced suppression of lithium-induced downregulation of AQP2 are in line with the 
above. Although we have not solidly proven that the mix of four siRNAs against the 
different CAs indeed downregulated the expression of each CA, a dogma concluded
from an extensive study in which thousands of siRNAs were tested to block cancer cell
growth (6, 7), our siRNA and CA-specific drug treatments clearly revealed that inhibition
of CA9, and possibly CA12, attenuated the lithium-induced AQP2 downregulation in 
mpkCCD cells. CA9 and -12 are normally located to the basolateral membrane of 
epithelial cells, but appear in the plasma membranes of proliferating cells (8-10). CA12 
Figure 1. Lithium induces aerobic glycolysis and glutaminolysis. Lithium treatment increases
the excretion of lactate, succinate, fumarate, citrate and ammonium. The increase in these
metabolites indicate that lithium switched the cellular metabolism from oxidative phosphoryla-
tion into aerobic glycolysis that often goes together with use of glutamine as energy source in 
glutaminolysis for the generation of energy and H+ acceptors. The mechanism by which lithium
induces these changes is still not known but likely involves the HIF and/or the c-Myc pathways 
that are known to regulate these metabolic processes.
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is abundantly expressed in the collecting duct of healthy kidneys, however the cell
specificity seems to depend on the species tested: while in humans and rabbits, CA12
is mainly found in principal cells, its expression seems restricted to type-A intercalated 
cells in rodents (8, 11, 12). CA9 is hardly expressed in healthy kidneys, but CA9 and 
CA12 expression is markedly increased in renal carcinomas, where they facilitate 
proliferation of these tumor cells by facilitating the cellular removal of acids (13, 14). 
HCO3-, extracellularly generated by CA9/12, is taken up by tumor cells to neutralize
their excessive production of acids, such as lactate, produced during aerobic glycolysis 
(15, 16). The action of CA9/12 allows tumor cells to continue their Warburg-like
proliferation and acid secretion, of which the latter helps cell proliferation by 
disassembling junctional proteins (17-19).
Unfortunately, inhibition of aerobic glycolysis with 2DG did not attenuate Li-NDI. 
In vitro, 2DG attenuated the Li-induced downregulation of total and apical membrane
abundance of AQP2. In vivo, the urinary lactate excretion normalized, illustrating the
blocking effect of aerobic glycolysis of 2DG in our experiments, but not those of 
succinate, fumarate, citrate and ammonium, indicating that 2DG did not block the
effect of lithium on glutaminolysis. Our data indicate that lithium, which can still enter 
principal cells through ENaC in our 2DG experiment, induces aerobic glycolysis and
glutaminolysis through different pathways, and may suggest that the increased
glutaminolysis is of more relevance to Li-NDI, as Li-NDI was not improved with 2DG. As 
such, future studies should focus on the potential role of glutaminolysis in the 
pathogenesis of Li-NDI. Furthermore, although we did not determine pathways
involved in this metabolic switch, glycolysis and glutaminolysis are possibly induced
by HIF and/or c-Myc (20). We found that HIF1т was significantly increased in medulla
of mice that were treated with lithium for 10 days (Figure 2). Additionally, increased 
cyclin D1 abundance indicate that c-Myc is probably increased as the transcription 
factor for both c-Myc and cyclin D1 is у-catenin (21). Future research will have to 
determine whether these or other pathways are responsible for this switch.
Li-NDI and ADPKD
Although blocking aerobic glycolysis with 2DG did not attenuate Li-NDI, the 
resemblance between Li-NDI and ADPKD is striking, as both involve cell proliferation
and aerobic glycolysis (chapter 4 and (22). Interestingly, 62.5% of bipolar patients on 
long-term lithium therapy also develop microcysts (23), but it is at present unclear 
whether that has any relationship with cysts being formed in ADPKD. Of interest in this
respect is that, to stimulate cyst formation in conditional ADPKD knockout mice, a 
stress factor (1,2-dichlorovinyl-cysteine; DCVC) is given (24). It would be interesting to 
test whether lithium could also serve as such a stress factor, as this could be an 
indication that patients developing microcysts with lithium therapy may be carriers of 
subclinical mutations in the ADPKD genes.
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Moreover, due to the increased diuresis in both disorders, both are characterized by
elevated plasma vasopressin levels (25, 26), which, in ADPKD, has been found to 
contribute to cyst growth and ADPKD development (27). Indeed, vasopressin type-2 
receptor (AVPR2) antagonists, such as tolvaptan, have shown to be beneficial in
attenuating ADPKD development and have recently been approved as a therapy for 
ADPKD (28). It is highly unlikely, however, that AVPR2 antagonists will be of use in 
Li-NDI, for several reasons. At first, the loss of AQP2 expression and principal cell
numbers is central to Li-NDI and blocking the AVPR2 will only worsen NDI, increase
RAAS and therewith increase lithium entry in remaining proper principal cells.
Moreover, the developing microcysts with lithium are (thus) small and, although
typical for kidneys of lithium-using patients, they have never been associated with a 
worsened kidney function. Furthermore, while microcysts have been suggested to be 
derived from principal cells, vasopressin levels are already elevated in the early phase 
of Li-NDI, whereas microcysts have only been found in kidneys of patients treated with 
lithium for >10 year. As such, the elevated vasopressin levels in Li-NDI is unlikely to 
induce development nor growth of microcysts in kidneys of lithium-treated patients 
but more likely by the increased renal flow as proposed in chapter 9 of this thesis.
Lithium, aerobic glycolysis, and the brain
Administration of lithium to rats was found to affect brain glucose metabolism where 
the concentrations of brain glucose, brain lactate and brain glycogen were increased,
Figure 2. Lithium increases cyclin D1 and HIF1ʸ abundance in the renal medulla. Mice were 
treated for 10 days with a control or lithium containing diet. After sacrifice, kidneys were rapidly
isolated, one kidney was dissected into cortex and medulla, snap frozen in liquid nitrogen, and
stored at -20°C. Immunoblot analysis (A) of medulla lysates was performed to determine protein
abundance of cyclin D1 and HIF1т, which were subsequently semi-quantified (B/C) The 
abundance of both proteins was increased with lithium. A significant difference (P= *<0.05) from 
CTR is denoted by an asterisk. CTR, control; Li+, lithium; HIF1т, hypoxia-inducible factor 1 alpha
and Cm, coomassie blue staining.
A B C
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and the concentration of brain glutamate was decreased (29). The incorporation of 
(14)C from U-(14)C D-glucose, administered intraperitoneally to the rats, was increased
in brain glucose and brain lactate, and decreased in brain glutamate (29). Therefore,
we think that increased glucose uptake and lactate release in the brain is also due to 
a metabolic switch towards aerobic glycolysis. Decrease in glutamate concentration
might be due to increased glutamate consumption because of glutaminolysis.
However, other metabolites were not measured in this study to support this.
Interestingly, however, in the last decades, a beneficial side of lactate as an alternative
‘glucose sparing’ fuel of the brain has been demonstrated and extensively reviewed by
Taher et al. (30). Aerobic glycolysis induced lactate release might be beneficial for 
bipolar disorder patients as released lactate might also serve as fuel in the brain. It is 
worth to mention, however, that a number of studies have indicated that lactate is 
increased and pH is decreased in the brain of patients with bipolar disorder (31-33). It 
is important to determine whether these changes are part of the pathophysiology of 
bipolar disorder or they are treatment artifacts as most of the patients with this 
disorder receive chronic lithium treatment throughout their lives. New studies should 
determine glucose uptake and lactate release in the brain of medication-free patients 
with bipolar disorder to elucidate the importance of these changes in the unset of 
bipolar disorder.
Impact of the cell cycle on AQP2 abundance
In chapter 4, we showed that lithium induced proliferation and a metabolic switch
towards aerobic glycolysis in principal cells. Aerobic glycolysis did not seem to affect
AQP2 abundance but the impact of proliferation on AQP2 abundance was still not 
determined. While we were investigating the pathophysiology of SIADH in chapter 8,
we found that AQP2 abundance was the highest in the G0 phase and strongly reduced 
in all other phases of the cell cycle (34). These results are also important in 
understanding the role of the cell cycle in the downregulation of AQP2 in Li-NDI and 
whether it is worth to target proteins in this pathway to rescue AQP2 and propose this
as a new treatment for Li-NDI. Most proliferation inhibitors stop the cell cycle at the
restriction point in G1 phase or in later phases (35). For example, this was shown in
mice where rapamycin, which inhibits the cell cycle at the G1 phase (36), prevented 
lithium induced proliferation but did not attenuate lithium induced NDI and did not 
restore the expression of collecting duct AQP2 (37). This means that principal cells
have to remain in the G0 phase to maintain high AQP2 abundance. However, there are 
currently no drugs available that can do this. Nevertheless, the finding that AQP2 
abundance is highly dependent on the state of the cell in the cell cycle is interesting
and also raises the question whether the body also regulates AQP2 abundance by 
modulating the cell cycle status under physiological conditions. In chapter 8, we used 
the methods of systems biology in a well-established rat model of SIADH to identify 
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signaling pathways activated at the onset of vasopressin-escape. On Day 2 of water 
loading, transcriptomic changes mapped to the transition from G0 into the cell cycle 
but arrest at the G2/M stage. There was no evidence of actual cell division. This
highlights the impact of the cell cycle on AQP2 in diseases other than Li-NDI.
Finally, although the mechanism of lithium induced proliferation is still poorly 
understood, we can, based on current knowledge, propose a mechanism that involves 
GSK3у. It has been shown that lithium inhibits GSK3у in vitro and in vivo (38-40).
GSK3у is a core component of the у-catenin destruction complex that prevents
у-catenin translocation into the nucleus (41). In the nucleus, у-catenin serves as a 
transcription factor for several genes including cyclin D1 which, together with cyclin E,
phosphorylates the Retinoblastoma (Rb) protein. This results in the release of E2F,
which induces the transcription of several proliferation genes (Figure 3) (42).
Additionally, GSK3у also directly regulates cyclin D1 proteolysis (43). Thus, the 
inhibition of GSK3у by lithium results in increased expression and activity of cyclin D1 
that stimulates the cells to enter the cell cycle.
Figure 3. A likely mechanism by which lithium induces cell proliferation. GSK3у is a core 
component of the у-catenin destruction complex and normally this complex prevents у-catenin 
translocation into the nucleus. In the nucleus, у-catenin acts as a transcription factor for cyclin 
D1. Increased cyclin D1 together with the cyclin E, phosphorylate Retinoblastoma (Rb) protein.
Phosphorylation of the Rb protein result in detachment of E2F from Rb, which induces
transcription of several proliferation genes. GSK3у furthermore also regulates cyclin D1 
proteolysis. Lithium is known to inhibit GSK3у. Thus, the inhibition of GSK3у by lithium results 
in increased expression and activity of cyclin D1 that passes the cell from the G0 phase into the
G1 phase of the cell cycle, which eventually result in downregulated AQP2 water channels.
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Lithium induced collecting duct remodeling 
Besides the loss of AQP2 expression, lithium treatment induces collecting duct 
remodeling, in which the ratio of principal-to-intercalated cells decreases (44, 45). The
paradoxical finding that lithium induces cell proliferation of principal cells, but
nevertheless ends up in a reduced principal/intercalated cell ratio is not understood.
Christensen et al. checked different options, but only sparsely observed apoptosis of 
principal cells or conversion into intercalated cells during lithium treatment and
therefore excluded these as potential causes for the reduced percentage of principal
cells (1). In chapter 2 of this thesis, we provided an explanation for this paradox as a
large proportion of PCNA-positive principal cells is arrested in the late G2 phase, 
indicating that they do not divide further. 
We, however, believe that the G2-phase arrest of principal cells is not the sole 
factor leading to collecting duct cell remodeling. Different earlier studies demonstrated 
that lithium treatment of rats induced an increased number of cells in the collecting 
duct (46-48). The increased number of cells likely constitutes mostly intercalated cells. 
The question remains why intercalated cells proliferate. An important stimulus could
be the development of metabolic acidosis, which is often, but not always, observed 
with lithium treatment in rodents and man (49, 50), because a state of metabolic
acidosis increases the numbers of т-intercalated cells as an adaptive response (51, 52).
Earlier studies suggested that lithium-induced metabolic acidosis and collecting duct 
remodeling could be due to a direct inhibition of H+-ATPase and H+/K+-ATPase these
transporters of intercalated cells (53, 54). However, if true, the effect of lithium on 
collecting duct remodeling should be independent from its influx in the principal cells, 
which does not seem to be the case for the following reasons: Kortenoeven et al. 
showed that amiloride, which inhibits lithium entry in principal cells only, attenuated 
collecting duct remodeling (55). Moreover, the abundance of H+-ATPase, a marker 
protein for т-intercalated cells, was not increased in lithium-treated ENaC-KO mice 
(56). These studies, thus, indicate that lithium-induced remodeling is a direct effect of 
principal cell lithium entry. In chapter 4 of this thesis we showed that lithium induced
aerobic glycolysis in principal cells, a condition coinciding with increased lactic acid 
production and principal cell acid secretion. As such, the increased number of 
т-intercalated cells in Li-NDI might be induced by lactic acid release during aerobic
glycolysis (Figure 4). Thus, the lithium-induced collecting duct remodeling could be 
explained by a rather stable population of principal cells, which are partly in a cell
cycle arrest, and a proliferating population of intercalated cells due to lithium-induced 
aerobic glycolysis.
Fluid shear stress-mediated aggravation of Li-NDI
Lithium-induced NDI is caused by the direct downregulation of AQP2 in principal cells. 
However, reduced AQP2 abundance in the collecting duct results in increased water 
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flow that might aggravate NDI development. Kunnen et al. showed, in an in vitro study, 
that fluid shear stress induces TGFу signaling in renal epithelial cells (57) and in 
chapter 8 we showed that TGFу downregulates AQP2 (34). Therefore, fluid shear 
stress induced activation of the TGFу pathway might contribute to the inability of 
the principal cells to concentrate urine. However, the release of TGFу as a consequence 
of increased renal flow and shear stress has not been determined. Therefore, 
measurement of urinary TGFу in Li-NDI patients or rodents is highly desirable to
determine the importance of TGFу in the aggravation of Li-NDI.
In chapter 9, we showed that flow-mediated purinergic signaling also reduced AQP2
abundance. MpkCCD cell were grown under shaking and non-shaking conditions and 
in the presence or absence of a selective adenosine receptor antagonist. Flow 
mediated AQP2 downregulation was only seen in the untreated samples. Purinergic
signaling mediated by extracellular nucleotides opposes the action of AVP on renal 
collecting duct by decreasing the cellular cAMP and thus AQP2 protein levels. This was
also shown in ex-vivo studies of AVP stimulated rat inner medullary collecting ducts 
that were perfused with ATP and resulted in reduced intracellular cAMP levels and 
Figure 4. Lithium treatment causes collecting duct remodeling. Besides the downregulation 
of AQP2 water channel, lithium also causes renal collecting remodeling that is marked by a 
decrease in the percentage of principal cells and increase in the percentage of intercalated
cells. This is surprising, as lithium treatment also induces proliferation mainly in the principal
cells. In this thesis, we provided an explanation for this paradox. Besides proliferation, lithium 
also induces aerobic glycolysis that is marked by lactic acid release that stimulates acid
secreting intercalated cells to proliferate and secrete this acid in the urine. So, while principal
cells get arrested at G2 phase, intercalated cells continue to increase and eventually represent 
the majority of the collecting duct.
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subsequent reduced water permeability (58). In addition, Kishore et al. studied the 
potential involvement of ATP/UTP-activated P2Y2  receptor in lithium-induced NDI in
rats, and showed that P2Y2 receptor knockout mice are significantly more resistant to 
develop Li-NDI (59). They also showed that ADP-activated P2Y12 receptor is expressed
in the kidney, and its blockade by the administration of clopidogrel bisulfate 
ameliorates Li-induced NDI in rodents. These findings indicate that by targeting the
purinergic signalling pathway, we might enhance the sensitivity of the kidney to AVP 
action to reduces the severity of Li-NDI.
Lithium-induced renal interstitial fibrosis 
Besides the effect of lithium on the urinary concentrating ability, long-term lithium 
treatment results in the development of renal interstitial fibrosis that is a hallmark and 
common outcome in the development of chronic kidney disease (CKD). The final stage
of CKD is end stage renal disease (ESRD), which is defined by a complete loss of kidney
function. Such patients can only be treated by either dialysis or transplantation (60).
The decay in renal function is highly dose-dependent and can be ameliorated by close
monitoring of serum Li-concentrations in patients (61, 62). Approximately 1.5% of 
lithium-users develop ESRD, which is six to eight times more frequent than in the 
general population (60, 63, 64). To fully understand the development of lithium-
induced renal fibrosis, the use of animal models is essential. Therefore, we performed
a proof of principle experiment in chapter 7 to determine whether, upon administration
of diet-contained lithium to pregnant mice and to pups after weaning, would lead to 
renal fibrosis after 40 weeks of lithium treatment. We have shown that the 
most-commonly used mouse model C57BL/6, which is already extensively used to
study Li-NDI, develops interstitial fibrosis when mothers and subsequent pups are
treated with a lithium dose that yields clinically-relevant blood lithium levels. We
furthermore showed that the histological and molecular changes with lithium-induced 
interstitial fibrosis formation is alike that found in lithium using patients, indicating
that this approach allows the usage of C57Bl6 mice as a model to uncover the 
underlying mechanism, and to identify ways to prevent or treat, human Li-induced 
renal fibrosis and, possibly, ESRD. Furthermore, based on our data shown in chapter 7
and the extensive literature data on fibrosis development (65-67), the following order 
of lithium-induced fibrosis formation is anticipated. Lithium-induced interstitial fibrosis 
is likely initiated in the principal cells that release chemotactic factors that affects the 
glycocalyx layer on the surface of endothelial cells. Then, adhesion molecules that are 
expressed on the cell surface of endothelial cells bind and facilitate the entrance of 
monocytes into the interstitium, where they differentiate into macrophages. Epithelial
cells, macrophages and endothelial cells then produce TGFу, which stimulates the
proliferation and conversion of fibroblasts into myofibroblasts. Myofibroblasts are 
extracellular matrix-producing cells that deposit collagen in the interstitium (Figure 5). 
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Concluding remarks
In this thesis, I studied the molecular mechanisms involved in the pathophysiology of 
lithium-induced nephrogenic diabetes insipidus. We found that besides proliferation, 
lithium also alters the metabolism of principal cells by inducing aerobic glycolysis and 
glutaminolysis. Targeting glycolysis did not rescue lithium induced AQP2 down- 
regulation in mice but targeting glutaminolysis might still be an interesting target that 
might eventually lead to novel treatment for Li-NDI. We also explored the use
acetazolamide as an alternative treatment for Li-NDI and found that this drug has 
similar effects as hydrochlorothiazide and amiloride in the inhibition of Li-NDI but with 
fewer side effects. We also found that AQP2 abundance was the highest in the G0
phase of the cell cycle and was strongly reduced even in the G1 phase. Thus, targeting
the cell cycle is not recommended as cell cycle inhibitors usually have major side 
Figure 5. Proposed mechanism by which lithium may induce renal interstitial ﬁbrosis. The
mechanism by which lithium induces interstitial fibrosis is poorly understood. However, we can 
postulate the following model: after entry of lithium in the principal cells, an (inflammatory)process 
is initiated that results in the release of chemotactic substances, which affect the glycocalyx 
layer on the surface of endothelial cells. Subsequently, adhesion molecules that are also
expressed on the cell surface of endothelial cells bind monocytes that enter the interstitial 
space and differentiate to macrophages. Epithelial cells, macrophages and endothelial cells
produce TGFу, which stimulates the proliferation and conversion into fibroblasts into myofibro-
blasts that produces extracellular matrix proteins such as collagen and lead to the observed 
fibrosis.
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effects and probably inhibit the cell cycle in later phases and therefore, will not rescue
AQP2. Finally, we were also able to set up for the first time an experimental condition 
that resulted in the development of interstitial fibrosis in mice. The application of this 
model will allow mechanistic research into the cause of lithium induced interstitial
fibrosis. 
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 202
202 | Chapter 10
References
1. Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium treatment induces a marked proliferation of 
primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol. 
2006;291(1):F39-48.
2. de Groot T, Alsady M, Jaklofsky M, Otte-Holler I, Baumgarten R, Giles RH, et al. Lithium causes G2 arrest 
of renal principal cells. J Am Soc Nephrol. 2014;25(3):501-10.
3. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation.
Annu Rev Cell Dev Biol. 2011;27:441-64.
4. Li C, Zhang G, Zhao L, Ma Z, Chen H. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, 
and Bcl-2 proteins as novel therapeutic targets for cancer. World J Surg Oncol. 2016;14(1):15.
5. Weiner ID, Verlander JW. Renal ammonia metabolism and transport. Compr Physiol. 2013;3(1):201-20.
6. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, et al. A large-scale RNAi 
screen in human cells identifies new components of the p53 pathway. Nature. 2004;428(6981):431-7.
7. Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis 
BJ, et al. Functional genetic screens identify genes essential for tumor cell survival in head and neck and 
lung cancer. Clin Cancer Res. 2013;19(8):1994-2003.
8. Kyllonen MS, Parkkila S, Rajaniemi H, Waheed A, Grubb JH, Shah GN, et al. Localization of carbonic 
anhydrase XII to the basolateral membrane of H+-secreting cells of mouse and rat kidney. The journal of 
histochemistry and cytochemistry : official journal of the Histochemistry Society. 2003;51(9):1217-24.
9. Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, Hocker M, et al. Gastric hyperplasia in mice with 
targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology. 2002;123(6):1889-903.
10. Saarnio J, Parkkila S, Parkkila AK, Waheed A, Casey MC, Zhou XY, et al. Immunohistochemistry of 
carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial 
cells with the highest proliferative capacity. The journal of histochemistry and cytochemistry : official 
journal of the Histochemistry Society. 1998;46(4):497-504.
11. Parkkila S, Parkkila AK, Saarnio J, Kivela J, Karttunen TJ, Kaunisto K, et al. Expression of the membrane-as-
sociated carbonic anhydrase isozyme XII in the human kidney and renal tumors. JHistochemCytochem. 
2000;48(12):1601-8.
12. Schwartz GJ, Kittelberger AM, Watkins RH, O’Reilly MA. Carbonic anhydrase XII mRNA encodes a hydratase 
that is differentially expressed along the rabbit nephron. Am J Physiol Renal Physiol. 2003;284(2):F399-410.
13. Tostain J, Li G, Gentil-Perret A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a
marker for diagnosis, prognosis and treatment. Eur J Cancer. 2010;46(18):3141-8.
14. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of 
tumor-associated carbonic anhydrases. Cancer research. 2000;60(24):7075-83.
15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic 
requirements of cell proliferation. Science. 2009;324(5930):1029-33.
16. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev 
Drug Discov. 2008;7(2):168-81.
17. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression 
in kidney cancer. European journal of cancer. 2005;41(18):2935-47.
18. Svastova E, Zilka N, Zat’ovicova M, Gibadulinova A, Ciampor F, Pastorek J, et al. Carbonic anhydrase IX
reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Experimental
cell research. 2003;290(2):332-45.
19. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer cell. 2008;13(6):472-82.
20. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism 
and proliferation. Cancer Cell. 2007;12(2):108-13.
21. Kaldis P, Pagano M. Wnt signaling in mitosis. Dev Cell. 2009;17(6):749-50.
22. Magistroni R, Boletta A. Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney
disease: from animal models to humans. J Nephrol. 2017;30(4):511-9.
23. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D’Agati VD. Lithium nephrotoxicity: a 
progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol. 2000;11(8):1439-48.
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 203
General discussion and summary | 203
24. Happe H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, et al.
Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by 
dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet. 
2009;18(14):2532-42.
25. Padfield PL, Park SJ, Morton JJ, Braidwood AE. Plasma levels of antidiuretic hormone in patients receiving 
prolonged lithium therapy. Br J Psychiatry. 1977;130:144-7.
26. Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, et al. Vasopressin, copeptin,
and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without 
renal impairment. Clin J Am Soc Nephrol. 2012;7(6):906-13.
27. van Gastel MDA, Torres VE. Polycystic Kidney Disease and the Vasopressin Pathway. Ann Nutr Metab. 
2017;70 Suppl 1:43-50.
28. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in
patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18.
29. Plenge P. Acute lithium effects on rat brain glucose metabolism - in vivo. Int Pharmacopsychiatry. 
1976;11(2):84-92.
30. Taher M, Leen WG, Wevers RA, Willemsen MA. Lactate and its many faces. Eur J Paediatr Neurol. 
2016;20(1):3-10.
31. Machado-Vieira R, Zanetti MV, Otaduy MC, De Sousa RT, Soeiro-de-Souza MG, Costa AC, et al. Increased 
Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive 
Bipolar Disorder: A 3-T 1H-MRS Study. J Clin Psychopharmacol. 2017;37(1):40-5.
32. Chu WJ, Delbello MP, Jarvis KB, Norris MM, Kim MJ, Weber W, et al. Magnetic resonance spectroscopy 
imaging of lactate in patients with bipolar disorder. Psychiatry Res. 2013;213(3):230-4.
33. Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophys-
iology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem. 2015;15(5):355-65.
34. Lee JW, Alsady M, Chou CL, de Groot T, Deen PMT, Knepper MA, et al. Single-tubule RNA-Seq uncovers 
signaling mechanisms that defend against hyponatremia in SIADH. Kidney Int. 2017.
35. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 
2009;16(2):36-43.
36. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev 
Drug Discov. 2006;5(8):671-88.
37. Gao Y, Romero-Aleshire MJ, Cai Q, Price TJ, Brooks HL. Rapamycin inhibition of mTORC1 reverses lithi-
um-induced proliferation of renal collecting duct cells. Am J Physiol Renal Physiol. 2013;305(8):F1201-8.
38. Kortenoeven ML, Schweer H, Cox R, Wetzels JF, Deen PM. Lithium reduces aquaporin-2 transcription 
independent of prostaglandins. Am J Physiol Cell Physiol. 2012;302(1):C131-40.
39. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, et al. Lithium treatment inhibits renal GSK-3 
activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol. 
2005;288(4):F642-9.
40. Norregaard R, Tao S, Nilsson L, Woodgett JR, Kakade V, Yu AS, et al. Glycogen synthase kinase 3alpha 
regulates urine concentrating mechanism in mice. Am J Physiol Renal Physiol. 2015;308(6):F650-60.
41. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol. 
2013;5(1):a007898.
42. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. 
Cell Signal. 2008;20(4):581-9.
43. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis 
and subcellular localization. Genes Dev. 1998;12(22):3499-511.
44. Christensen BM, Marples D, Kim YH, Wang W, Frokiaer J, Nielsen S. Changes in cellular composition of kidney
collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol. 2004;286(4):C952-64.
45. Ecelbarger CA. Lithium treatment and remodeling of the collecting duct. Am J Physiol Renal Physiol. 
2006;291(1):F37-8.
46. Kling MA, Fox JG, Johnston SM, Tolkoff-Rubin NE, Rubin RH, Colvin RB. Effects of long-term lithium 
administration on renal structure and function in rats. A distinctive tubular lesion. Lab Invest.
1984;50(5):526-35.
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 204
204 | Chapter 10
47. Ottosen PD, Nyengard JR, Jacobsen NO, Christensen S. A morphometric and ultrastructural study of lithium-
induced changes in the medullary collecting ducts of the rat kidney. Cell Tissue Res. 1987;249(2):311-5.
48. Jacobsen NO, Olesen OV, Thomsen K, Ottosen PD, Olsen S. Early changes in renal distal convoluted 
tubules and collecting ducts of lithium-treated rats: light microscopy, enzyme histochemistry, and 
3H-thymidine autoradiography. Lab Invest. 1982;46(3):298-305.
49. de Groot T, Sinke AP, Kortenoeven ML, Alsady M, Baumgarten R, Devuyst O, et al. Acetazolamide 
Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus. J Am Soc Nephrol. 2016;27(7):2082-91.
50. Weiner ID, Leader JP, Bedford JJ, Verlander JW, Ellis G, Kalita P, et al. Effects of chronic lithium administration 
on renal acid excretion in humans and rats. Physiol Rep. 2014;2(12).
51. Bagnis C, Marshansky V, Breton S, Brown D. Remodeling the cellular profile of collecting ducts by chronic 
carbonic anhydrase inhibition. Am J Physiol Renal Physiol. 2001;280(3):F437-48.
52. Welsh-Bacic D, Nowik M, Kaissling B, Wagner CA. Proliferation of acid-secretory cells in the kidney during 
adaptive remodelling of the collecting duct. PLoS One. 2011;6(10):e25240.
53. Dafnis E, Kurtzman NA, Sabatini S. Effect of lithium and amiloride on collecting tubule transport enzymes. 
The Journal of pharmacology and experimental therapeutics. 1992;261(2):701-6.
54. Eiam-Ong S, Dafnis E, Spohn M, Kurtzman NA, Sabatini S. H-K-ATPase in distal renal tubular acidosis: 
urinary tract obstruction, lithium, and amiloride. The American journal of physiology. 1993;265(6 Pt 2): 
F875-80.
55. Kortenoeven ML, Li Y, Shaw S, Gaeggeler HP, Rossier BC, Wetzels JF, et al. Amiloride blocks lithium entry
through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney 
Int. 2009;76(1):44-53.
56. Christensen BM, Zuber AM, Loffing J, Stehle JC, Deen PM, Rossier BC, et al. alphaENaC-mediated lithium 
absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol. 2011;22(2):253-61.
57. Kunnen SJ, Leonhard WN, Semeins C, Hawinkels L, Poelma C, Ten Dijke P, et al. Fluid shear stress-induced 
TGF-beta/ALK5 signaling in renal epithelial cells is modulated by MEK1/2. Cell Mol Life Sci. 2017;
74(12):2283-98.
58. Kishore BK, Chou CL, Knepper MA. Extracellular nucleotide receptor inhibits AVP-stimulated water 
permeability in inner medullary collecting duct. Am J Physiol. 1995;269(6 Pt 2):F863-9.
59. Kishore BK, Carlson NG, Ecelbarger CM, Kohan DE, Muller CE, Nelson RD, et al. Targeting renal purinergic 
signalling for the treatment of lithium-induced nephrogenic diabetes insipidus. Acta Physiol (Oxf). 
2015;214(2):176-88.
60. Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. End-stage renal disease associated with 
prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24(4):540-4.
61. Gupta S, Kripalani M, Khastgir U, Reilly J. Management of the renal adverse effects of lithium. Advances 
in psychiatric treatment. 2013;19:457–66.
62. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part 
III: clinical safety. CNS Drugs. 2009;23(5):397-418.
63. Bendz H, Schon S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is 
uncommon. Kidney Int. 2010;77(3):219-24.
64. Alsady M, Baumgarten R, Deen PM, de Groot T. Lithium in the Kidney: Friend and Foe? J Am Soc Nephrol. 
2016;27(6):1587-95.
65. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121(11): 
4210-21.
66. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15(3-4):290-301.
67. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med.
2012;18(7):1028-40.
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 205
General discussion and summary | 205

519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 207
Nederlandse samenvatting
Chapter 11
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 208
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 209
Nederlandse samenvatting | 209
Inleiding
Elke dag filtreren onze nieren ongeveer 170-180 liter bloed. Als deze grote volumes 
ultrafiltraat onveranderd als urine zouden worden uitgescheiden zou het nodig zijn om 
grote hoeveelheden water en zouten in te nemen om in balans te blijven. Dit wordt
voorkomen door de selectieve reabsorptie van water, zouten en andere bloedbestand-
delen uit het filtraat dat langs het nefron stroomt. Het reguleren van waterhomeostase
vindt plaats in de hoofdcellen van de verzamelbuis die het AQP2-waterkanaal bezitten. 
Toename of afname van de hoeveelheid AQP2 op het celoppervlak heeft directe 
invloed op urine concentrerend vermogen en daarmee ook de hoeveelheid water in 
het lichaam. Dus afwijkingen van de hoeveelheid AQP2 kunnen leiden tot ziekten zoals
het syndroom van inadequate secretie van antidiuretisch hormoon (SIADH) of 
nefrogene diabetes insipidus (NDI). De meest voorkomende vorm van NDI is verkregen 
en is een bijwerking van lithium, dat als behandeling aan bipolaire patiënten wordt 
gegeven. Het doel van dit proefschrift was meer inzicht krijgen in de pathofysiolo-
gische mechanismen die betrokken zijn bij de ontwikkeling van renale bijwerkingen 
van lithium. Daarnaast zijn nieuwe mogelijkheid onderzocht om Li-NDI te behandelen.
Lithium verlaagt de verhouding hoofdcellen tot intercalaire cellen 
in de verzamelbuis
Zoals hierboven gemeld, is de regulatie van AQP2 waterkanalen in de luminale 
membraan van de renale hoofdcellen essentieel voor de urine concentrerend 
vermogen. Ongeveer 20% van de patiënten die lithium behandeling krijgt, ontwikkelt 
NDI waarbij de urine concentrerend vermogen van de patiënten verstoord raakt. Lithi-
um-geïnduceerde NDI wordt veroorzaakt door een verlaging in de hoeveelheid van het
AQP2 eiwit. Daarnaast wordt de ziekte erger door een verlaagde percentage 
hoofdcellen in de verzamelbuis. Het is echter verrassend dat lithium proliferatie van
voornamelijk de hoofdcellen induceert. In hoofdstuk 2 hebben we onderzoek gedaan 
naar hoe lithium-geïnduceerde proliferatie gepaard kan gaan met een verlaagd
percentage aan hoofdcellen. Dit hebben we bestudeerd in 2D en 3D gekweekte nier 
cellen die afkomstig zijn van verzamelbuizen (mpkCCD-cellen) van muizen en dieren 
experimenten in muizen. Dit zijn muizen die behandeld werden met klinisch relevante
lithiumconcentraties. We hebben het effect van lithium op de celcyclus bestudeerd
met behulp van DNA-beeldcytometrie en door te immunoblotten voor eiwitten van
verschillende celcyclusstadia. In deze studie laten we zien dat lithium inderdaad 
proliferatie van mpkCCD-cellen induceert. Maar dit leidt ook tot een verhoogde 
G2/S-fase verhouding, wat een G2/M-fase stop aangeeft. De muizen werden gedurende
4, 7, 10 of 13 dagen behandeld met lithium. Deze muizen ontwikkelden NDI (polyurie,
verminderde osmolaliteit van de urine en AQP2 verlaging) en lieten veel PCNA-positieve
hoofdcellen in de papilla zien. Opmerkelijk was dat 30-40% van de PCNA-positieve
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hoofdcellen ook kleurden voor pHistone-H3, een late G2/M-fase-marker. Onze
resultaten tonen dus aan dat lithiumbehandeling de proliferatie van renale hoofdcellen 
initieert, maar dat een significant percentage wordt geremd in de late G2-cyclusfase,
wat een verklaring biedt voor de verminderde hoofdcel percentage.
Wij zijn echter van mening dat de remming van de hoofdcellen in de G2-fase niet de
enige factor is die leidt tot de remodeling van de verzamelbuis. Verschillende eerdere 
onderzoeken hebben aangetoond dat de lithiumbehandeling van ratten het aantal 
cellen, voornamelijk intercalaire cellen, in de verzamelbuis verhoogd. Waarom 
intercalaire cellen prolifereren is nog niet bekend. Een belangrijke stimulus zou de 
ontwikkeling van metabole acidose zijn, die vaak, maar niet altijd, waargenomen
wordt bij lithiumbehandeling van knaagdieren. Een toestand van metabole acidose 
verhoogt het aantal т-intercalaire cellen als een adaptieve respons. Eerdere studies
suggereren dat lithium geïnduceerde metabole acidose en verzamelbuis remodeling
veroorzaakt worden door een directe remming van H+-ATPase en H+/K+-ATPase die in
de intercalaire cellen tot expressie worden gebracht. Recentere data laten echter zien
dat dit niet waar kan zijn om de volgende redenen: in het experiment van Kortenoeven 
en anderen (2009), is amiloride, die de toegang van lithium tot de hoofdcellen remt, 
niet alleen Li-NDI tegen gegaan maar ook verzamelbuis remodeling. Bovendien was de 
hoeveelheid H+-ATPase, een markereiwit voor т-intercalaire cellen, niet verhoogd bij
lithium behandelde ENaC-KO muizen. Deze studies suggereren dus dat lithium 
geïnduceerde remodeling van de verzamelbuis een direct effect is van lithium in de
hoofdcellen. In hoofdstuk 4 van dit proefschrift tonen we aan dat lithium aerobe
glycolyse induceert in hoofdcellen, een proces dat gepaard gaat met een verhoogde 
productie van lactaat en waterstof. Zodanig kan de toename aan het aantal 
т-intercalaire cellen dus ook een gevolg zijn van de zuurafgifte tijdens aerobe 
glycolyse. In het kort, de remodeling van de verzamelbuis door lithium kan verklaard
worden door een stabiele populatie van hoofdcellen, die gedeeltelijk geremd zijn in de
G2-fase van de celcyclus en delende populatie intercalaire cellen als gevolg van
lithium geïnduceerde aerobe glycolyse.
De impact van aerobe glycolyse op lithium-geïnduceerde nierpathologie
Lithium-geïnduceerde metabole herprogrammering van hoofdcellen
Eerder hebben anderen en wij aangetoond dat lithium de hoofdcellen binnenkomt 
door het epitheliale natrium-kanaal (ENaC). Eenmaal binnen de hoofdcel induceert 
lithium proliferatie van de hoofdcellen. In hoofdstuk 4 van dit proefschrift laten we in 
vitro en in vivo data zien die aangeeft dat lithium-geïnduceerde proliferatie gepaard 
gaat met metabole veranderingen richting aerobe glycolyse en glutaminolyse. Lithium 
behandeling induceerde een toename (in vitro) en afgifte (in vivo) van lactaat die 
afwezig zijn in muizen die ENaC eiwit niet bezitten. De NMR-analyse toont verder aan 
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dat lithiumbehandeling sterk de urine niveaus van succinaat, fumaraat en citraat 
verhoogde. Het is bekend dat deze metabolieten verhoogd zijn tijdens een proces
genaamd glutaminolyse. Tijdens aerobe glycolyse wordt glutaminolyse verhoogd 
omdat glutamine afbraak de cel voorziet van stikstof en citraat, die nodig zijn voor 
aminozuren en lipiden synthese, respectievelijk. Bovendien vindt tijdens aerobe 
glycolyse verhoogde intracellulaire zuurproductie plaats. Tijdens glutaminolyse
komen twee moleculen NH3 vrij die de vrijgekomen H+ bufferen. 
Onze in vitro experimenten met  siRNA- en behandeling met carboanhydrasen (CA)
remmers van mpkCCD-cellen laten zien dat van de acht CA-en die aanwezig zijn in 
mpkCCD-cellen CA9 en tot op zekere hoogte CA12 voornamelijk betrokken zijn bij de
effecten van lithium. CA9 en -12 bevinden zich normaal gesproken op de basolaterale 
membraan van epitheelcellen, maar lijken sterk verhoogd te zijn in de plasmamem-
branen van delende cellen. CA9 wordt nauwelijks tot expressie gebracht in gezonde 
nieren. Maar CA9 en CA12 expressie zijn aanmerkelijk verhoogd in renale carcinomen. 
Deze eiwitten vergemakkelijken de groei van tumorcellen door de vrijgekomen zuren 
te neutraliseren die tijdens aerobe glycolyse vrijkomen. Helaas remde de remming van 
aerobe glycolyse met 2DG Li-NDI niet. In vitro ging 2DG de Li-geïnduceerde down- 
regulatie van AQP2 tegen. In vivo, werd de excretie van lactaat in de urine genormaliseerd, 
wat aanduidt dat aerobe glycolyse geremd werd door 2DG in onze experimenten. 
Echter werden succinaat, fumaraat, citraat en ammonium niet verlaagd door 2DG, wat 
aangeeft dat 2DG glutaminolyse niet remde. Toekomstige studies zouden zich op de
mogelijke rol van glutaminolyse moeten richten waarbij de remming hiervan mogelijk
de pathogenese van Li-NDI tegen kan gaan.
Impact van de celcyclus op de expressie van AQP2
Zoals eerder aangegeven, veroorzaakt lithiumbehandeling verlaging in hoeveelheid 
AQP2 in de hoofdcellen van de verzamelbuis. Deze verlaging gaat gepaard met 
proliferatie en metabole switch richting aerobe glycolyse. Hoewel de impact van
aerobic glycolyse op AQP2 verlaging nu onwaarschijnlijk lijkt, was de invloed van cel 
proliferatie op de expressie van AQP2 nog niet bepaald. Terwijl we de pathofysiologie 
van SIADH onderzochten in hoofdstuk 8, vonden we dat AQP2 eiwit expressie het 
hoogste was in de G0-fase en sterk gereduceerd was in alle andere fasen van de 
celcyclus. Deze resultaten zijn niet alleen van belang om de rol van de celcyclus bij
SIADH te begrijpen maar ook belangrijk om de pathogenese van Li-NDI te snappen 
aangezien lithium ook proliferatie induceert in de hoofdcellen. In hoofdstuk 8
gebruiken we methoden van de systeembiologie om bij een rattenmodel van SIADH 
cascades te identificeren die betrokken zijn bij de ontwikkeling van de ziekte. Door het 
inplanteren van minipompen die constant vasopressine afgeven en verhoogde water 
opname in voedsel ontstaat een fenomeen dat vasopressine-escape wordt genoemd 
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waarbij AQP2 verlaagd wordt ook al is vasopressine niveau hoog. Veranderingen op
transcriptie niveau werden in deze model in kaart gebracht en bleek dat cascades die
belangrijk zijn bij de overgang van G0 naar de celcyclus sterk verhoogd waren. Hierdoor 
lijk het remmen van eiwitten die betrokken zijn bij celdeling een logische en
aantrekkelijke keuze lijkt om Li-NDI tegen te gaan. Maar onze data laten zien dat het 
geen zin heeft om te investeren in blokkers voor dit proces. Dit komt doordat proliferatie 
remmers de celcyclus stoppen in de G1 of latere fasen. Maar voor het behouden van
een hoge AQP2 eiwit expressie moeten de cellen in de G0 fase blijven, wat niet
mogelijk is met huidige celcyclus blokkers. 
Verergering van Li-NDI door shear-stress
Verminderde AQP2 in de verzamelbuis resulteert in een verhoogde waterstroom die 
NDI-ontwikkeling zou kunnen verergeren. Kunnen en anderen (2017) lieten zien dat
shear-stress, geïnduceerd door verhoogde flow, leidt tot de activatie van de TGFу
signalering cascade in renale epitheelcellen. In hoofdstuk 8 tonen we aan dat TGFу
AQP2 eiwit expressie verlaagd. Aldus kan de verhoogde flow de activering van TGFу
cascade initiëren, wat leidt tot de verlaging van AQP2 en daarmee bijdraagt aan het 
onvermogen van hoofdcellen om urine te concentreren. Maar de afgifte van TGFу in de
urine als gevolg van verhoogde renale flow en shear-stress is nog niet vastgesteld. 
Daarom is de bepaling van TGFу in de urine van Li-NDI-patiënten of knaagdieren van 
belang om het belang van TGFу in de verergering van Li -NDI te bepalen.
In hoofdstuk 9 hebben we verder laten zien dat de flow-gemedieerde purinerge 
signalering ook invloed heeft op AQP2 eiwit expressie. MpkCCD-cellen worden
gekweekt onder statische en schuddende omstandigheden in aanwezigheid of 
afwezigheid van een selectieve adenosine receptor antagonist. Flow gemedieerde 
AQP2 downregulatie wordt alleen waargenomen in de onbehandelde condities.
Purinerge signalering gemedieerd door extracellulaire nucleotiden gaan de werking
van AVP op de hoofdcellen tegen door verlaging van de cellulaire cAMP en dus AQP2 
eiwitniveaus. Dit wordt ook aangetoond in een ex-vivo studie van AVP gestimuleerde 
rat verzamelbuizen die waren geperfundeerd met ATP. De onderzoekers zagen een 
afname in intracellulaire cAMP-niveaus en de daaropvolgende lagere waterpermeabi-
liteit. Bovendien, bestudeerde Kishore en collega’s de mogelijke betrokkenheid van de 
ATP/UTP geactiveerd P2Y2 receptor in lithium-geïnduceerde NDI bij ratten. Ze toonden 
aan dat P2Y2 receptor knockout muizen significant resistenter waren tegen de 
ontwikkeling van Li-NDI. Ze toonden ook aan dat ADP-geactiveerde P2Y12 receptor tot
expressie wordt gebracht in de nier en de blokkade hiervan door de toediening van 
clopidogrel bisulfaat Li-geïnduceerde NDI tegen gaat bij knaagdieren. Deze bevindingen 
geven allemaal het belang purinerge signaleringsroute in de ontwikkeling van Li-NDI.
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Lithium-geïnduceerde renale interstitiële fibrose
Naast het effect van lithium op het urine concentratievermogen leidt langdurige
lithium behandeling tot het ontwikkelen van renale interstitiële fibrose die een kenmerk
is van chronische nierfalen (CKD). De laatste fase van CKD is terminale nierziekte 
(ESRD), die wordt gedefinieerd door een volledig verlies van nierfunctie. Dergelijke
patiënten kunnen alleen behandeld worden met dialyse of transplantatie. Het verval in 
nierfunctie is sterk dosisafhankelijk en kan worden verbeterd door zorgvuldige 
controle van serum Li-concentraties bij patiënten. Ongeveer 1,5% lithium-gebruikers
ontwikkelen ESRD dat zes tot acht keer hoger is dan bij de algemene populatie. Om de 
ontwikkeling van lithium-geïnduceerde nier fibrose volledig te begrijpen, is het gebruik 
van diermodellen essentieel. In hoofdstuk 7 tonen we aan dat het meest gebruikte 
muismodel, C57BL/6, gebruikt kan worden om Li-CKD te bestuderen. Lithium-geïndu-
ceerde interstitiële fibrose wordt waarschijnlijk geïnitieerd in de hoofdcellen die 
chemotactische factoren uitscheiden die de glycocalyx laag op het oppervlak van en-
dotheelcellen aantasten. Vervolgens zou de expressie van adhesiemoleculen op het 
oppervlak van endotheelcellen verhoogd worden waardoor monocyten makkelijker 
aan de endotheelcellen binden en het interstitium binnentreden en differentiëren tot
macrofagen. Epitheelcellen, macrofagen en endotheelcellen scheiden dan TGFу af die
de proliferatie en de transformatie van fibroblasten tot myofibroblasten stimuleren.
Myofibroblasten produceren colageen in het interstitium wat uiteindelijk tot functie-
verlies in de niet leidt.
De behandeling van Li-NDI?
Om Li-NDI te verminderen, worden bipolaire patiënten behandeld met thiazide/
amiloride, waarvan wordt gedacht dat ze antidiurese induceren door een compensatoire 
verhoogde pro-urine opname in proximale tubuli. Maar thiazide induceerde ook een
antidiurese bij lithium-NDI-muizen zonder de natriumchloride-co-transporter (NCC) en
maakte hun urine basaal. Dit suggereert dat de remming van carboanhydrasen door 
thiazide de mogelijk oorzaak kan zijn van de gunstige effect van thiazide. Daarom 
besloten we in hoofdstuk 3 het effect van de CA-specifieke blokker, acetazolamide, in
lithium-NDI te bestuderen.
Acetazolamide ging, in mpkCCD-cellen het effect van lithium op AQP2 verlaging 
tegen. Behandeling van lithium-NDI-muizen met acetazolamide of thiazide/amiloride 
onthulde een vergelijkbare antidiurese, verhoogde urine osmolaliteit en verhoogde 
hoeveelheid AQP2. Onze data wijzen erop dat de waargenomen antidiurese en 
verminderde GFR met acetazolamide het gevolg is van een tubulaire glomerulaire
feedbackrespons veroorzaakt door de remming van carboanhydrasen in de proximale
tubulus. Met thiazide/amiloride behandelde muizen hadden ook hyponatriëmie,
hyperkaliëmie, hypercalciëmie, metabole acidose en verhoogde serumlithiumconcen-
traties. Deze bijwerkingen worden ook waargenomen bij patiënten, maar werden niet 
519287-L-bw-Alsady
Processed on: 3-5-2018 PDF page: 214
214 | Chapter 11
gezien bij met acetazolamide behandelde muizen. Samengevat hebben we aangetoond 
dat CA-activiteit bijdraagt aan de ontwikkeling van lithium-NDI. Acetazolamide vermindert 
lithium-geïnduceerde NDI door het induceren van een TGF-reactie en door een direct 
effect op de cellen van de verzamelbuis. Verder verlaagt acetazolamide lithium-NDI-
ontwikkeling vergelijkbaar met thiazide/amiloride, maar met minder bijwerkingen.
Of acetazolamide uiteindelijk in de kliniek toegepast zal worden is de vraag. Er zijn
ondertussen meerdere humane studies die het effect van acetazolamide hebben
bestudeerd waarbij zowel positieve als negatieve uitkomsten waargenomen zijn. 
Ondertussen blijft amiloride tot heden de beste manier om de effecten van lithium 
tegen te gaan waarbij, zoals eerder beschreven, de toegang van lithium in de cellen 
geremd wordt. Hoewel, het effect van amiloride op AQP2 goed is bestudeerd, is het
effect van amiloride op andere bijwerkingen van lithium nog niet onderzocht.  Daarom 
kijken we in hoofdstuk 6 of amiloride, naast het verlagen van Li-NDI, ook metabole
acidose en het verlagen in het percentage van hoofdcellen voorkomt. In deze studie 
zagen we dat amiloride ook hier Li-NDI tegen ging waarbij AQP2 nog wel in de cortex 
verlaagd werd maar niet de medulla. Bovendien verlaagde amiloride ook de door 
lithium geïnduceerde proliferatie van hoofdcellen en ging het verzamelbuis remodeling 
tegen. Lithium induceerde in deze studie geen hypercalciëmie noch had het invloed
op de pH van het bloed. Analyse van ammonium in de urine toont aan dat amiloride
lithium-geïnduceerde toename in ammonium in de urine verlaagt. Samengevat liet 
onze studie zien dat amiloride niet alleen de verlaging van AQP2 tegen gaat, maar ook
de ontwikkeling van verschillende andere neveneffecten in de nier voorkomt.
Slotopmerkingen
In dit proefschrift, worden de moleculaire mechanismen bestudeerd die betrokken zijn
bij de pathofysiologie van lithium geïnduceerde nefrogene diabetes insipidus. We
vinden dat naast proliferatie, lithium ook het metabolisme verandert van de hoofdcellen
door het induceren van aerobe glycolyse en glutaminolyse. Remmen van glycolyse 
gaat het lithium geïnduceerde AQP2 downregulatie bij muizen niet tegen. Mogelijk is
het remmen glutaminolyse interessant en zou uiteindelijk kunnen leiden tot 
ontwikkelen van nieuwe middelen om Li-NDI tegen te gaan. Verder hebben we het 
gebruik van acetazolamide als een alternatieve behandeling voor Li-NDI onderzocht 
en vonden dat deze middel eenzelfde effect heeft als hydrochloorthiazide en amiloride
in de remming van Li-NDI, maar met minder bijwerkingen. We vonden ook dat AQP2 
eiwit expressie het hoogste was in de G0 fase van de celcyclus en sterk werd 
gereduceerd in alle andere fasen. Ten slotte konden we ook voor het eerst een 
experimentele conditie opstellen die resulteerde in de ontwikkeling van interstitiële
fibrose bij muizen. De toepassing van dit model zal mechanistisch onderzoek mogelijk 
maken naar de oorzaak van lithium-geïnduceerde interstitiële fibrose.
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List of abbreviations 
A
AQP2 Aquaporin-2
ADP Adenosine diphosphate
AMP Adenosine monophosphate
ANOVA Analysis of variance
ATP Adenosine triphosphate
AVP Arginine vasopressin
C
°C Degree Celsius
Ca2+ Calcium ion 
cAMP Cyclic AMP
cDNA Complementary DNA
CD Collecting Duct
CKD Chronic kidney disease 
Cl- Chloride
CREB cAMP responsive element binding protein
D
DI Diabetes insipidus
DMEM Dulbecco’s modified eagle’s medium
DNA Deoxyribonucleic acid 
DTT Dithiothreitol
E
ECL Enhanced Chemiluminescence
EDTA Ethylene diamine tetraacetic acid 
eGFR Estimated glomerular filtration rate
ENaC Epithelial Na+ channel
ER Endoplasmic reticulum
ESRD End stage renal disease
G
GFR Glomerular filtration rate 
GSK Glycogen synthase kinase
H
HCTZ Hydrochlorothiazide
I
IB Immunoblotting 
IHC Immunohistochemistry
K
K+ Potassium
KDa Kilo Dalton
KO Knockout
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L
Li+ Lithium
M
Mg2+ Magnesium
MQ Milli-Q water 
mRNA Messenger ribonucleic acid
N
Na/K-ATPase Na+/K+ pump
Na+ Sodium
NCC NaCl cotransporter
NDI Nephrogenic diabetes insipidus
NHE3 Na+/H+ exchanger type 3
P
PCR Polymerase chain reaction
PKA Protein kinase A
PKC Protein kinase C
RNA Ribonucleic acid
PNGase F N-glycosidase F 
PT Proximal tubule
PVDF Polyvinylidene difluoride 
R
RAAS Renin-angiotensin-aldosterone system 
RT-qPCR Reverse transcriptase quantitative PCR
S
SEM Standard error of the mean 
SIADH Syndrome of inappropriate antidiuretic hormone secretion
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
W
WT Wildtype
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Research data management 
Research data presented in this thesis and obtained during this PhD at the department
of Physiology, Radboud university medical center (Radboudumc) were archived according 
to the Findable, Accessible, Interoperable and Reusable (FAIR) principles. Initially,
the data was stored digitally at local server of the department of Physiology and on 
paper in the form of labjournals. Later, Labguru, a digital lab book, was introduced
at our department that replaced the regular labjournals. Both the local server of our 
department and Labguru are supported by the Information and Communications 
Technology (ICT) of Radboudumc. Moreover, labguru is daily backed up on the 
local server of Radboudumc, while data stored on the local servers were weekly backed-
up on the servers of the university. The data files on Labguru and the local server 
are accessible by the associated scientific staff members. Human studies in Chapters 5
and 9 were conducted according to the principles accepted in the declaration of 
Helsinki. All participants gave written informed consent to participate in the study. 
The study protocols, including the data management plan were approved by the 
associated Medical Ethics Committee of the Radboudumc (Chapter 9) and New 
Zealand (Lower South Regional) Ethics Committee (Chapter 5). Animal studies
performed in Chapters 2, 3, 4, 5, 6, 7 and 8 were approved by the Animal Ethical 
Committees of the associated Universities. All data generated or analyzed in this 
thesis are included in published articles and its additional files are available from
the associated corresponding authors on request. To ensure general accessibility of 
the data, all files were documented according to the protocol of the department of 
Physiology.
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